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of left ventricular assist devices (LVADs) as a bridge to
heart transplantation (BTT), as a bridge to myocardial
recovery (BTR) or as a long-term chronic support
(LTCS) for people with end-stage heart failure (ESHF). 
Data sources: For the systematic review, electronic
databases and bibliographies of related publications plus
experts and manufacturers. For the economic
evaluations, data originated from the systematic review
of clinical and cost-effectiveness, UK hospitals, device
manufacturers and expert opinion.
Review methods: For the systematic review, studies
were selected and assessed against a set of rigorous
criteria; data were then synthesised using a narrative
approach through subgroup analysis based on the
indication for treatment, type of LVAD and quality of
studies. The economic evaluation developed two
models to evaluate the use of LVADs, first as a BTT
and second as LTCS for patients suffering from ESHF. 
Results: Sixteen studies assessed the clinical
effectiveness of LVADs as a BTT. Despite the poor
methodological quality of the evidence, LVADs
appeared beneficial compared to other treatment
options (i.e. inotropic agents or usual care) or to no
care (i.e. the natural history of ESHF) improving the
survival of people with ESHF during the period of
support and following heart transplantation. Patients
supported by an LVAD appeared to have an improved
functional status compared with those on usual care
and experienced an improvement in their quality of life
from before device implantation to the period during
support. Serious adverse events are a risk for patients
with an LVAD. With a scarcity of evidence directly
comparing different devices, it is difficult to identify
specific devices as the most clinically effective. The
HeartMate LVAD is the only device that has evidence
comparing it with the different alternatives, appearing
to be more clinically effective than inotropic agents and
usual care and as clinically effective as the Novacor
device. Second generation devices, such as Jarvik 2000
and MicroMed Debakey LVADs, are early in their
development but show considerable promise that
should be assessed through long-term studies. Evidence
of the clinical effectiveness of LVADs as a BTR was
limited to seven non-comparative observational studies
that appeared to show that the LVADs were beneficial
in providing support until myocardial recovery. It was
not possible to assess whether the LVADs are more
effective than other alternatives or specific devices. No
evidence was found on the quality of life or functional
status of patients and limited information on adverse
events was reported. Six studies assessed the clinical
effectiveness of LVADs as an LTCS and from these it
was evident that LVADs provided benefits in terms of
improved survival, functional status and quality of life.
Nineteen studies assessed the costs and cost-
effectiveness of LVADS for people with ESHF, with the
majority being simple costing studies and very few
studies of the cost-effectiveness of LVADs. With no
relevant cost-effectiveness studies available, an
economic evaluation for BTT and LTCS was developed.
The economic evaluation has shown that neither LVAD
indication considered, that is, BTT and LTCS, is a cost-
effective use. For the HeartMate LVAD used as a BTT
the cost per QALY was £65,242. In the less restrictive
indication, LTCS, where LVADs are not just given to
patients awaiting transplantation, the analysis has
shown that LTCS is not cost-effective. The baseline
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Abstract
The clinical and cost-effectiveness of left ventricular assist
devices for end-stage heart failure: a systematic review and
economic evaluation
AJ Clegg,1* DA Scott,2 E Loveman,1 J Colquitt,1 J Hutchinson,2 P Royle3
and J Bryant1
1 Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development,
University of Southampton, UK
2 Fourth Hurdle Consulting Ltd, London, UK
3 University of Aberdeen, UK
* Corresponding authorcost per QALY of the first-generation HeartMate LVAD
was £170,616. One- and multi-way sensitivity analysis
had limited effect on the cost per QALY. A hypothetical
scenario based on the cost of a second-generation
MicroMed DeBakey device illustrated that a 60%
improvement in survival over first-generation devices
was necessary before the incremental cost-
effectiveness approached £40,000 per QALY. 
Conclusions: Although the review showed that LVADs
are clinically effective as a BTT with ESHF, the economic
evaluation indicated that they are not cost-effective.
With the limited and declining availability of donor
hearts for transplantation, it appears that the future of
the technology is in its use as an LTCS. Further
research is needed to examine the clinical effectiveness
of LVADs for people with ESHF, assessing patient
survival, functional ability, quality of life and adverse
events. Evaluations of the clinical effectiveness of
LVADs should include economic evaluations, as well as
data on quality of life, utilities, resources and costs. 
A systematic review of the epidemiology of ESHF
should be undertaken to assess its potential impact.
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Executive summary
Background
Heart failure is an increasing health problem in
England and Wales. Its incidence and prevalence
are increasing, leading to frequent admissions to
hospital and long-term drug costs. Concerns about
the effects on the duration and quality of life of
people and costs upon the NHS have resulted in
several government policy initiatives. End-stage
heart failure (ESHF) is associated with major
disability and a poor prognosis. Heart
transplantation has become the accepted form of
treatment for people with ESHF, improving
survival and patient quality of life. With continued
decreases in organ donation in England and
Wales, it is an option available to few. Mechanical
circulatory support through left ventricular assist
devices (LVADs) has attracted increased interest as
an option for patients with ESHF whether as a
bridge to heart transplantation (BTT), as a bridge
to myocardial recovery (BTR) or as a long-term
chronic support (LTCS). Continued developments
of LVADs, declining costs and improvements in
associated care have made their wider use a reality. 
Objectives
The objectives of this study were to carry out a
systematic review and an economic evaluation to
examine the clinical and cost-effectiveness of
LVADS as a BTT, BTR and LTCS for people with
ESHF. The study focused on the effect of LVADs
on the duration and quality of life of people with
ESHF, the groups who may benefit from their use
and assesses the implications for developing such
a service within the NHS in England and Wales.
Methods
A systematic review of the evidence and an
economic evaluation were undertaken using a
priori methods.
Data sources
Eighteen electronic databases were searched from
inception to October 2003. Bibliographies of
related papers were assessed for relevant studies
and experts and manufacturers were contacted to
identify additional published and unpublished
references.
Study selection
Studies were included if they fulfilled the following
criteria:
  Interventions: studies that evaluated currently
available LVADs used as a BTT, BTR and LTCS
for people with ESHF were considered for
inclusion. 
  Participants: people aged 16 years or older
with ESHF and considered suitable for receipt
of an LVAD as BTT, BTR or LTCS. 
  Outcomes: survival, functional capacity [e.g.
New York Heart Association (NYHA) functional
classification, activities of daily living] and
quality of life were the primary outcome
measures considered within the systematic
review. 
  Design: systematic reviews, randomised
controlled trials (RCTs), controlled clinical
trials, cohort studies, case series, case studies,
economic evaluations and cost studies were
included. 
Studies identified were assessed for inclusion
through two stages with titles and abstracts and
full papers of retrieved studies assessed by two
reviewers, with differences in decisions resolved
through discussion or through recourse to a third,
independent reviewer. 
Data extraction and quality assessment
Data were extracted by two reviewers using data
extraction forms developed a priori, with any
disagreements resolved through discussion or
through recourse to independent assessment by a
third reviewer. The methodological quality of the
studies included in the systematic review of clinical
and cost-effectiveness were assessed using
recognised quality assessment tools using
individual components of methodological quality
rather than relying upon summary scores. The
quality criteria used were applied by two reviewers,
with any disagreements resolved through
discussion or through recourse to a third,
independent reviewer. x
Data synthesis
Studies were synthesised using a narrative
approach through subgroup analysis based on the
indication for treatment, type of LVAD and quality
of studies.
Economic evaluation
The economic evaluation developed two models to
evaluate the use of LVADs, first as a BTT and
second as LTCS for patients suffering from ESHF.
Insufficient data prevented the assessment of the
use of LVADS as a BTR. The outcomes in the
evaluation were assessed in terms of the benefits to
patients (survival and quality of life) and costs
incurred, with results presented in terms of a
cost–utility analysis. Although medical therapy was
the comparator treatment in the two models, the
patients differed. Patients in the BTT model were
those on the heart transplantation waiting list,
whereas those in the LTCS model were excluded
from the heart transplant waiting list owing to the
severity of their condition. The models focused on
those LVADs that were found in the systematic
review to be clinically effective for the different
indications and relevant to the UK setting.
Results
Clinical effectiveness of LVADs as 
a BTT for people with ESHF
Sixteen studies (one controlled clinical trial, five
cohort studies with comparators, five cohort
studies with no comparator, three case series and
two case reports) assessed the clinical effectiveness
of LVADs as a BTT, 11 studies of first-generation
devices and five of second-generation devices. The
methodological quality of the studies was generally
weak, reflecting the quasi-experimental and
observational study designs used and poor
reporting of study characteristics. Despite the poor
quality evidence, LVADs compared with other
treatment options appeared to be beneficial for
patients with ESHF when assessed using patient
survival, functional status and quality of life. When
compared with inotropic agents, LVADs appeared
to provide a benefit in patient survival that
increased with the length of support (difference in
actuarial survival: 1 month 3%; 3 months 17%)
and extended beyond heart transplantation
(difference in actuarial survival: 1 year 24%;
4 years 30%). Comparisons of the use of LVADs
with usual care were less certain, with outcomes
varying from no difference in survival to, or after,
heart transplantation, to improved survival for
LVADs patients to heart transplantation (survival
difference: range 14–59%) and post-transplantation
(difference in actuarial survival: 1 and 2 years
100%). Studies of LVADs which did not include a
comparator were often the only evidence available,
particularly for the new devices. In these studies,
implantation of an LVAD provided support for up
to 390 days, with as many as 70% of patients
surviving to transplantation. Comparisons of
different LVADs were limited. Only the HeartMate
and Novacor LVADs were compared, with little
difference in survival to transplantation. There was
limited evidence assessing the effects of LVADs on
the functional status and quality of life of patients
with ESHF BTT. Patients supported by an LVAD
appeared to have an improved functional status
compared with those on usual care. Also, patients
with an LVAD experienced an improvement in
their quality of life from before implantation of
the device to the period during support. The use
of LVADs is associated with risks of adverse events,
with patients suffering mechanical device failures,
bleeding, thromboembolic events, infections,
reoperations and psychiatric conditions. Adverse
events rates varied between different LVADs and
studies and some caution should be exercised in
interpreting these results. With a scarcity of
evidence directly comparing the different LVADs it
is difficult, and perhaps inappropriate, to identify
specific devices as the most clinically effective.
However, the HeartMate LVAD is the only device
that has evidence comparing it with several
different alternatives, appearing to be more
clinically effective than inotropic agents and usual
care and as clinically effective as the Novacor
device. Of the second-generation devices, the
evidence suggests limited difference in the clinical
effectiveness of the Jarvik 2000 and the MicroMed
DeBakey LVADs. Although early in their
development, these second-generation devices
appear to show lower rates of adverse events, such
as infection, bleeding and thromboembolism,
which have affected the development and use of
the first-generation devices. However, longer term
outcomes are needed to ensure that these
apparent benefits are maintained in practice and
that the consequences associated with the non-
pulsatile nature of the devices do not result in
additional adverse events.
Clinical effectiveness of LVADs as a BTR
for people with ESHF
Evidence of the clinical effectiveness of LVADs as a
BTR for people with ESHF was limited to seven
non-comparative observational studies (two case
series and five case reports) of first-generation
devices, which were judged to be of poor
methodological quality. The seven identified
studies appeared to show that the LVADs provided
Executive summarybenefit in providing support for the patients until
myocardial recovery. As there were no direct
comparisons of different interventions, it is not
possible to assess whether the LVADs are more
effective than other alternatives or specific devices.
No evidence was found to judge the effects of the
devices on the quality of life or functional status of
patients. Limited information on adverse events
was reported, although infections and bleeding
were the main concerns.
Clinical effectiveness of LVADs as 
an LTCS for people with ESHF
Six studies (one RCT, one case series and four case
reports) assessed the clinical effectiveness of
LVADs as an LTCS for people with ESHF.
Although the nature and methodological quality
of the evidence varied between the different
devices, it was evident that LVADs provided
benefits for patients in terms of improved survival,
functional status and quality of life. The
REMATCH trial provided good-quality evidence
that the HeartMate LVAD provided a statistically
significant 48% reduction in the risk of death from
any cause when compared with optimal medical
management. Actuarial survival was significantly
higher for patients with the HeartMate LVAD
compared with optimal medical management at
1 year (52% versus 25%) and 2 years (23% versus
8%) follow-up. Importantly, improvements in 
1-year survival were evident for patients aged
under 60 years and those aged 60–69 years. Less
rigorous evidence for the Novacor, Toyobo and
Jarvik 2000 devices showed relatively high survival
(90%), with patients supported for up to 4 years.
Limited information on changes in patients’
quality of life and functional status suggested that
patients experienced improvements on specific
scales following implantation of the HeartMate
and Jarvik LVADs. Inevitably there are adverse
events associated with the use of LVADs, with
device malfunctions, infection and bleeding
associated with their use. The HeartMate LVAD
was associated with twice as many serious adverse
events than optimal medical management, with
significantly higher rates of non-neurological
bleeding and neurological dysfunction. Other
adverse events affected the different treatment
options, whether devices or drug treatment.
Despite these adverse events, the benefits of these
LVADs appear to outweigh limitations. Evidence of
the clinical effectiveness of the different devices
indicates that the HeartMate LVAD appears to be
effective when compared with optimal medical
management. For the second-generation devices,
the early evidence suggests that the Jarvik 2000
shows promise; however, further research is
needed to assess whether these benefits are
replicated in the longer term and whether there
will be any long-term consequences associated with
the change in the nature of the circulatory
support.
Systematic review of the cost-
effectiveness of LVADs for people 
with ESHF
Nineteen studies assessed the costs and cost-
effectiveness of LVADS for people with ESHF, with
the majority being simple costing studies and very
few studies of the cost-effectiveness of LVADs. A
number of the costing studies had serious
methodological flaws. Even those judged of
‘higher quality’ had caveats limiting applicability
and generalisability to a UK population.
Significant limitations were the limited sample size
and the lack of comparators against which to
judge the significance of the reported costs. There
was only one UK-based cost–utility analysis, which
was populated with costs based on treatment
protocols, data from individual NHS Trust finance
departments and utilities derived from a US base
study. The UK study reported cost per quality-
adjusted life-year (QALY) values at the boundary
of acceptability given recent decision-making.
Based on total treatment costs of both LVAD BTT
support and heart transplantation, the discounted
cost per QALY was approximately £39,790 (range
£28,510–74,000). Threshold analysis found that an
LVAD device and procedure cost of £19,300 would
equate to a cost per QALY of £20,000 or less.
Economic evaluation to assess 
the cost-effectiveness of LVADs for
people with ESHF within the UK
The economic evaluation has shown that neither
LVAD indication considered, that is, BTT and
LTCS, is a cost-effective use. For the HeartMate
LVAD used as a BTT the cost per QALY was
£65,242. Stochastic simulation calculated the 95%
confidence interval at £34,194 to £364,564. Only
when the survival gain falls significantly does the
cost-effectiveness rise to such upper bounds. A
cost-effectiveness acceptability curve showed the
likelihood of acceptability at current cost-
effectiveness thresholds. The BTT indication
approaches cost-effectiveness only when the one-
off costs associated with an LVAD fall considerably.
At a combined LVAD device and operation cost of
£50,000 (compared with £87,877 in our model),
the cost per QALY fell to approximately £40,000.
Unfortunately, even assuming this eventuality, the
BTT indication use parallels an ever-decreasing
supply of donor hearts capping the ability of this
innovative technology to yield widespread benefit.
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LVADs are not just given to patients awaiting
transplantation, the analysis has shown that LTCS
is not cost-effective. The baseline cost per QALY
of the first-generation HeartMate LVAD was
£170,616. One- and multi-way sensitivity analysis
had limited effect on the cost per QALY. A
hypothetical scenario based on the cost of a
second-generation MicroMed DeBakey device
illustrated that a 60% improvement in survival
over first-generation devices was necessary before
the incremental cost-effectiveness approached
£40,000 per QALY. Although the analyses
recognise the benefits in terms of survival and
quality of life, these are outweighed by associated
increases in cost. Uncertainties remain,
particularly with the lack of trial data on LTCS,
research on second-generation devices and
ongoing costs of medical management. The use of
expert-based utilities in the LTCS data is also
innovative but the sensitivity testing has shown this
not to be an influential factor on cost-effectiveness
at the margin. 
Discussion and conclusions
Implications for practice
Although the systematic review of clinical
effectiveness showed that LVADs are clinically
effective as a BTT for people with ESHF, the
economic evaluation indicated that they are not
cost-effective. With the limited and declining
availability of donor hearts for transplantation, it
appears that the future of the technology is in its
use as an LTCS. At present the evidence of clinical
and cost-effectiveness of LVADs as an LTCS is less
certain, particularly for the second-generation
devices, and further study is needed. The limited
research available showed some clinical benefit for
patients receiving LVADs as an LTCS, but the
economic evaluation suggested that they were not
a cost-effective option. Limited numbers of
patients with ESHF receive an LVAD within
England and Wales and uncertainty remains about
the potential need and demand that may exist. As
a consequence, it is likely that there will be limited
availability of clinical teams who can undertake
these procedures and manage the patients
subsequently and there would need to be a rapid
increase in the training of staff and a step change
in the development of the necessary infrastructure.
To provide the service to meet the needs of 
a conservative estimate of 3000 patients would
result in a discounted cost to the NHS annually of
£321 million. With less conservative estimates
putting the potential need at between 7000 and
34,000 patients, the actual cost may be far higher. 
Recommendations for future research
Although LVADs appear to be effective in
improving the survival of patients with ESHF,
whether as a BTT, BTR or LTCS, the
methodological quality and strength of the
evidence are poor. Further research is needed to
examine the clinical effectiveness of LVADs for
people with ESHF, assessing patient survival,
functional ability, quality of life and adverse
events. Although difficult to undertake with such
fast-changing technologies, such evaluations
should be RCTs and look at the head-to-head
comparisons of different devices or usual medical
care. Importantly, these studies should encompass
the breadth of patient groups that may benefit
from these devices. Evaluations of the clinical
effectiveness of LVADs should include economic
evaluations. It has become evident from this study
that data for undertaking such studies are very
limited. Data on quality of life, utilities, resources
and costs are not readily available. Also, there is
limited research on the epidemiology of ESHF
and, as a consequence, it is difficult to establish
the possible need and demand for the service. A
systematic review of the epidemiology of ESHF
should be undertaken to assess its potential
impact.
Executive summary
xiiAim
To review systematically the evidence assessing the
clinical and cost-effectiveness of left ventricular
assist devices (LVADs) as a bridge to heart
transplantation (BTT), bridge to recovery (BTR)
and as a long-term chronic support (LTCS) for
people with end-stage heart failure (ESHF). It will
examine the effect of LVADs on the duration and
quality of life (QoL) of people with ESHF, in
addition to providing the opportunity to assess the
number of people who could benefit from the use
of LVADs, the possible demand that may be placed
upon the NHS in England and Wales and the costs
of operating such a service. In addition, the study
will identify the different groups who may benefit
from the use of LVADs. If the systematic review of
economic evaluations shows that there are no
appropriate good-quality economic evaluations, an
economic model relevant to the UK setting will be
developed.
Background
Heart failure is a major health problem in England
and Wales. Its incidence and prevalence continue
to increase, partly owing to an ageing population
but also to a high prevalence of cardiovascular
disease.1 Heart failure is associated with substantial
morbidity and mortality leading to frequent
admissions to hospital and long-term drug costs.
As a consequence, it is a major cost to the NHS
and increasingly the focus of policy initiatives.2,3
Heart failure in England and Wales is usually due
to ischaemic heart disease, but is also caused by
cardiomyopathy (often in young people),
hypertension and myocarditis. It has a wide
clinical spectrum from mild heart failure that has
little effect on a person’s day-to-day life, through
to severe or ESHF, which is associated with major
disability and a poor prognosis (1-year mortality of
50% or more).1,4,5 This is despite advances in drug
treatment which have improved survival, such as
angiotensin-converting enzyme (ACE) inhibitors
and beta-blockers.6
Heart transplantation has become an accepted
form of surgical treatment for patients at risk of
dying from, or incapacitated by, severe or ESHF.7
Allograft transplantation has resulted in actuarial
survival of 81% at 1 year, 65% at 5 years and 45%
at 10 years8 with return to a near normal QoL.9
Scarcity of donor organs means that only about
150 heart transplants are performed annually in
the UK, and that fewer than half of potential
recipients receive an organ.9 Evidence suggests the
potential demand in patients under 60 years old
for transplantation in England and Wales is
between 10 and 15 per million, far exceeding the
supply of donor hearts (2 per million).10 The
supply of donor organs has decreased considerably
in the UK over the last 10 years, which, along with
improvements in the treatment of heart failure,
has led to a decrease in the number of people
admitted to the transplant waiting list and
receiving a heart transplant (Table 1). The growing
disparity between the supply of donor organs and
the need and demand for heart transplantation
has resulted in prolonged time and increasing
mortality on the waiting list. A large number of
potential transplant candidates, estimated at
between 20 and 40%, die whilst on the waiting list
before a donor heart becomes available.11 As a
partial consequence, mechanical circulatory
support has increasingly been considered an
option for patients with severe heart failure.
LVADs are mechanical pumps that are used to
help people with ESHF who suffer from
considerable limitations and discomfort from any
physical activity owing to cardiac disease, despite
the use of maximal medical therapy. The devices
assist the function of the damaged left ventricle
and help to restore normal haemodynamics and
end-organ blood flow.12 Originally developed
during the 1960s in the USA as a BTT, they have
increasingly been thought useful as a BTR, with
the potential for being an LTCS or permanent
alternative to heart transplantation.12 As a BTT,
LVADs provide patients who have ESHF without
irreversible end-organ failure with an increased
chance of survival while awaiting a donor heart,
and also an increased QoL and improved
physiological status at transplantation.12,13
Duration of support to heart transplantation has
extended to nearly 2 years for some people,
although most are supported for a shorter period.
Prolonged mechanical LVAD support in the BTT
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Aim and backgroundsetting has led to the observation that in some
patients the myocardium shows the propensity to
recover, allowing removal of the device rather than
the previously necessary heart transplantation,
termed BTR.12,14 The duration of LVAD support
for those who recover varies from days to up to
1 year. However, usually patients classified as a
BTR have received an LVAD as a BTT, but recover
from the underlying condition before heart
transplantation is possible. The increasing
duration of LVAD implantation in many patients
has led to the question of the suitability of
implantable LVADs for permanent use as an
alternative to heart transplantation, often refered
to as LTCS or destination therapy.12 This may
have the advantage of earlier intervention and
rehabilitation of patients with ESHF, and avoids
the not inconsiderable risks associated with
immunosuppression and organ rejection following
heart transplantation. It may also become possible
to treat those patients who, owing to age or
disease severity, would not have been considered
eligible for heart transplantation in the first
place.15 The use of LVADs as an LTCS is relatively
new and uncertainty remains as to the duration 
of support possible. However, a patient with a
Jarvik 2000 LVAD has survived for over 4 years
and remains alive. The continued development 
of LVADs (e.g. miniaturisation, low power use 
and ease of implantation of axial flow rotary
pumps) and the declining cost and the
improvements in associated care (e.g. cyclosporin
immunosuppression) have made their wider use,
particularly as a permanent replacement, a
reality.10
This chapter examines the extent of the problem
caused by heart failure, particularly ESHF, in
England and Wales. It looks to describe the
condition and its epidemiology, aetiology and
prognosis prior to estimating the possible need
and demand for healthcare from those with ESHF.
The chapter briefly outlines the current service
provided within the NHS in England and Wales to
ESHF patients prior to outlining the interventions
considered within this study.
Heart failure
Definition
Heart failure is a complex clinical syndrome
encompassing several different clinical states
(Table 2). Defining and describing heart failure can
be difficult owing to the lack of agreed and
standardised criteria, with terminology differing
widely. Commonly it is defined as a disease
characterised by a decline in the heart’s ability to
pump blood around a person’s body at normal
filling pressures to meet its metabolic needs.16,17 It
can result from any structural or functional cardiac
disorder that affects the ability of the ventricle to
fill with or eject blood.18 Historically it has been
described through different features such as
duration, initiating mechanism, the ventricle
primarily affected, the clinical syndrome and the
pathophysiological mechanisms, including ‘acute
or chronic’, ‘left or right’, ‘forward or backward’,
‘congestive or non-congestive’, ‘high or low output’
and ‘systolic, diastolic or mixed’ heart failure.19 For
the purposes of assessment and management, the
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TABLE 1 Annual figures for people registered on the heart-only transplant list, the number who died on the heart-only transplant list,
the number of heart-only transplants and the number of donors of hearts and heart/lung blocks in the UK, 1992–2003
Year Transplant list Died Transplants Donors
Active Suspendeda Active Suspendeda Heart only Heart/lung
1992 255 46 78 1 322 278 106
1993 237 28 69 2 302 254 95
1994 253 41 67 1 311 273 131
1995 277 44 60 2 319 246 128
1996 241 62 80 5 276 223 125
1997 230 75 67 2 264 201 104
1998 232 43 58 7 261 206 108
1999 212 52 59 3 227 159 115
2000 134 22 41 1 204 143 81
2001 105 8 32 2 166 142 69
2002 96 3 12 2 158 111 57
2003 99 5 8 1 148 94 74
a Patients suspended are those excluded from the transplant list for health, personal or other reasons.
Source: Pocock P , UK Transplant: personal communication, 2004.distinction between acute and chronic heart failure
(CHF) is usually made. Acute heart failure has a
dramatic clinical onset with an acutely dyspnoeic
patient (extreme difficulty in breathing)
demonstrating visible signs of cardiovascular
insufficiency (inadequate operation of
cardiovascular system) such as tachycardia (fast
heart beat), pulmonary or peripheral oedema
(fluid retention in the lungs and extremities of the
body) and under perfusion of systemic organs
(inadequate blood flow through the body). Chronic
heart failure is a more subtle condition, which may
have a more gradual onset. It is characterised by
the onset and persistence of left ventricular
dysfunction and pathophysiological changes to
other related organs that produce symptoms and
limit exercise. Often people will develop chronic
heart failure and suffer acute exacerbations.
When heart failure occurs, the heart usually tries
to compensate through changes in systemic
vascular resistance and redistribution of blood flow
(changes in blood pressure and flow).17 Although
the heart may be capable of maintaining cardiac
output at rest through such changes, it is unlikely
to be able to cope with the increased demands
that may result from normal exercise. Despite the
heart’s attempts to adapt, the demands and
stresses on the cardiovascular and related systems,
such as the renal and hepatic systems, tend to lead
to further decline and, without effective treatment,
to severe heart failure (decompensated or ESHF)
and eventual death. 
Although heart failure encompasses several
different clinical conditions, it does have a well-
recognised clinical pattern. As already indicated,
the key features of heart failure are that it is
initiated by a reduction in effective cardiovascular
(usually left ventricular) functional reserve, linked
with symptoms either at rest or at an unexpectedly
low level of exertion and associated with
characteristic pathophysiological changes
(including biochemical, hormonal, metabolic or
functional) in many disparate organ systems.19
Generally, it may manifest itself clinically through
patients suffering breathlessness (dyspnoea),
weakness or fatigue or through fluid retention in
tissues (peripheral oedema). 
As a clinical syndrome, heart failure has many
different causes. The main underlying cause of
heart failure in the UK and most other western
countries is coronary heart disease, which accounts
for approximately two-thirds of cases.2,18,21 The
remaining cases may have a non-ischaemic cause
of heart failure such as hypertension, valvular
disease, myocardial toxins or myocarditis, or may
have no identifiable cause such as idiopathic
dilated cardiomyopathy.2,18
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TABLE 2 International Classification of Diseases Version 1020
Code Disease
I50 Heart failure
Excludes: complicating: 
  abortion or ectopic or molar pregnancy (O00–O07, O08.8)
  obstetric surgery and procedures (O75.4) 
  due to hypertension (I11.0)
  with renal disease (I13.–)
  following cardiac surgery of due to presence of cardiac prosthesis (I97.1) 
  neonatal cardiac failure (P29.0)
I50.0 Congestive heart failure
Congestive heart disease
Right ventricular failure (secondary to left heart failure)
I50.1 Left ventricular failure With mention of heart disease
Acute oedema of lung NOS or heart failure
Acute pulmonary oedema
Cardiac asthma
Left heart failure
I50.9 Heart failure, unspecified
Biventricular failure
Cardiac, heart or myocardial failure NOS
NOS, not otherwise specified.Given the complexity of the syndrome and the
differing underlying causes and subsequent
treatment options, a range of disease
classifications have been developed to assess the
severity and impact of heart failure and its
treatment on patients’ lives.22 Most consider
aspects of QoL, although they are often limited to
measuring symptoms, functioning or depression.
A widely used measure is the New York Heart
Association (NYHA) functional classification of
heart failure (Table 3). The classification relies on
the assessment by the clinician of the occurrence
of symptoms of heart failure that result from
physical exercise, with the patient graded from I
to IV on their degree of impairment. Patients in
NYHA Class I have cardiac disease but are not
limited in the activities they can undertake and do
not suffer from the usual symptoms of fatigue,
palpitation or anginal pain following ordinary
exercise. Slight limitations are placed on NYHA
Class II patients due to their cardiac condition.
Although comfortable at rest or with mild physical
exertion, ordinary physical exercise will result in
the characteristic symptoms. Patients who
deteriorate to NYHA Class III are unable to
undertake any physical exercise without suffering
fatigue, palpitation, dyspnoea or anginal pain.
With increased severity of heart failure to NYHA
Class IV, patients experience discomfort with any
physical activity and will require complete rest or
confinement to bed. Symptoms of cardiac
insufficiency or of the anginal syndrome affect
patients at rest and are accentuated with physical
effort. Patients in NYHA Class IV are classified as
suffering from ESHF and are candidates for heart
transplantation or mechanical support.
Other classifications have been developed to take
account of the evolution and progression of heart
failure. The American College of Cardiology and
the American Heart Association Task Force on
Practice Guidelines developed a four-stage
classification of heart disease that should be used in
conjunction with the NYHA classification (Table 4).18
In stage A, patients are at high risk for developing
heart failure but have no structural disorder of the
heart. These patients have identified risk factors of
the disease, such as a familial or personal history of
predisposing risk factors (e.g. alcohol abuse) or
other diseases (e.g. rheumatic fever or
cardiomyopathy). Patients in stage B have
developed structural heart diseases that are strongly
associated with heart failure, although they have
not shown any signs or symptoms [e.g. previous
myocardial infarction (MI)]. Those with current or
prior symptoms of heart failure associated with
underlying structural heart disease are classified as
being in stage C. For example, these patients may
suffer from breathlessness or fatigue following left
ventricular systolic dysfunction or are undergoing
treatment for prior symptoms of heart failure. In
stage D, patients have advanced structural heart
disease with recognised symptoms of heart failure at
rest despite maximal medical therapy. These
patients are suffering from refractory ESHF and
require specialised interventions such as heart
transplantation, circulatory assist device support,
continuous intravenous support for symptom relief
or hospice care. 
Epidemiology of heart failure
Despite the increasing attention to heart failure,
particularly in Europe and the USA, difficulties
persist in developing an understanding of its
epidemiology.23 Differences in the definition of
heart failure and problems in identifying clear
diagnostic criteria, and also difficulties in devising
acceptable research criteria, have meant that
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TABLE 3 NYHA classification of heart failure22,23
Class I No limitation on activities: suffers from no symptoms from (performance of) ordinary activities. Patients with
cardiac disease but without resulting limitations on physical activities. Ordinary physical activity does not
cause fatigue, palpitation, dyspnoea or anginal pain
Class II Slight limitation on physical activities: comfortable at rest or mild exertion. Patients with cardiac disease
resulting in slight limitation on physical activities. They are comfortable at rest. Ordinary physical activity
results in fatigue, palpitation, dyspnoea or anginal pain
Class III Marked limitation on physical activities: comfortable only at rest. Patients with cardiac disease resulting in
marked limitations on physical activities. They are comfortable at rest. Less than ordinary physical activity
causes fatigue, palpitation, dyspnoea or anginal pain
Class IV Discomfort with any physical activity; should be completely rested or confined to bed. Patients with cardiac
disease resulting in an inability to carry out any physical activity without discomfort. Symptoms of cardiac
insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken,
discomfort is increasedclinical surveys of heart failure in the general
population are uncommon.24 In addition to these
factors, differences in sampling methods,
geographical factors and case finding methods
have rendered comparisons, whether regionally,
nationally and internationally, difficult.25–27
Although mortality, hospital admissions and
primary care data are often used to examine
disease epidemiology, they are poor surrogates for
assessing the incidence, prevalence and aetiology
of heart failure owing to the poor validity of
clinical diagnosis and the opportunity for
miscoding of routine patient data and death
certificates. Notwithstanding these difficulties,
several studies in the USA, UK and other
European countries have examined the
epidemiology of heart failure.28–36
Incidence
The incidence of heart failure appears to vary,
with rates differing depending on the definition of
heart failure used (i.e. whether all causes of heart
failure or the major causes such as congestive
heart failure), the demographic composition and
the socio-economic structure of the population
studied. In a review of the trends in the
epidemiology of congestive heart failure,
Dominguez and colleagues35 found that the
general incidence of congestive heart failure
ranged from one to 10 cases per 1000 individuals
per year. It was evident that incidence rates varied
between age and sex groups (Table 5). More recent
results from the Framingham Heart Study and the
Rochester study have confirmed these findings.
Lloyd-Jones34 reports that the age-adjusted
incidence of heart failure from the Framingham
Heart Study during the 1980s was estimated at 
7.2 cases per 1000 in men and 4.7 cases per 1000
women aged ≥45 years. Senni and colleagues33
assessed the incidence of congestive heart failure
in a community in Rochester (USA) in 1981 and
1991. The age- and sex-adjusted incidence of
congestive heart failure was 2.8 per 1000 person-
years [standard error (SE) 0.28; 95% confidence
interval (CI) 2.2 to 2.3; upper CI as reported in
study but is incorrect] in 1981 and 2.8 per 1000
person-years (SE 0.24; 95% CI 2.3 to 3.3) in 1991. 
Studies have shown similar differences in the
incidence of heart failure in the UK. Cowie and
colleagues24 examined the incidence and aetiology
of heart failure in a community of 150,582 people
attending 31 GP practices (82 GPs) in Hillingdon,
South London (UK) in 1996. During the
20 months of the study, 220 new cases of heart
failure were diagnosed among people aged
25 years and over, equating to a crude incidence
of 1.3 cases per 1000 population per year. The
incidence varied by age group, ranging from 0.02
cases per 1000 population per year for people
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TABLE 4 Stages of heart failure18
Stage Description Examples
A Patients at high risk of developing heart failure  Systemic hypertension; coronary artery disease; 
because of the presence of conditions that are  diabetes mellitus; history of cardiotoxic drug therapy or 
strongly associated with the development of heart  alcohol abuse; personal history of rheumatic fever; 
failure. Such patients have no identified structural  family history of rheumatic fever; family history of 
or functional abnormalities of the pericardium,  cardiomyopathy
myocardium or cardiac valves and have never 
shown signs or symptoms of heart failure
B Patients who have developed structural heart disease  Left ventricular hypertrophy or fibrosis; left ventricular 
that is strongly associated with the development of  dilatation or hypocontractility; asymptomatic valvular 
heart failure but who have never shown signs or  heart disease; previous MI
symptoms of heart failure
C Patients who have current or prior symptoms of heart  Dyspnea or fatigue due to left ventricular systolic 
failure associated with underlying structural heart  dysfunction; asymptomatic patients who are 
disease undergoing treatment for prior symptoms of heart
failure
D Patients with advanced structural heart disease and  Patients who are frequently hospitalised for heart 
marked symptoms of heart failure at rest despite  failure or cannot be safely discharged from the hospital; 
maximal medical therapy and who require specialised  patients in the hospital awaiting heart transplantation; 
interventions patients at home receiving continuous intravenous
support for symptom relief or being supported with a
mechanical circulatory assist device; patients in a
hospice setting for the management of heart failureaged 25–34 years to 11.6 cases per 1000
population per year for people aged ≥85 years
(Table 5). The median age at presentation was 
76 years (Table 5). Also, the incidence of heart
failure differed significantly between males and
females. Males had a higher incidence than
females for those groups aged ≥45 years 
[age-standardised incidence ratio 1.75 
(95% CI 1.34 to 2.29), p < 0.0001]. 
Johansson and colleagues38 found similar age and
sex variations in incidence of heart failure in the
UK, although the actual rates were higher. Using
the UK General Practice Research Database, they
identified patients aged 40–84 years who were
newly diagnosed with heart failure in 1996
(excluded people with previous diagnosis of heart
failure or cancer and pregnant women). Of the
689,467 people included in the study, 3123 had a
new diagnosis of heart failure. Of these, 1200 were
randomly sampled to validate their diagnosis, with
938 confirmed. The incidence of heart failure was
4.2 per 1000 person-years (4.4 per 1000 person-
years in men and 3.9 per 1000 person-years in
women). The relative risk (RR) of heart failure was
2.1 (95% CI 1.7 to 2.6) for men compared with
women <65 years old and 1.3 (95% CI 1.2 to 1.4)
aged >65 years. The incidence of heart failure
increased with age. Lower proportions of heart
failure patients were aged 40–49 years (males 3.5%
and females 0.9%) than those aged 70–79 years
(males 46.8% and females 52.1%).
Prevalence
Dominguez and colleagues’35 review of the
epidemiology of congestive heart failure showed
that the unadjusted prevalence rates in Europe
and the USA ranged from 3 to 20 per 1000. As
with the incidence of heart failure, prevalence rates
vary with age (Table 6). Prevalence rates increase
from around 20 per 1000 in people aged <45 years
to 50 per 1000 in those aged 70–79 years and over
100 per 1000 in people >80 years old. Recent
estimates from the Framingham Heart Study in
the USA show similar prevalence rates, with rates
in the 1980s of 24 per 1000 men and 25 per 1000
women aged ≥ 45 years.34 Other international
studies have shown similar prevalence rates. A
cross-sectional survey of 19,877 patients seeking
medical care in outpatient clinics in Poland aged
>65 years39 identified 53% with heart failure, with
higher rates among older age groups (48% of men
and 45% of women aged 65–69 years and 69% of
men and 68% of women aged >85 years). A study
in Australia that assessed the prevalence of chronic
heart failure in patients aged ≥ 60 years attending
general practitioners found that 13.2% suffered
the condition.40 As previously discussed, some of
the variability in these studies may result from the
methods of data acquisition and diagnostic criteria.
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TABLE 5 Incidence of heart failure per 1000 population
Study Age (years) Men Women Persons
Framingham34 45–54 2.0 1.0
55–64 4.0 3.0
65–74 8.0 5.0
75–84 14 13
Rochester37 45–54 0.8
55–64 4.0 1.3
65–74 13.2 7.2
0–74 0.7 1.6 1.1
Goteborg31 50–54 1.5
55–64 4.3
61–67 10.2
London, UK24 25–34 0.00 0.04 0.02
35–44 0.2 0.2 0.2
45–54 0.3 0.1 0.2
55–64 1.7 0.7 1.2
65–74 3.9 2.3 3.0
75–84 9.8 5.9 7.4
>85 16.8 9.6 11.6
Total 1.4 1.2 1.3
Source: adapted from Dominguez LJ, Parrinello G, Amato P , Licata G. Trends of congestive heart failure epidemiology:
constrast with clinical trials results. Cardiologia 1999;44:801–8.Within the UK, more recent estimates of population
prevalence rates for heart failure have tended to
come from small sample cross-sectional surveys.
Davies and colleagues36 investigated the prevalence
of heart failure and left ventricular systolic
dysfunction in the population served by a sample of
GP practices in the West Midlands (UK) between
1995 and 1999. In a random sample of 6826
people aged ≥ 45 years, 3960 people were screened
using patient history, examination,
electrocardiography and echocardiography.
Seventy-two people, 1.8% (95% CI 1.4 to 2.3), had
definite left-ventricular systolic dysfunction.
Prevalence increased with age and was higher in
males (see Table 6). Morgan and colleagues41
undertook a similar study to look at the prevalence
and characteristics of heart failure (left ventricular
dysfunction) within general practice in the UK,
examining 817 patients between the ages of 70 and
84 years at a four-centre GP practice in Poole,
Dorset (UK). Overall prevalence in this population
was 7.5% (95% CI 5.8 to 9.5). Left ventricular
dysfunction was significantly (p < 0.001) more
prevalent among men (12.8%; 95% CI 9.6 to 16.6)
than women (2.9%; 95% CI 1.8 to 5.0). When
considering the severity of dysfunction, the
prevalence of ‘mild’ dysfunction was 5.0%,
‘moderate’ dysfunction 1.6% and ‘severe’
dysfunction 0.7%. In a study of 16 general practices
in England, Davis and colleagues42 studied 1062
patients with previous MI, angina, hypertension or
diabetes to assess the prevalence of systolic
dysfunction and heart failure. Heart failure, defined
as symptoms of dyspnoea and evidence of cardiac
dysfunction, was reported in 16% (95% CI 11.6 to
21.2%) of patients with previous MI, 8.4% (95% CI
5.6 to 12.0%) in those with angina and 7.7% (95%
CI 4.5 to 12.2%) in those with diabetes. In a survey
of 10,022 registered patients in one primary care
practice in Scotland,43 191 patients with heart
failure were identified, relating to a prevalence rate
of 19 per 1000 population. This survey was based
on those with recorded symptoms and/or receiving
treatment and states that the estimates will have
missed symptomless patients and those with early
heart failure not requiring treatment. Heart failure
was most prevalent among the older age groups
with a mean age of 76.9 years. In fact, the majority
of cases were among those aged ≥ 65 years for
whom the prevalence was 90 per 1000.
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TABLE 6 Prevalence of heart failure (per 1000 individuals)
Study Age (years) Men Women Total
Framingham34 50–59 8 8 7.4
80–89 68 79 7.7
Tecumseh44 5.9 8.9 7.4
Evans County30 24.8 17.8 21.2
NHANES-I28 25–54 8 13 11
55–64 45 30 37
65–74 49 43 45
Rochester37 35–54 0 2 1
55–64 5 5 5
65–74 23 0 12
>75 69 80 76
Goteborg31 70 110 80 93
75 170 110 136
London, UK29 <65 0.6
>65 28
Italy32 55–59 60
60–64 114
West Midlands, UK36 45–54 6 0 3
55–64 30 5 18
65–74 48 11 29
75–84 49 26 37
≥ 85 87 0 30
Total 30 7 18
Source: adapted from Dominguez LJ, Parrinello G, Amato P , Licata G. Trends of congestive heart failure epidemiology:
constrast with clinical trials results. Cardiologia 1999;44:801–8.Heart failure: aetiology and
patient characteristics
As already indicated, people with heart failure in
the UK and other developed countries have
tended to suffer from coronary heart disease or
hypertension, although many will have
experienced several causative factors. McCallum
and colleagues43 found that 58.1% of patients with
heart failure registered with a general practice in
Scotland were suffering from coronary heart
disease, while 21.9% had hypertension. Morgan
and colleagues,41 in a study of elderly heart failure
patients attending a GP practice in Dorset (UK),
showed through multivariate regression analysis
that the strongest predictors of heart failure were a
previous diagnosis of heart failure [odds ratio
(OR) 5.8, 95% CI 2.9 to 11.5, p < 0.001), being
male (OR 5.1; 95% CI 2.6 to 10.1, p < 0.001) and
a previous diagnosis of either MI (OR 2.6; 95% CI
1.3 to 5.2, p = 0.007), stroke (OR 2.6; 95% CI 1.1
to 6.4, p = 0.034) or angina (OR 2.1; 95% CI 1.1
to 4.2, p = 0.031). Similar findings were described
by Cowie and colleagues24 in a study of heart
failure in London (UK). Coronary heart disease
was thought to be the most common aetiology
(36% of patients), although half of these also
suffered from hypertension (51%). In fact,
hypertension was the primary aetiology of heart
failure in 31% of patients. Some 34% of patients
could not have an aetiology allocated at review.
The aetiology of patients did not differ
significantly by sex (p = 0.11) or age (p = 0.65).
Johansson and colleagues38 examined the
characteristics and aetiology of 938 patients aged
40–84 years sampled from the UK General
Practice Research Database who were newly
diagnosed with heart failure, comparing them with
a similar age and sex cohort of 5000 controls
without heart failure. A history of smoking was
associated with an increased risk of heart failure.
Smokers (RR 2.0; 95% CI 1.6 to 2.5) and ex-
smokers (RR 1.5; 95% CI 1.2 to 2.0) were more
likely to suffer from heart failure than non-
smokers. Also, heart failure patients were more
likely to suffer from obesity [body mass index
(BMI) ≥ 30] (RR 2.1; 95% CI 1.5 to 2.8). Although
there were several prior comorbities associated
with heart failure, coronary heart disease had the
strongest association (RR 3.2; 95% CI 2.7 to 3.7).
Davies and colleagues36 examined the
epidemiology of patients aged >45 years with
heart failure identified in a cross-sectional
population survey among general practices in the
West Midlands, UK. The 92 patients with definite
heart failure were predominantly male (64%) and
had smoked previously (62%). These patients had
tended to suffer from angina (41%), hypertension
(39%), MI (30%) or diabetes (13%). In addition,
29% had a previous family history of MI before
the age of 65 years.
Prognosis of heart failure
Heart failure often has a poor prognosis,45 with
survival rates worse than for breast and prostate
cancer. Despite grading heart failure by severity of
symptoms, it is difficult to specify a prognosis for
people with heart failure as they have a high risk
of sudden death. Annual mortality for those with
heart failure ranges from 10% to >50% depending
on severity.46,47 Approximately 50% of patients
with a diagnosis of heart failure may die within
4 years and in patients with severe heart failure
>50% may die within 1 year.33,46–48 Cowie and
colleagues stated that 5-year mortality can range
from 26 to 75%.48 There is evidence that people
with heart failure have a worse QoL than people
with most other common medical conditions.
Psychosocial function is impaired with over one-
third experiencing severe and prolonged
depressive illness.
Epidemiology of end-stage heart
failure
The epidemiology of ESHF has received less
attention than that given to heart failure. As
already discussed, the lack of information reflects
the difficulties in establishing a definition,
diagnostic criteria and measures of severity for
heart failure. Information on incidence and
prevalence of ESHF originates from studies of
heart failure that have assessed the severity of
disease through measures such as the NYHA
functional classification. Although these studies
provide some indication of the incidence and
prevalence of ESHF, caution should be exercised
in interpreting the information owing to
differences in definitions used for heart failure,
the populations included, the study designs
employed and the measures of severity applied.
Incidence
Limited information was available on the
incidence of ESHF (Table 7). Johansson and
colleagues38 examined the severity of heart failure
in 805 of 938 newly diagnosed patients aged
40–84 years sampled from the UK General
Practice Research Database (for 133 patients
severity was unknown). The severity of heart
failure was assessed through the NYHA functional
Aim and background
8classification, with ESHF defined as NYHA Class
IV. Some 16% of patients were identified as NYHA
Class IV suffering the severe symptoms of ESHF.
Of the remaining patients, 37% were in NYHA
Class III suffering marked limitations on activity,
43% were in Class II with slight limitations on
their activities and 5% were in NYHA Class I
suffering no limitations. A slightly higher
proportion of males (17.2%) than females (14.9%)
were classified as Class IV. In a study in the USA of
the incidence of congestive heart failure, Senni
and colleagues33 found that 71% of patients in
1981 and 57% in 1991 were classified as NYHA
Class III or IV. 
Prevalence
The studies of the prevalence of ESHF have
assessed different types of heart failure and
patient groups and, as a consequence, have shown
variations in rates (Table 7). Two surveys of the
management of heart failure in primary and
secondary care within Europe provide an
indication of the prevalence of different severities
of heart failure.49,50 In an international survey of
clinical practice in primary care (IMPROVEMENT
Survey) among 15 European countries undertaken
by Cleland and colleagues,49 primary care
physicians kept a log of all patients they saw with
heart failure or who had a MI with or without
heart failure. Of the 11,062 patients included in
the study, 8361 (76%) had symptoms of heart
failure and were reported to suffer breathlessness,
fatigue and ankle swelling. Some 1144 (10%)
people were thought to have severe symptoms of
heart failure. In the UK, 358 of the 559 patients
surveyed (60%) had symptoms of heart failure and
were reported to have breathlessness, fatigue and
ankle swelling, with 65 (11%) having severe
symptoms. Although the study provides an
indication of the proportion of people with heart
failure who have severe symptoms, it might
provide an overestimate as these patients tend to
visit primary care more frequently and
practitioners may have underreported those with
less severe symptoms whilst their diagnosis may
have been uncertain. In a second international
survey, Cleland and colleagues examined patterns
of treatment and aspects of the characteristics and
outcomes of patients with known or suspected
heart failure admitted to hospital.50 The survey
recorded deaths and discharges from general
medical, cardiology, cardiac surgery and care of
the elderly wards of patients with a discharge
diagnosis of acute MI or new onset atrial
fibrillation or who had diabetes. Inclusion was
based on patients having either a clinical diagnosis
of heart failure on admission or recorded on
hospital notes in the last 3 years, administration of
loop diuretics for any reason other than renal
failure in the 24 hours prior to discharge or
administration of treatment for heart failure or
major ventricular dysfunction within 24 hours of
death or discharge. Some 46,788 deaths and
discharges were examined, with 24% meeting the
criteria for enrolment in the survey. Of these
patients, 3260 who had undergone treatment and
survived were asked to attend for a 12-week follow-
up interview and physical examination. The
follow-up survey found that 26% of patients were
in NYHA Class III or IV, although in the UK the
figure was higher with 40% in NYHA Class III or
IV. The study may have overestimated the extent
of heart failure owing to the broad definitions
used to classify the condition and the exclusion of
certain specialties. 
Davies and colleagues36 examined the
epidemiology of patients aged >45 years with
heart failure identified in a cross-sectional
population survey among general practices in the
West Midlands, UK. Of the 3960 people surveyed,
only 2% of patients were in NYHA Class IV
suffering from severe symptoms of heart failure at
rest. Similarly, 2% of patients experienced marked
limitations on their physical activity and were
classified as being in NYHA Class III. The
majority of patients were in NYHA Class I (82%)
or Class II (14%), incurring no or slight
limitations on their activities. Of the 92 patients
with definite heart failure, 16% were in Class IV
and 15% in Class III. In another study of patients
with previous MI, angina, hypertension or
diabetes in 16 general practices in England, Davis
and colleagues42 found similar prevalence rates for
ESHF, with 3% of patients in Class IV and 6% in
Class III. Morgan and colleagues41 assessed the
severity of heart failure among patients aged
70–84 years attending GP practices in Poole,
Dorset (UK), undertaking a qualitative assessment
of left ventricular dysfunction. Although the
majority of patients were thought to have normal
left ventricular function (92.7%) or mild
dysfunction (5%), 1.6% had ‘moderate’ dysfunction
and 0.7% had ‘severe’ dysfunction. Similar rates of
ESHF were found in a cross-sectional survey of
patients aged ≥ 65 years in Poland, with 6% of
men and 4% of women in NYHA Class IV and
32% of men and 30% of women in Class III.39
Studies in Italy of elderly hospitalised patients or
patients attending hospital due to heart failure
showed a higher prevalence of ESHF. Rengo and
colleagues51 found that 9.6% of patients in a
cohort of elderly hospitalised patients (aged
≥ 65 years) were in NYHA Class IV and 24.4% in
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examined the characteristics of patients with
suspected or known heart failure attending 395
cardiology units, found that 12.6% of patients were
in NYHA Class IV and 36% in Class III. Albanese
and colleagues’53 study of CHF patients admitted
to a hospital in Italy found that 50% were in
NYHA Class IV, 28% in Class III and 22% in Class
I or II.
End-stage heart failure and the
needs and demands for healthcare
Despite the lack of evidence on the epidemiology
of heart failure, the information on the incidence
and prevalence of ESHF found provides some
indication of the likely need and demand for
treatment with either heart transplantation or
mechanical support. The review of the
epidemiology of heart failure showed widely
differing incidence and prevalence rates
depending on the nature of the study and the
structure of the populations examined. Using
studies of the incidence and prevalence of heart
failure and population estimates relevant to
England and Wales, it was possible to estimate 
the people who might suffer from ESHF 
(Table 8). Estimates of prevalence suggest that
there would probably be between 250,000 and
400,000 people with heart failure in England 
and Wales, with approximately 7000–8000 people
with ESHF. Incidence rates suggest that there
would be between 50,000 and 100,000 new 
cases of heart failure annually, with approximately
10,000–15,000 new cases of ESHF. The 
disparity in the prevalence and the incidence of
ESHF reflects the poor prognosis for sufferers.
The majority of people with ESHF have the
condition for a short period and die, with 
only a small number receiving treatment and
surviving.
Estimates from the incidence and prevalence of
ESHF provide a crude estimate of the population
that may benefit from the different treatment
options available, specifically heart transplantation
or support with a mechanical device. Identifying
those who would benefit from an LVAD as a BTT,
BTR or LTCS is more difficult. UK transplant and
waiting list figures give some indication of the
potential numbers of LVAD recipients, but these
do not represent the actual need. With limited and
decreasing numbers of organ donors and, as a
consequence, the managed and selective nature of
transplant waiting lists, these data provide a
significant underestimate of actual demand, let
alone the actual need. However, attempts have
Aim and background
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TABLE 7 Percentage of patients with heart failure by severity classifications (NYHA functional classification unless stated otherwise)
Study NYHA classification
I II III IV
Incidence
Johansson et al., 200138 Persons 4.6 42.7 36.6 16.0
Senni et al., 199933 1981 29 71
1991 43 57
Prevalence
Davies et al., 200136 Persons ≥ 45 years 82 14 2 2
Davis et al., 200242 Persons 59 32 6 3
Rengo et al., 199651 Persons ≥ 65 years 25.6 40.5 24.4 9.6
Tavazzi et al., 199752 Persons 6.9 43.8 36.0 12.6
Albanese et al., 199953 Persons 3 19 28 50
Rywik et al., 200039 Men 14.8 47.8 31.7 5.7
Women 12.4 53.4 30.0 4.2
Morgan et al., 199941a Persons 70–84 years 92.7 5.0 1.6 0.7
Cleland et al., 200249b Persons 12 34 31 10
Cleland et al., 200350 Persons 36 37 26
a Severity was assessed as either no, mild, moderate or severe dysfunction rather than NYHA functional classification I, II, III
and IV.
b Severity was assessed as either asymptomatic, mild, moderate or severe rather than NYHA functional classification I, II, III
and IV, with 12% having no severity recorded and 3% dead.been made to try to identify the extent of the
problem presented by ESHF.
In a study of cardiac replacement, Evans56
examined the need and demand for and supply of
heart transplants within the USA. The study
identified six key concepts in defining the need
and demand for heart transplantation and the
relationships that exist between need, demand and
supply (Table 9). Need for heart transplantation
was identified as those people with diagnoses of
specific cardiac conditions as the primary cause of
death that were considered suitable for heart
transplantation (Table 10). It is likely that this may
represent an overestimate as people may have had
other conditions that would have rendered them
unsuitable candidates for transplantation or they
may have died suddenly without opportunity for
transplant. The actual supply of donor hearts was
recognised by Evans56 to represent only a fraction
of the potential supply, up to 50%, owing to the
failure to obtain consent from relatives. Based on
these relationships, Evans56 was able to estimate
the need, demand and supply within the USA
(Table 11).
Applying the general principles established by
Evans,56 estimates were made for the UK of the
need and demand for heart transplantations using
two different approaches. The first approach
employed the definitions of need, demand and
supply (Table 9) and the mathematical relationships
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TABLE 8 Estimate of the number of patients with ESHF in England and Wales (NYHA functional classification unless stated otherwise)
Incidence/ Population in  No. of heart  Percentage of No. of ESHF 
prevalence of  England and  failure patients heart failure  patients
heart failure  Wales  patients in 
(per 1000 people) (mid-2002)54 NYHA Class IV
Incidence
UK – persons  4.2 23,710,000 99,582 16.0 15,933
(40–84 years)38
UK – persons  1.3 52,455,300 68,192 16.055 10,911
(all ages)24
Prevalence
UK – persons  18 20,944,000 376,992 2 7,540
(>45 years)36
UK – persons  75 5,059,000 379,425 0.7 2,656
(70–84 years)41a
UK – persons  0.6 44,069,000 26,441 342 7,837
(<65 years)
Persons 28 8,386,000 234,808
(≥ 65 years)35
a Severity was assessed as either no, mild, moderate or severe dysfunction rather than NYHA functional classification I, II, III
and IV.
TABLE 9 Definitions of heart transplant concepts56
Unrecognised need – the number of suitable people never placed on the transplant waiting list
Unmet demand – the number of people awaiting transplantation plus the number of people who die while on the waiting
list
Met demand – the number of transplantations performed
Unmet need – the number of suitable people never placed on the transplant waiting list plus the number of people awaiting
transplantation plus the number of people who die while on the waiting list
Total demand – the number of people awaiting transplantation plus the number of people who die while on the waiting list
plus the number of transplantations performed
Total need – the number of people never listed for transplantation plus the number of people awaiting transplantation plus
the number of people who die on the waiting list plus the number of transplantations performedbetween the different categories in the USA to
produce relative weights (Table 11) that could be
applied to known variables, such as the number of
heart transplants, to estimate the need, supply and
demand in the UK. Heart transplant data for the
UK in 1995 (Table 11) were used so as to be
consistent with the base year used by Evans. With
319 people receiving a heart transplant, it was
estimated that there could be some 6782 people
who could need a heart transplant, although only
893 people would demand treatment. This
suggests an unmet demand of 574 people and
unmet need of 6463 people. When compared with
the estimates of the prevalence of ESHF (Table 8),
it is evident that the estimates for the UK from
populating the model developed by Evans are
relatively similar at around 7000 patients. A
second set of estimates were calculated using heart
Aim and background
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TABLE 10 Diagnoses at death for which cardiac transplantation could have been indicated57
ICD-9 code Descriptiona
164.1 Malignant neoplasm of the heart
394.0 Mitral valve stenosis
394.1 Rheumatic mitral insufficiency
394.2 Mitral stenosis with insufficiency
394.9 Other and unspecified mitral valve disease
395.0 Rheumatic aortic stenosis
395.1 Rheumatic aortic insufficiency
395.2 Rheumatic aortic stenosis with insufficiency
395.9 Other and unspecified rheumatic aortic diseases
396 Diseases of mitral and aortic valves
398.0 Rheumatic myocarditis
398.9 Other and unspecified rheumatic heart diseases
414.0 Coronary atherosclerosis
414.1 Aneurysm of the heart
414.8 Other specified forms of chronic ischaemic heart disease
424.1 Aortic valve disorders
425.0 Endomyocardial fibrosis
425.4 Other primary cardiomyopathies
428.0 Congestive heart failure
428.1 Left heart failure
428.9 Heart failure, unspecified
429.0 Myocarditis, unspecified
429.1 Myocardial degeneration
429.3 Cardiomegaly
a Each condition must be listed as the primary cause of death. Excludes indications for paediatric heart transplantation.
TABLE 11 UK projections of Evans’ need, demand and supply
USA56 Relative weight UKa
1995
1995 2003 2000
Total need 50,204 21.26 6,782 3,146 34,329b
Total demand 6,599 2.80 893 414 402c
Unmet demand 4,238 1.80 574 266 198c
Transplants (met demand) 2,361 1.00 319c 148c 204c
Actual donor supply 2,506 1.06 338 157 224c
Potential donor supply 8,749 3.71 1,183 549 756
Unmet need 47,843 20.26 6,463 2,998 34,125
Waiting list 3,468 1.47 469 218 156c
Unrecognised need 43,605 18.47 5,892 2,734 33,927
a Figures in bold are from published sources whereas those in italics were estimated.
b Total need for 2003 relates to England and Wales.58
c Source: Pocock P , UK Transplant, personal communication, 2004.transplant data for the UK for 2003. As the
number of heart transplants in the UK had
decreased in 2003 to <50% of the number
undertaken in 1995, estimates of need and
demand have consequently fallen to unrealistic
levels. 
A second approach was taken to estimate need,
demand and supply for heart transplants. Using
the definitions identified by Evans, data were
collected to populate the different components of
the model. Using diagnoses at death identified by
Evans as the main indications for adult heart
transplantation, it was estimated that 34,329
people in England and Wales in 2000 would need
a heart transplantation (Table 12). In the UK in
2000, 402 demanded a heart transplant with only
204 undergoing a transplant, meaning an unmet
demand of 198 people and an unmet need of over
34,000 people (Table 11). 
Some caution should be exercised when
interpreting these estimates. First, opinions may
differ as to the underlying conditions that might
identify people as potential candidates for heart
transplantation and the proportions of these
people who may actually meet the criteria for
heart transplantation or mechanical support.
Second, Evans used mortality data based on the
primary cause of death to estimate the total need
for heart transplantations. In England and Wales,
mortality data are based on the underlying cause
of death rather than the primary cause and, as a
consequence, it is likely that the estimates for
these conditions in England and Wales, will far
exceed those expected given the definition used in
the USA. Third, the estimates of need and
demand are based on experiences within the USA,
which operates a different health economy to that
within the UK; as a consequence, it is likely that
the relationship between the need, demand and
supply of heart transplantation will differ. Fourth,
the estimates are of the need and demand for
heart transplantation. Although these patients
may also benefit from the use of mechanical
devices, other people who do not meet the criteria
for transplantation may benefit from mechanical
devices. It is difficult to estimate the number of
patients who would fall into this category,
although they are likely to be a relatively small
group of people with ESHF who are considered
too old for transplantation or whose condition has
worsened to the extent that they would not survive
heart transplantation. Fifth, the UK government is
endeavouring to increase organ donations, but
although this may increase supply, current practice
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TABLE 12 Number of deaths in England and Wales in 2000 from conditions identified by Evans56 as the main indications for adult
heart transplantation58
ICD-9 Description Male Female Total
164.1 Malignant neoplasm of the heart 6 4 10
394.0 Mitral valve stenosis 24 155 179
394.1 Rheumatic mitral insufficiency 4 8 12
394.2 Mitral stenosis with insufficiency 1 5 6
394.9 Other and unspecified mitral valve disease 213 552 765
395.0 Rheumatic aortic stenosis 7 6 13
395.1 Rheumatic aortic insufficiency 1 0 1
395.2 Rheumatic aortic stenosis with insufficiency 0 0 0
395.9 Other and unspecified rheumatic aortic diseases 5 5 10
396 Diseases of mitral and aortic valves 79 259 338
398.0 Rheumatic myocarditis 0 0 0
398.9 Other and unspecified rheumatic heart diseases 30 102 132
414.0 Coronary atherosclerosis 11,049 6,733 17,782
414.1 Aneurysm of the heart 41 15 56
414.8 Other specified forms of chronic ischaemic heart disease 564 423 987
424.1 Aortic valve disorders 1,103 1,146 2,249
425.0 Endomyocardial fibrosis 1 0 1
425.4 Other primary cardiomyopathies 834 427 1,261
428.0 Congestive heart failure 2,264 4,011 6,275
428.1 Left heart failure 553 878 1,431
428.9 Heart failure, unspecified 335 567 902
429.0 Myocarditis, unspecified 112 92 204
429.1 Myocardial degeneration 309 1,026 1,335
429.3 Cardiomegaly 211 169 380
Total 17,746 16,583 34,329suggests that any increase is unlikely to be
substantial. Patterns of heart donation have been
in decline over the last 20 years in England and
Wales (see Table 1). Sixth, the intention was to
assess the likely need, demand and supply for
heart transplantation in England and Wales. The
UK Transplant Authority publishes heart
transplantation data for the UK, whereas the
mortality and population data are for England
and Wales. As a consequence, the heart transplant
data and any calculated data based on such data
may be an overestimate if applied to England and
Wales.
Irrespective of these possible limitations, it is
evident from the incidence and prevalence of
ESHF, the patterns of heart transplantation in the
UK and the estimates of need and demand for
treatment of ESHF in England and Wales that
there is a large potential need for treatment that
could be addressed through the use of other forms
of treatment, such as mechanical assist devices. It is
likely that there are some 6000–8000 people who
could benefit from treatment in England and Wales
currently, with as many as 10,000–15,000 new cases
of ESHF annually. Given the age distribution of
cases of heart failure and ESHF, most of these
patients will be elderly (aged >65 years). Current
guidelines for heart transplantation recommend
that candidates should be limited to those in the
younger age groups and/or who do not suffer from
serious co-morbidities that may limit the success of
the heart transplantation. As a consequence, it is
this group of younger patients who will be
considered for implantation of an LVAD as a BTT.
In contrast, the elderly patients with ESHF who are
not candidates for heart transplantation and for
implantation of an LVAD as a BTT provide a
relatively large group for whom consideration
would need to be given as to whether they should
receive an LVAD as an LTCS or the alternative of
best supportive or palliative care. With limited
guidance concerning the use of LVADs as an LTCS,
it will be important to consider the benefits and
costs of their use for the different patient groups
whether defined by age, co-morbidity or
indications for treatment and the alternatives
available.
Current service provision for
heart failure
Recent years have seen considerable progress in
the effectiveness of treatments available for heart
failure that control symptoms, reduce treatment-
related adverse events, improve QoL and slow the
progression of the syndrome, so extending
patients’ length of survival.2 The changing
epidemiology of heart failure, a partial
consequence of an ageing population and the
effectiveness of the different treatments, has led to
an increased need and demand for health services
for heart failure. Unfortunately, differences remain
as to the availability of these services and the
quality of care provided in terms of geography,
age, gender and ethnic group.2 Increased efforts
to tackle coronary heart disease have resulted in
the development of a National Service Framework
to address these issues as part of the 10-year
modernisation of the NHS in England and Wales.2
This section briefly outlines the treatment options
used to manage people suffering from heart
failure; it does not discuss their effectiveness.
Clinical management of heart failure focuses on
the diagnosis of the condition suffered and
establishing appropriate strategies either to treat
the underlying cause (e.g. ischaemic heart disease)
or to relieve symptoms of the condition (e.g.
breathlessness) and/or any other precipitating
factors (e.g. infections, arrhythmias). Treatment
strategies will reflect the nature and the severity of
the condition suffered. Usually management of
the condition will intend to relieve symptoms,
improve QoL and functional capacity and improve
prognosis. However, palliative care may be the
primary focus for some patients nearing the end
of their lives and in such instances symptom relief
should be accompanied by psychological and
other forms of support. For other patients, the
clinical management of their heart failure will
involve drug therapy and, in some instances, heart
transplantation or mechanical support.
As previously discussed, the reduced pump
function in heart failure activates adaptive
responses in the body which initially help to
maintain cardiac output. However, these
mechanisms often only maintain adequate cardiac
output at rest, and eventually can drive the
progression of cardiac deterioration. Therapy for
heart failure aims to inhibit these responses. The
main symptoms of CHF are breathlessness
(dyspnoea) and fluid retention in tissues (oedema).
Clinical manifestations are an enlarged heart and
liver and a high venous pressure. The ejection
fraction is reduced. Treatments for CHF also aim
to improve these signs and symptoms.
First-line treatment for mild/asymptomatic CHF is
with ACE inhibitors.2 These inhibit the conversion
of angiotensin I to angiotensin II. Angiotensin II
causes vasoconstriction, and prevention of its
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vasodilation reduces pulmonary congestion,
oedema and cardiac workload and slows CHF
progression, lengthens survival time and improves
haemodynamic parameters.59 The restriction of
activity and reduction of dietary sodium can also
help to lessen cardiac workload and fluid
retention. In moderate/symptomatic CHF,
additional treatments include diuretics, cardiac
glycosides and beta-blockers. Diuretics reduce fluid
retention by increasing the excretion of renal salt
and water and can provide rapid symptomatic
relief.2 Cardiac glycosides (most often digoxin) act
on the sodium pump in cardiac muscle and
enhance contractility, and slow the heart. These do
not reduce mortality, but can reduce symptoms
and hospital admission for worsening heart
failure.2 Beta-blockers block the action of
adrenaline and can relieve stress to the heart
muscle and in people with controlled heart failure
can reduce mortality.60
When existing therapy fails to control symptoms
adequately and/or heart failure is severe, then
other categories of vasodilators can also be given,
for example isosorbide dinitrate and hydralazine.
These have been shown to prolong survival,61
although not as effectively as ACE inhibitors.62
The addition of the diuretic spironolactone can
also reduce mortality and morbidity.2 Additionally
inotropic sympathomimetics and positive
inotropes may also be used, although their long-
term use is not beneficial.60 The cardiac stimulants
dobutamine and dopamine act on  1-receptors in
cardiac muscle and increase contractility with little
effect on rate. Positive inotropic drugs such as
milrinone increase the force of contraction of the
myocardium. In patients whose heart failure is
refractory to treatments, LVADs and/or cardiac
transplantation are also options. Palliative care
and home oxygen are also treatments that are
offered to severe heart failure and ESHF patients.
Description of LVADs
Brief history of the development of
LVADs8
Mechanical systems to support circulation evolved
soon after the first use of coronary pulmonary
bypass (CPB) in the 1950s. It followed the growth
of cardiac surgical procedures which established a
need for developing a means of extending
circulatory support for patients who could not be
weaned from CPB following cardiac surgery. The
intra-aortic balloon pump (IABP) was developed
in the late 1960s as a form of partial cardiac assist
and used in the early 1970s to support patients
who could not be weaned from CPB. The early
1960s also saw the introduction of the first
ventricular assist devices (VADs), evolving from a
simple pneumatically actuated silicone-rubber
tube pump to a pneumatically driven diaphragm
pump. During the same period the potential
benefits of non-pulsatile blood pumps (e.g.
reduced complexity, smaller size and lower power
needs), first recognised in the 1930s, were being
developed into blood pumps. 
The importance of mechanical support was
recognised in the USA with the National Institute
of Health setting up in 1964, following
recommendations of the National Heart Advisory
Group, the Artificial Heart Program. Initial focus
was on the development of a total artificial heart
(TAH). By 1970, the program was renamed the
Medical Devices Applications Branch within the
National Heart and Lung Institute and its efforts
were refocused towards developing and evaluating
LVADs. A programme of sponsored research was
developed over the following 20 years,
investigating different types of early device (e.g.
pneumatically driven sac pumps, axiosymmetric
pumps and tether-free pumps), the components of
pumps (i.e. pumps, energy converters, controllers
and power transmission) and implantable
integrated electrically powered LVADs. The
programme led in 1989 to the development of
plans to evaluate clinically the Novacor system, the
first of the LVADs to achieve the preclinical
criteria. Although this study was not undertaken,
further initiatives were funded in 1996 to develop
long-term ‘improved’ VADs including first-
generation rotary devices, two axial flow
(Nimbus/University of Pittsburgh, Jarvik
Heart/Texas Heart Institute), one centrifugal
device (CCF/Ohio state University) and a non-
blood-contacting mechanical ‘muscle’ wrap pump
(Abiomed/Columbia Presbyterian Hospital), a
conditioned skeletal muscle-powered pump
(Whalen Biomedical/University of Utah) and an
electromechanical left ventricular assist system
(LVAS) (PSU/Arrow). 
Although a VAD was used in 1978 in an attempt to
bridge a patient to transplantation, it was in 1984
that two patients were bridged to transplantation
with a Novacor implantable electric LVAD and a
paracorporeal pneumatic Thoratec VAD and in
1988 that the HeartMate implanted pneumatic
(IP) VAD was first used successfully as a BTT.
These early devices were limited to console-based
power and control, limiting patient care to within
hospitals despite their clinical rehabilitation. The
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outpatient care, improving QoL and reducing
costs of care. The HeartMate vented electric (VE)
LVAD in 1991 and the Novacor LVAS in 1993
using battery power provided support for patients
to transplantation, allowing them greatly
improved mobility. Second-generation untethered
rotary pump LVADs were first introduced in 1998
with the axial flow DeBakey VAD. Subsequently,
the Jarvik 2000 in 1999 and HeartMate II LVADs
in 2000 have been used to support patients to
heart transplantation. The developments in LVADs
as a BTT has led to patients returning to more
normal activities of life and being supported for
longer periods on the transplant waiting list. With
the shortage in donor hearts for transplantation
and the improved survival and QoL of patients on
mechanical support, the use of LVADs as a means
of permanent support has become a possibility.
Several studies of LVADs as a permanent support
have been initiated. A randomised controlled trial
(RCT) of the Novacor VAS was started in 1994 but
failed to progress past the pilot phase. The
Randomized Evaluation of Mechanical Assistance
in Treatment of Chronic Heart Failure
(REMATCH) trial assessing the HeartMate VE
LVAS began in 1996 and has reported outcomes at
2 years’ follow-up. Other studies of the HeartMate
IP LVAD (PHADE, 1999), the Novacor wearable
LVAD (INTrEPID, 2000), the Arrow LionHeart
LVAS and the Jarvik 2000 for permanent support
are under way. Several devices have received US
Food and Drug Adminstration (FDA) approval
and/or CE marking for BTT and/or permanent
support. For BTT the HeartMate IP (1994) and
VE (1998) LVADs, Thoratec VAD (1996) and
Novacor wearable LVAS (1998) received FDA
marketing approval in the USA. European CE
marking was usually received prior to FDA
approval. The HeartMate VE and the Novacor
wearable LVADs are commercially approved and
currently available for permanent support. The
LionHeart LVAS, DeBakey, Jarvik 2000,
HeartMate II, Thoratec, Berlin Heart and Toyobo
VADs are undergoing clinical trials. 
Description of LVADs included in the
systematic review and economic
evaluation
Although some 20 or more devices have been
developed and used as LVADs, it is evident that
some are either targeted at specific patient groups
not included in the study (e.g. paediatric devices)
and others have not progressed past their early
development stages or are at too early a stage of
development to have undergone assessment of
efficacy. To ensure that the systematic review
focused on those devices that are relevant to the
NHS in England and Wales, the expert advisory
group was asked to identify and justify those
devices that should be included. The list of devices
included in the review is shown in Tables 13 and 14
and the full list of devices is given in Appendix 1.
The remainder of this section discusses the devices
by category/type of device, identifying their
characteristics, the method of placement and
licensing or marketing approval. It does not
provide a detailed description of the mechanical
components of the devices or of the differing
implantation and explantation techniques used.
Details of some devices were fairly limited,
whether through publications, company websites
or contact with the particular manufacturers. As a
consequence, the information presented on the
different devices may vary in completeness, and
for some devices no information was available. It
was evident throughout the assessment of LVADs
for ESHF that the categorisation and terminology
used to identify and describe the various devices
differ. LVADs may be displacement pulsatile blood
pumps or rotary continuous flow devices, whether
axial or non-axial flow pumps. Some have
classified the devices as either extracorporeal,
paracorporeal or implantable, and others have
differentiated devices as being first- or second-
generation devices. Within this study, devices will
be referred to as either first- or second-generation
devices based on the specifications outlined in
Tables 13 and 14. The use of the terminology is
not intended to convey any predetermined
assessment of clinical and cost-effectiveness, but
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TABLE 13 Blood pumps
Displacement blood pumps Rotary blood pumps
Pulsatile LVADs Continuous flow devices
First-generation devices Second-generation devices
Axial flow pumps Non-axial flow pumps
HeartMate, Novacor, LionHeart,  Jarvik 2000 Heart,  HeartQuest
Thoratec, Medos, Berlin Heart,  MicroMed DeBakey Terumo
Abiomed, Nippon Zeon, Toyoborather to differentiate between devices on several
characteristics. Any assessment of the clinical and
cost-effectiveness of the different devices will be
based on evidence for those devices for the
different indications.
Displacement pulsatile LVADs
The most widely used displacement, pulsatile
devices have been the Abiomed, HeartMate,
Novacor and Thoratec LVADs. Such devices are
connected to the patient’s left ventricle and
provide circulatory support by taking over the
workload of the failing heart. An inflow conduit
directs blood from the left ventricle into the blood
pump. The external control system triggers
pumping by a pusher plate mechanism, which is
either electrically or pneumatically driven. The
pump ejects blood through an outflow conduit to
the body’s arterial system via the aorta or arterial
system. Bioprosthetic heart valves dictate the
direction of flow. This mechanism mimics the
native left ventricle by providing a pulsatile stroke
volume while the patient’s own left ventricle is
completely off-loaded. The system is operated and
monitored by a controller and powered by an
external source. Implanted pumps are connected
by percutaneous leads through the patient’s skin.
The system can be self-regulating in response to a
patient’s needs or use a fixed pump rate. There
are differences in the configuration of the
displacement pulsatile devices in terms of the
position of the pump (i.e. extracorporeal,
paracorporeal or implantable), implantation
position (e.g. intraperitoneally or preperitoneal
pocket), method of driving the mechanism (i.e. IP
or VE), type of power source (i.e. wall-mounted,
console-based or battery packs), positioning of
cannulae and leads delivering the power and valve
structure and the nature of the internal surfaces of
the devices. Although the original large external
pneumatic consoles have been replaced by
implantable electric systems with a portable
controller and power source, the serious problems
of LVAD size, noise, driveline infection and
thromboembolism persist. As a consequence, the
next generation of displacement devices are likely
to be totally implantable systems without the need
for percutaneous power or communication in an
attempt to solve some of these issues (e.g. Arrow
LionHeart).
HeartMate LVADs (Thoratec Corporation, USA)63
Development of the HeartMate LVAD began
during the late 1960s, with the first implantable
LVAD with pneumatic driver and the first
integrated implantable electric LVAD emerging in
the early to mid 1970s. Initial clinical trials led to
the FDA awarding an investigational device
exemption for the pneumatic pusher plate
HeartMate device. The first clinical implant of the
device was in 1986 at the Texas Heart Institute. In
1990 the FDA awarded an investigational device
exemption for the electric HeartMate device, with
its first clinical implant taking place shortly
afterwards. A portable, wearable driver was
developed in 1995 to allow patients to be
supported as outpatients and to enhance their
QoL. In 1997, the first patient was discharged
home with an implantable LVAD. 
The HeartMate LVAD is an implantable pulsatile
LVAD available as either a pneumatically driven
(HeartMate IP) or an electrically powered
(HeartMate VE) device. Although sharing some
components and similar flow characteristics, the
HeartMate IP and VE are different in aspects of
their operation. The HeartMate IP has a
maximum stroke volume of 83 litres, a maximum
pump rate of 140 beats per minute (bpm) and
flow rates of up to 12 litres/minute. It is an
implantable VAD placed in the intracorporeal
position to support the left ventricle and all blood-
touching surfaces are HeartMate textured surfaces
designed to reduce the risk of clot formation.
Percutaneous cannulae connect to an air-driven
pump which is powered by an external drive
console. It can be transported on a wheeled cart,
but is for in-hospital use only. It has a regulator
that is designed to respond to changing flow
demands of the body; if activity increases, a
change in flow is triggered. There is also a fixed
mode with a preset beat rate. The HeartMate VE
is an implantable VAD for the left ventricle with
percutaneous cannulae, suitable for home use. It
has a capacity of 10 litres/minute, a maximum
stroke volume of 83 ml, and a pump rate of up to
120 bpm. It is designed to respond to changing
flow demands of the body. A preset beat is also
available. It is powered by a power base unit and
wearable battery, although a belt-worn system
controller and batteries can provide approximately
6 hours of mobility. HeartMate textured surfaces
reduce the risk of clot formation. The HeartMate
devices have external back-up mechanisms so that
reoperation may not be required in the event of
device failure. With the control unit externally
sited, it is possible to rectify problems outside the
body. In addition, a hand-held portable pump
provides a means of operating the pusher plate
mechanism if the motor device should fail. The
HeartMate IP and VE LVADs are licensed for BTT
in Europe and the USA, and the HeartMate VE
LVAD is also licensed in Europe for permanent
support in patients with CHF.
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The Novacor LVAS was the first electrically
powered heart assist device designed as an
integrated, implantable system for definitive
treatment of ESHF. The device consists of a
pump/drive unit, an electronic controller with
rechargeable battery, a subcutaneous belt skin
transformer secondary for transcutaneous power
transfer across the intact skin and variable-volume
compensator. The Novacor LVAS is placed in the
intracorporeal position and used to support the
left ventricle with percutaneuos cannulae. It is self-
regulating, responding and adjusting
instantaneously to the patients’ heartbeat and
circulatory demand. Stroke volume is 70 ml and
capacity is 8.5 litres/minute. The system has
continued to evolve from the first systems
developed in the early 1970s. In 1984, a partially
implantable version of the Novacor system with a
bedside console system was used as a BTT for a
male patient. By 1993 a wearable controller and
battery pack was developed to improve mobility
and patient QoL. The current system, the Novacor
N100PC, received regulatory approval as a BTT in
Europe in 1993 and was first implanted in that
year as a BTT. Regulatory approval in the USA for
BTT came in 1998 following a multi-centre study
and was also approved in Canada and Japan in
1999. In addition, it has received regulatory
approval for long-term therapeutic use in Europe
and the USA. 
Abiomed BVS 5000 (ABIOMED Cardiovascular
Inc., USA)65
The Abiomed BVS 5000 was the first cardiac assist
device approved by the FDA in 1992. Currently the
device is approved by the FDA for all forms of
recoverable heart failure, including as a BTR or
BTT in failed transplant. Its most common
indication for use is short-term (10 days)
postcardiotomy support (recovery after heart
surgery). It is a dual-chamber VAD placed outside
the body (extracorporeal) and is suitable for short-
term left, right, or biventricular support. The
Abiomed BVS 5000 consists of three components: a
transthoracic cannula, disposable external
(bedside) pumps and an automated self-regulating
pulsatile microprocessor-controlled pneumatic
drive console. The device has a constant stroke
volume of ~80 ml and a maximum output of
6 litres/minute if patient hydration is adequate. It is
driven by a pneumatic drive console which is large
in size and suitable for in-hospital use only. Some
limited mobility is available with the battery
providing 1 hour of support, which also acts as a
safety backup system. In addition, it has a foot
pump for manual operation. The VAD is fully
automatic and compensates for changes in preload
and afterload and is asynchronous to the native
cardiac rhythm. In biventricle use the left and right
ventricles are triggered independently of each
other. The Abiomed BVS 5000 was developed with
the aim of being a safe, simple and effective device.
The safety of the device comes from its design,
incorporating a dual-chamber pump and built-in
reservoir with blood draining through gravity,
avoiding the need for a vacuum. The simplicity is
based on its automated control systems, requiring
minimal operator input. The device has certain
limitations, including restricted device mobility,
limited flow capability and the need for full
anticoagulation due to thrombus formation.
Thoratec VAD and IVAD (Thoratec Corporation,
USA)66
The Thoratec VAD was first used in 1982 for
postcardiotomy support and later in 1984 as a
BTT. The device received premarketing approval
from the FDA for use as a BTT in 1996. Currently
the Thoratec VAD has approval as a BTT and as a
BTR in Europe and the USA. The device is an
extracorporeal VAD placed in the paracorporeal
position that can support the work of the left,
right and bilateral ventricles. It consists of four
main components: a drive console, inflow
cannulae, outflow cannulae and a pump. With the
pump in the paracorporeal position, the cannulae
enter the patient below the costal margin, crossing
the diaphragm and into the mediasternum, where
they are connected to the heart. The operation
and monitoring of the pump occur through
connection to a dual-drive console. Capacity
ranges from 1.3 to 7.2 litres/minute with a stroke
volume of 65 ml and up to 100 bpm and is
suitable for use in small adults and adolescents but
not children. It is powered by a large and heavy
dual driver but can be ambulatory with a portable
driver (9.8-kg battery) which is licensed for use
within 2 hours of the hospital. It has three
operating modes: asynchronous (to heart) mode
with a preset rate and ejection time, volume mode
(ejection when VAD filling occurs) and
synchronous mode (counterpulsation). The
asynchronous mode is recommended for most
indications. The paracorporeal position of the
Thoratec VAD has advantages and disadvantages.
With the major components external to the body,
the device can be implanted in smaller patients,
although not paediatric patients. Also, its position
allows identification of thrombus formation in the
pump and the exchange through non-invasive
techniques. However, as with many of the
mechanical pumps, its position provides the
opportunity for infection. Another limitation is the
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accompanied by the large drive console, meaning
that the patient must remain within hospital
during support. The limitations associated with
use within small patients, particularly paediatric
cases, and with the limited mobility of the device
have resulted in the development of the ‘Berlin
Heart’ in Europe, a portable power and control
unit and an implantable device known as the
‘Thoratec IVAD’. The Thoratec IVAD is a
pneumatically actuated implantable VAD which
can support left, right or both ventricles. It weighs
339 g and has a volume of 252 ml. It uses the
same internal working components as the VAD.
Percutaneous leads connect to an external briefcase-
sized battery-powered control unit. The IVAD has
a smooth contoured, polished titanium housing. It
is licensed for trial use in Europe and the USA. 
Nippon Zeon LVAD (Nippon Medical
Corporation, Japan)
The Nippon Zeon LVAD is a sac-type, air-driven
pump that is placed in the paracorporeal position
that is available for adults. It has a stroke volume
of 11 ml with inflow in the left or right atrium and
operates using mechanical disc valves. Limited
information was available on the specification of
this device.
Toyobo LVAD (Toyobo Co. Ltd, Japan)
The Toyobo LVAD is an L-shaped extracorporeal
air-driven pneumatic diaphragm-type device using
Bjork–Shilley inlet and outlet valves. It has a
stroke volume of 70 ml and a maximum output of
7.0 litres/minute. The operating modes include
the full-fill to full-empty (F/E) mode, manual set
rate, the ECG or pressure trigger mode and the
automatic level control mode using a control drive
unit. The device is supported by an automatic
backup system.
Displacement: intracorporeal
Arrow LionHeart 2000 LVAD (Arrow
International, USA)
The Arrow LionHeart 2000 LVAD is an
implantable pulsatile VAD that consists of a pump,
a controller and power source. The pump
comprises a titanium case with motor, seam-free
blood sac, pusher plate and unidirectional
inlet/outlet mechanical heart valves. The pump
has a stroke volume of 64 ml and a maximum
sustained output of 8 litres/minute. It is monitored
by the pump controller through Hall effect
sensors. A pump controller is implanted,
regulating the external power supply, the motor
and monitoring. Also, it houses rechargeable
batteries that provide temporary power supply of
up to 30 minutes when the patient is disconnected
from the external supply. The pump controller
provides data on the system operation and the
opportunity to modify its settings depending on
clinical needs. Pumping characteristics are
automatically adjusted by a software algorithm
through changes to the pump speed. The pump is
powered by a transcutaneous energy transmission
system (non-invasive), consisting of an external
power pack with rechargeable and replaceable
batteries, a power transmitter and a primary
power coil. The primary power coil is located over
an implanted secondary power coil that provides
energy to the device. Currently it is licensed for
trials in Europe and the USA for long-term
support for patients with ESHF. The European
trials are nearly complete.
Berlin Heart EXCOR (Mediport Kardiotechnik,
Germany)67
The Berlin Heart EXCOR assist device is a
pneumatically driven paracorporeal support
system that can be used for left, right or both
ventricles and is approved for BTT in Europe. It is
not available in the USA. The Berlin Heart was
first used in 1988 as a BTT and in 1992 became
the first commercially available pulsatile device for
small children. Although its main use is as a BTT,
it has supported patients to cardiac recovery. An
extracorporeal VAD, the Berlin Heart is suitable
for use in small adults, adolescents and children.
The system consists of a paracorporeal air-driven
blood pump, cannulae for connection of the pump
to the heart and an electropneumatic driving
system (stationary or mobile drive units are
available). The mobile unit has total running time
of 6 hours, weighs 8.7 kg and is on wheels. The
operating regulation is in either synchronous or
asynchronous modes with the stationary unit (the
synchronous mode is said to prevent a paradox
movement of the septum and potentially makes
recovery easier). The mobile unit self-regulates by
automatically adapting to the patient’s
requirements within preselected operating
parameters. It achieves stroke volumes of between
10 and 80 ml depending on its application and its
blood-contacting parts have a heparin coating. As
with other extracorporeal devices, the Berlin
Heart suffers from certain limitations associated
with infection, thrombus and poor device mobility. 
Medos HIA-VAD
The Medos HIA-VAD has external ventricular
chambers and is pneumatically operated for either
left, right or bilateral ventricles. A range of sizes
are available for adults, children and infants and
the capacity will change, depending on the
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driven independently. A trolley houses the control
unit which consists of a touch-screen monitor
which ensures easy adjustment of operating
parameters. Both fixed-rate and ECG-triggered
modes of operation are available. Also on the
trolley is the power supply system, which is a
compressor unit driven by either the mains or
batteries, allowing patient mobility. It is licensed in
Europe for BTT and weaning off/recovery. 
Terumo Duraheart (Terumo Corporation, Japan)
This is a magnetically suspended centrifugal
pump, with impeller blades, a magnetic bearing
and direct current brushless motor. It weighs 400 g
and has a volume of 196 ml. It can provide a blood
flow of 5–6 litres/minute at pump speeds between
2000 and 3000 rpm. It is implanted in the thoracic
cavity and used for left ventricular support.
Rotary LVADs
The new rotary pumps, particularly the axial flow
impeller pumps, have been developed following
the encouraging results reported from the use of
pulsatile devices, with the aim of addressing some
of the shortcomings of these devices such as their
size and complexity, the difficulties of
implantation and adverse events (e.g.
perioperative bleeding, infection, thrombosis and
device malfunction). These miniaturised
implantable pumps provide continuous, non-
pulsatile flow using an electromagnetic mechanism
consisting of a rotor with impeller blades. These
blades are the only moving parts of the device,
there are no valves, the devices are biocompatible
and there is lower blood damage and no need for
anticoagulation with heparin. The control systems
and power delivery mechanisms are easily portable
and manageable by the patient. The non-pulsatile
axial flow pumps currently being developed, such
as the Jarvik 2000, MicroMed DeBakey and
Nimbus devices, tend to be compact in design, use
a single moving part and have lower energy needs.
Although these attributes are potentially
advantageous, little is known about effects of non-
pulsatile flow and concerns have been raised.
The axial flow devices considered in this review
are the Jarvik 2000 Heart and the MicroMed
DeBakey LVAD. The MicroMed DeBakey device is
implanted in a preperitoneal abdominal pocket
created by detaching the anterior portion of the
left hemidiaphragm, with an inflow cannula to the
left ventricle and outflow to the aorta. The Jarvik
device is unique in that it is implanted into the
body of the left ventricle and therefore has no
need for an inflow cannula. The external batteries
and controller are carried on a belt. For
permanent implants a novel approach is to deliver
power via internal electric wires through the left
pleural cavity to the apex of the chest and
subcutaneously across the neck to the base of the
skull. Here, a rigidly fixed percutaneous titanium
pedestal transmits fine electrical wires across the
skin of the scalp. The combination of immobility
and highly vascular scalp skin, which is known to
resist infection from experience in cochlear
implant technology, is of benefit here. Two further
novel rotary blood pumps considered in this
review are the HeartQuest, a diagonal pump
which is implanted in the abdomen, and the
Terumo, a radial pump.
Implantation techniques for smaller LVADs are
easier than those for larger devices, with only one
body cavity being entered and with shorter times
on coronary artery bypass (CAB). The
intraventricular position is an advantage as the
LVAD stays aligned should there be changes in left
ventricular shape during unloading. Mal-
alignment of the device can cause haemolysis,
thrombus formation and thromboembolism.
Concerns have been expressed over long-term
non-pulsatile blood flow. However, there is some
evidence that non-pulsatile blood pumps do
provide pulsatility in the circulation as function
improves in the off-loaded left ventricle. Complete
unloading of the left ventricle leads to a change in
the geometry of the right ventricle and an
improvement in the right ventricular function
which provides pulsatile flow through the lungs so
that the preload of the blood pump becomes
pulsatile. Pulsatility does not appear to be
dependent on pump flow, blood pressure or
systemic vascular resistance. 
Axial flow devices
Jarvik 2000 (Jarvik Heart Inc., USA)68
The Jarvik 2000 is the smallest axial flow device,
with an adult version measuring 25 mm in
diameter by 55 mm in length, weighing 85 g and
with a displacement volume of 25 ml, and a
smaller paediatric version at one-fifth of the
dimensions of the adult device and weighing 18 g
and displacing 5 ml. The device is designed for
implantation with intraventricular placement. It
consists of a rotor housed in a titanium case and
supported by ceramic bearings immersed in the
bloodstream. The impeller is powered by an
electromagnetic field using a small percutaneous
cable, with regulation through a brushless direct
current motor that determines its speed. The
current adult device operates at fixed rate motor
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8000 and 12,000 rpm with an average capacity of
5 litres/minute. A permanently implantable model
is under development that will be responsive to
heart rate and which can be set by the patient
according to their needs. The Jarvik 2000 has
FDA approval for evaluation as BTT in the USA.
MicroMed DeBakey (MicroMed Technology Inc.
USA)69
The MicroMed DeBakey VAD is a miniature axial
flow pump that has been under development since
1988. The intention was to design a device that
overcame the problems associated with other
devices, such as haemolysis, thrombosis, noise and
heat generation, and also to provide a system that
allowed patients to be mobile. The system consists
of a pump, a controller and a clinical data
acquisition system. The blood pump is a titanium
electromagnetically actuated axial flow pump,
measuring 30.5 mm in diameter and 76.2 mm in
length and weighing 93 g. It has a flow capacity of
5 litres/minute at 10,000 rpm and a maximum
flow capacity of over 10 litres/minute.The titanium
inflow cannula connects the pump to the
ventricular apex and a Dacron vascular graft
connects the pump to the ascending aorta. A
probe placed around the outflow conduit measures
blood flow. The wiring of the motor and probe
leaves the body through the abdominal wall and is
attached to the external controller system. The
VAD system aims to be simple to use, although the
pump should not be adjusted by the patient. The
data acquisition system is used to adjust operating
parameters during operation and ITU. A patient
home-support system weighing ~4.5 kg is used for
night-time and resting. A controller for mobility
weighing ~2.3 kg can be carried and powered for
6–8 hours. The device has certain limitations,
specifically the uncertainties surrounding the
long-term effects of non-pulsatile flow on
neurovascular and neuroendocrine systems, the
problems associated with regurgitant blood flow
following pump stoppage and the fact that the
pump speed is fixed and does not react to the
patient’s changing needs. A controller with an
adjustable flow rate algorithm that adapts to
patients’ needs is under development. The
MicroMed DeBakey VAD is approved for BTT in
the USA for clinical trial use and in Europe for
BTT. In the future it is intended for it to be used
as a BTR and for chronic support.
Other rotary
Berlin Incor I (Mediport Kardiotechnik, Germany)
The Berlin Heart Incor I is an implantable axial
flow pump. It weighs 200 g and has a diameter of
30 mm. Its capacity is up to 7 litres/minute and
the magnetically suspended impeller is designed
to diminish the risks of clots. Percutaneous
cannulae run to an external power pack, which
weighs ~1500 g. Batteries can give the patients up
to 12 hours of mobility. The device received CE
mark certification for EU use as BTT and BTR in
April 2003. It was intended to seek FDA approval
for the Incor device in 2004. 
HeartQuest VAD (MedQuest Products Inc., USA)
The HeartQuest VAD is a diagonal rotary
implantable VAD with percutaneous cannulae. It
weighs 600 g and has a volume of 275 cm3. The
rotational speed is 2500 rpm, with a flow rate of
10 litres/minute. It uses a magnetic impeller and
this, together with a QuestCoat™ coating, reduces
the risk of coagulation. The VAD is able to self-
regulate by adjusting to patients’ demands and is
designed for long-term support. 
Assessing the effectiveness of
LVADs for ESHF
Evaluation of the effectiveness of health
interventions has increasingly necessitated the
assessment of rigorous evidence on their benefits,
risks and costs.70 The importance of strict
evaluation is evident in the regulatory
requirements for licensing and for funding of
healthcare interventions. Although the RCT is
widely recognised as the ‘gold standard’ for the
evaluation of effectiveness, it too has
limitations.71–73 Conducting RCTs of surgical
interventions, such as those involved in
implantation of LVADs, requires consideration of
certain technical (expertise of clinicians/centres
and evolution of procedures), ethical
(randomisation in trials) and methodological
issues (survival analysis of high-risk
interventions).70 Importantly, these concerns need
to be taken into account when assessing the
effectiveness of LVADs for ESHF through
systematic review.
With new and complex surgical procedures, the
skill of the surgical team and the clinical centre
may dramatically affect the outcome of any
assessment. If surgeons or clinical centres are
selectively assigned to the different procedures,
this may explain any apparent difference in
outcome. In addition, clinical trials are often
conducted by skilled, enthusiastic clinicians within
tertiary care centres, which differ considerably
from the usual setting in which the service would
be delivered. Unsurprisingly, this often limits the
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to identify the expertise of different surgeons or
clinical centres, rendering any assessment of the
effects on the outcomes of treatment difficult.
Surgical procedures often undergo continued
development as they diffuse into practice, leading
to two concerns. If clinical trials to assess the
surgical procedure are delayed until it has been
refined and is relatively stable in terms of
development, it may have become common
practice and difficult to assess its effectiveness and
alter practice. In contrast, if assessed too early in
the surgical procedure development, it may
provide results that do not represent the
procedure that will ultimately be used. 
Unfortunately, the nature of surgical interventions
often leads to ethical concerns in conducting
clinical trials. New interventions tend to be
considered as breakthrough treatments for life-
threatening conditions, which may cause
difficulties for patients and investigators in
accepting the outcome of randomisation. With
surgical interventions, patients and clinicians are
likely to be aware of the intervention used and will
have expectations of the potential outcomes. It
may result in people refusing to take part in the
trial or to seek treatment outside the trial, causing
loss to follow-up or out-of-protocol crossover. It
follows that blinding of treating clinicians and
patients to such interventions is difficult, if not
impossible. A partial solution to preventing
observer bias is to use independent observers to
assess outcomes. Blinding patients depends on the
interventions considered; if they differ
considerably, it will be impossible to achieve. 
Another methodological concern in the
comparison of surgical and medical therapies is
the assessment of patient survival. If surgical
interventions involve high operative risk but
subsequently offer a lower mortality compared
with the medical therapy, then survival curves will
cross. Analysing the differences in survival 
curves will be dependent on the analytical
methods used and the time period of the analysis.
If the analytic method used averages risk over the
follow-up period, any changes to the period
analysed will have the potential to alter the
relative efficacy. Importantly, assessment of
effectiveness must take into account not only the
differential survival of patients, but also the effects
on their QoL.
Aim and background
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he a priori methods for systematically
reviewing the evidence of clinical and cost-
effectiveness of LVADs for ESHF and the methods
used for developing the economic evaluation are
described in the research protocol (Appendix 2).
Expert comments on the protocol were obtained
from members of the advisory group to the study
(see Acknowledgements). Although helpful
comments were received relating to the general
content of the research protocol, there were none
that identified specific problems with the methods
proposed. Some changes, additions or points of
clarification were made to the methods discussed
in the original protocol, as follows:
  It was emphasised that the assessment should
identify clearly the different devices that offer
left ventricular replacement and those that offer
left ventricular assistance and that require some
residual heart function. Information on the
nature of the different devices included in the
systematic review will be presented where
available, providing some understanding of
their conditions of operation.
  The issue of the long-term effects on organ
function of the second-generation devices that
use impeller pumps and have a non-pulsatile
flow should be assessed. This was recognised as
an important issue and, where available,
evidence will be presented.
  Aldosterone antagonists as part of the triple
therapy and enhanced counterpulsation should
be included as a comparator intervention. As
the inclusion criteria state that comparators
should include LVADs, heart transplantation
and/or usual care, this option was not excluded
as a comparator.
  The systematic review and economic evaluation
should ensure that the methodological quality
of the evidence used to assess the clinical and
cost-effectiveness is appropriately judged. The
research protocol clearly states the methods that
will be used to assess methodological quality of
included studies and the possible inadequacies
of the different measures. As the criteria used
are widely recognised as appropriate, it was felt
that no further action was needed.
  As part of the assessment of clinical and cost-
effectiveness of LVADs for ESHF, particularly the
implications for developing a service, it would
be important to take account of the differences
in the nature of the patient groups and the
indications for use of the devices. It is likely that
most people with ESHF will be elderly and be
suffering from co-morbidities which prevent
them from receiving a heart transplantation
and, as a consequence, from receiving an LVAD
as a BTT. In fact, these patients are likely to be
candidates for receipt of an LVAD as an LTCS
depending upon the guidelines adopted for
their use. Younger ESHF patients are more likely
to be candidates for heart transplantation and to
require an LVAD as a BTT. However, some of
these patients will be candidates for LTCS with
an LVAD owing to the limited supply of donor
hearts. The effects of the different patient
groups and the indications for use of LVADs will
be assessed in the section in Chapter 5
examining the implications for developing a
service, including aspects of budget
management and resource management.
The methods outlined in the protocol are
summarised below.
Research question
To assess the clinical and cost-effectiveness of
LVADs as a BTT, BTR and potential LTCS for
people with ESHF through a systematic review of
the evidence and, if necessary, through the
development of an economic evaluation. 
Search strategy
Sources of information, search terms and a
flowchart outlining the identification of studies for
the systematic review and economic evaluation are
described in Appendix 3. The electronic search
strategy aimed to generate a comprehensive list of
studies meeting the inclusion criteria for the
systematic review and to provide information for
developing the economic evaluation. It included
studies published in all languages to reduce the
Health Technology Assessment 2005; Vol. 9: No. 45
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Chapter 2
Research methods for systematic review of 
clinical and cost-effectiveness of LVADs for ESHFpotential effects of an English language bias.
Reference lists from all publications retrieved were
checked for additional publications not identified
by the electronic searches. Researchers in the topic
area and manufacturers of LVADs included in the
systematic review were contacted to check that
relevant studies had been identified and to obtain
any studies that remain unpublished. In addition,
the expert advisory group were asked to assess the
comprehensiveness of the search to try to identify
any studies not included in the systematic review.
It was hoped that these efforts would reduce the
effects of publication bias and inaccurate indexing
in databases. Searches were updated periodically;
the last update was undertaken in October 2003.
Although all manufacturers of devices included in
the study were contacted for any additional
information relevant to the systematic review and
economic evaluation, only three submitted any
references or data for consideration in the review
(Appendix 4). Additional references and
information were provided by members of the
advisory group and by the key NHS trusts within
England and Wales for use in the economic
evaluation; these will be discussed further in
Chapter 5.
Inclusion and exclusion criteria for
systematic review
Studies identified in the search strategy were
assessed for inclusion in the systematic review of
clinical and cost-effectiveness depending on the
interventions used, the patient groups, the
outcomes assessed and the study design.
Interventions
Studies that evaluated currently available LVADs
used as a BTT, BTR recovery and potential long-
term alternative to heart transplantation for
people with ESHF were included. LVADs that were
in the very early stages of development, no longer
available or not used, TAHs, biventricular assist
devices (BiVADs), right ventricular assist devices
(RVADs) and other blood pumps were excluded.
Studies using LVADs for any condition other than
left ventricular support were also excluded. Also,
studies were excluded from the systematic review
of clinical effectiveness if the LVAD was used in
conjunction with other interventions where it is
impossible to separate out the effects of the
different interventions on outcomes or if the study
did not clearly identify the LVAD used or 
included several different devices together and 
did not report their outcomes separately. However,
such studies were considered for inclusion in 
the systematic review of cost-effectiveness, as 
it was felt that these studies would contribute
information for the development of the economic
evaluation. Importantly, the economic evaluation
focused on those LVADs that were shown in the
systematic review to be clinically effective for the
different indications and relevant to the UK
setting. 
Searches identified over 35 devices that were
considered to be or were used as LVADs
(Appendix 1). Advice was sought from the expert
advisory group as to the LVADs that should be
included in the systematic review and economic
evaluation and the reasons as to why devices
should be included or excluded. A list of 13 LVADs
were included in this systematic review (Table 14).
Participants
People aged 16 years or older with ESHF and
considered suitable for receipt of an LVAD as BTT,
BTR or potential long-term alternative to heart
transplantation were included in the systematic
review. Although certain LVADs have been used to
support children with ESHF, it was felt that other
factors may affect outcomes and as a consequence
these should be examined separately. Patients
supported with an LVAD during the perioperative
period or when used as an emergency rescue
strategy during an operation were also excluded
from the systematic review. Again, these patients
were thought to represent a different group of
patients from the three main indications.
Study designs
Systematic reviews, RCTs, controlled clinical trials
(CCTs), cohort studies, case series, case studies,
Research methods for systematic review of clinical and cost-effectiveness of LVADs for ESHF
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TABLE 14 Devices included in the systematic review of clinical
effectiveness
Device
AB-180 iVAD (implantable)
Abiomed BVS 5000 
Arrow LionHeart VAD
Berlin Heart
Berlin Incor I
HeartMate IP (Implanted pneumatic LVAS)
HeartMate VE (vented electric LVAS)
Jarvik 2000
MicroMed DeBakey VAD (Baylor/NASA)
Nippon-Zeon
Novacor (Novacor Medical Corporation/Baxter 
Healthcare, Oakland, CA)
Thoratec (implantable VAD, IVAD)
Toyoboeconomic evaluations and cost studies were
included. Emphasis was placed on studies
including an appropriate comparator group, such
as people receiving an LVAD with those
undergoing heart transplantation, those receiving
usual care whilst on the transplantation waiting list
or with people receiving a different LVAD. Owing
to the scarcity of evidence using an experimental
design, natural history studies were sought, as they
may provide useful evidence of effectiveness in
situations where outcomes are poor and
predictable without treatment.74 Where there was
evidence from different types of study design for a
specific LVAD, only those studies with the most
rigorous designs were included and data
extracted.75 Those studies excluded on the rigor
of design are listed in Appendix 5. All relevant
economic evaluations and cost studies were
considered within the systematic review of cost-
effectiveness and as a source for the economic
evaluation.
Outcome measures
Patient outcomes including survival, functional
capacity (e.g. NYHA functional classification,
activities of daily living) and QoL were the
primary outcome measures considered within the
systematic review. Other secondary outcomes
included other measures of cardiac function,
haemodynamic function, end organ function,
adverse events, device-related complications,
length of stay, exercise capacity and reoperation.
Primary outcome measures were used for
judgements regarding the inclusion or exclusion of
studies. However, both primary and secondary
outcomes were extracted from the included studies
and analysed in the systematic review and
economic evaluation.
Synthesis of evidence
Studies were synthesised using a narrative
approach through subgroup analysis based on the
indication for treatment, type of LVAD and quality
of studies. Tables were generated that summarised
the results of the included studies, and these are
discussed fully in the text. Statistical synthesis by
meta-analysis of the data was not appropriate
owing to the many differences between the studies
in terms of study design, patients or outcomes.
Application of methods for systematic
review
Studies identified by the search strategy were
assessed for inclusion through two stages, using
criteria described above. For the systematic review
of clinical effectiveness, the titles and abstracts of
all studies identified by the search strategy were
screened independently by two reviewers with any
differences in decisions to include or exclude
being resolved through discussion or through
recourse to a third, independent reviewer. Studies
included in the systematic review at this stage were
obtained to allow examination of the full text of
the study. Any studies on which a decision to
include or exclude could not be made at the title
and abstract stage owing to a lack of information
were also ordered. The full text of the retrieved
studies was examined by two independent
reviewers to check the decision made. Any
disagreements were resolved by discussion or
recourse to independent assessment by a third
reviewer. These procedures were used to reduce
the effects of bias in study selection, which can
occur due to the effects of pre-existing opinions of
the researcher, and to minimise the risk of errors
of judgement. Studies excluded from the review of
clinical effectiveness are listed in Appendix 6. The
systematic review of cost-effectiveness followed a
similar two-stage process differing only in that one
reviewer assessed studies at the different stages
with a second reviewer checking decisions.
In order to obtain the information needed for the
systematic review of clinical effectiveness from the
included studies, data were extracted
independently by two reviewers using a data
extraction form developed a priori (Appendices 7
and 8). The data extraction form noted all of the
data items to be extracted in order to minimise
bias. The forms for data extraction and guidance
for their use were developed and piloted prior to
the systematic review, with the aim of familiarising
reviewers with the process and reducing
subjectivity and error. As with other decisions in
the systematic review of clinical effectiveness, any
disagreements were resolved through discussion or
through recourse to independent assessment by a
third reviewer. An historical record of the data
extraction processes was maintained as part of the
systematic review of clinical effectiveness to allow
possible audit of decisions made. Any studies with
multiple publications had data extracted on to one
form, with any differences between the
publications identified and explicitly referenced. If
publications from different studies had overlap of
their patient cohorts, such as in a multicentre
study reporting the results from different
combinations of the centres involved, data were
extracted from each individual study with a note
of potential overlaps on the extraction forms.
Where overlaps in the cohorts of different studies
were suspected but uncertainty remained, the
studies were assessed separately but a note was
made of the potential overlap. A similar process
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effectiveness. A form for the extraction of data was
developed and piloted a priori (Appendix 9). Data
were extracted by one reviewer and checked by a
second reviewer, with differences being resolved
through discussion or through recourse to a third
reviewer.
The methodological quality of the studies
included in the systematic review of clinical and
cost-effectiveness was assessed using recognised
quality assessment tools (Appendices 9, 10 and
11). The assessment of the methodological quality
of studies is an essential element of the systematic
review of evidence as it allows a judgement to be
made as to the rigour of the study and the
potential for bias and, as a consequence, the
validity of the results.76 Judgements about the
methodological quality of studies were based on
the assessment of individual components of
methodological quality rather than relying upon
summary scores from particular scales. Although
quality scales are appealing owing to their ease of
use, the choice of scale may determine the
apparent quality of the study and interpretation of
the results is often difficult.76 It is particularly
problematic with the assessment of fast-changing
health technologies which encompass evidence
from several different levels of the hierarchy. No
single quality assessment tool can accurately
capture the methodological quality of such
different studies into a summary score. 
Different quality assessment tools were used for
the various types of study design. Systematic
reviews and meta-analyses of clinical effectiveness
were assessed using criteria specified by NHS
Centre for Reviews and Dissemination (CRD) (see
Appendix 10), which focuses on the adequacy and
appropriateness of inclusion/exclusion criteria,
search strategy, assessments of validity, study detail
and synthesis of results. The methodological
quality of primary studies of clinical effectiveness
was assessed using a quality assessment tool
developed by Thomas and colleagues77 (see
Appendix 11). This tool has been recognised as
one of the more comprehensive sets of criteria for
assessing the quality of different study designs.78
The quality assessment tool looks at elements of
selection bias, study design, confounders,
blinding, data collection methods, withdrawals
and drop-outs, intervention integrity and analysis.
Although it provides the opportunity to produce
summary assessments for the different groups of
components and globally, this was not undertaken
and reporting of the results of the analysis was
based on the components. Interpretation of the
quality of primary studies requires caution. With a
broad range of study designs included in the
assessment of clinical effectiveness, it is inevitable
that studies adopting more rigorous experimental
designs, such as RCTs or non-randomised clinical
trials, are likely to be considered to be of higher
methodological quality than observational studies,
such as case studies. Using a single quality
assessment tool means that a high-quality
observational study will not score highly as the
tool encompasses components of quality that the
observational study does not address by design.
With the analysis of methodological quality
focused on the opportunities for bias, whether
inherent in the design of the study or within the
conduct of the study, any high-quality
observational studies will be likely to be judged of
moderate to weak methodological quality
compared with the ‘gold standard’ RCT. Similarly,
RCTs assessing differing types of health
technology, such as an operation or device against
drug therapy, will not be able to meet all the
criteria that are considered to identify a good-
quality evaluation (e.g. blinding of patients and
clinician). Although such studies may be the most
methodologically rigorous given the
circumstances, they may be judged as being weak
on certain criteria. Although this may be judged to
be unfair or inappropriate, it is important to
undertake a comparative assessment of the quality
and strength of the evidence available for the
different devices and indications. The quality
criteria used in the assessment of the studies of
clinical effectiveness were applied independently
by two reviewers, with any disagreements resolved
through discussion or through recourse to a third,
independent reviewer.
The methodological quality of the economic
evaluations included in the systematic review of
cost-effectiveness were assessed using a 10-point
quality checklist adapted from the methods
developed by Drummond and colleagues79 (see
Appendix 9). As in the systematic review of clinical
effectiveness, the components of the quality
assessment tool are considered separately rather
than as an overall score. The criteria were applied
by one reviewer with decisions checked by a
second reviewer. Disagreements were resolved
through discussion or through recourse to a third
reviewer.
Research methods for systematic review of clinical and cost-effectiveness of LVADs for ESHF
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The clinical effectiveness of LVADS for ESHF was
assessed separately for the three indications for
treatment of ESHF, specifically as a BTT, BTR and
LTCS. For each indication, the quantity and
quality of research evidence available for the
different LVADs will be discussed and the
outcomes of the treatment assessed.
LVADs as a bridge to heart
transplantation for ESHF
Quantity of research
Sixteen studies assessing the clinical effectiveness
of LVADs as a BTT met the inclusion criteria for
the systematic review, with 11 studies of first-
generation devices and five studies of second-
generation devices (Table 15 and Appendices
12–17). Seven of the studies of first-generation
LVADs investigated the use of the HeartMate IP
and/or VE devices, with one CCT,80 three
retrospective cohort analytical studies81–83 and
three cohort studies, either before and after84 or
compared with a historical control group.85,86 Of
the six studies comparing the use of the
HeartMate LVADs with an alternative
intervention, one study compared the HeartMate
VE LVAD with the Novacor N100 LVAD,80 two
studies used inotropic agents as the
comparator82,83 and three studies did not define
the medical care given to the control
group.81,85,86 The other studies of first-generation
LVADs were a cohort analytic study comparing
the short- and long-term use of the Novacor
LVAD,87 a case series of the Toyobo LVAD,88 and
two case reports of the Thoratec device.89,90 Of
the five studies of second-generation LVADs,
three were before and after cohort studies of the
MicroMed DeBakey LVAD91–93 and the other two
were case series of the Jarvik 2000 LVAD, one of
which was a multicentre case series, with
individual centres reporting their patient data at
different periods of follow-up for different
subgroups.94–100
Methodological quality of research
First-generation LVADs
HeartMate
The methodological quality and the quality of
reporting in the studies assessing the HeartMate
LVADs were generally weak (Table 15 and
Appendix 12). One study, a CCT comparing the
HeartMate VE and Novacor N100 LVADs, had a
moderate risk of allocation bias as it used an
alternative procedure for allocating people.80 The
other six studies used a cohort design with non-
randomised allocation of patients to the groups
included in the studies, providing the opportunity
for allocation bias. The risk of selection bias and
confounding was particularly high in five of the
studies,81–83,85,86 a consequence of either the poor
reporting of patient characteristics or the
imbalance in the characteristics of the different
groups. Although the CCT comparing the
HeartMate and Novacor LVADs had a high risk of
selection bias owing to the limited information
provided on patient selection, there appeared to
be no major differences between the groups
limiting the possible effects of confounding.80 The
study by Grady and colleagues84 provides
information on the selection of participants
limiting the opportunity for selection bias. As a
before and after cohort study, the effects of
confounding were not assessed.84 None of the
studies adequately described blinding of patients
or investigators. Although it is unlikely that
patients or investigators would be blinded given
the different treatment options under comparison,
it would be possible to blind those assessing the
outcomes. As a consequence, all seven studies may
be affected by measurement bias. Details of the
reliability and validity of the methods of data
collection used were reported in only one study,84
which focused on assessing QoL. The other six
studies80–83,85,86 provided very limited information
on their methods of data collection and as a
consequence were rated as being methodologically
weak. However, the studies focused on survival,
organ function and functional capacity as the main
outcomes, which tend to be more objective
measures and less prone to bias. Three studies
Health Technology Assessment 2005; Vol. 9: No. 45
27
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
Chapter 3
Systematic review of the clinical effectiveness of 
LVADs for people with ESHFSystematic review of the clinical effectiveness of LVADs for people with ESHF
28
T
A
B
L
E
 
1
5
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
q
u
a
l
i
t
y
 
a
n
d
 
q
u
a
l
i
t
y
 
o
f
 
r
e
p
o
r
t
i
n
g
 
o
f
 
s
t
u
d
i
e
s
 
a
s
s
e
s
s
i
n
g
 
t
h
e
 
c
l
i
n
i
c
a
l
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
o
f
 
L
V
A
D
s
 
a
s
 
a
 
B
T
T
 
f
o
r
 
p
e
o
p
l
e
 
w
i
t
h
 
E
S
H
F
a
R
e
f
e
r
e
n
c
e
S
t
u
d
y
 
d
e
s
i
g
n
 
a
n
d
 
D
e
s
i
g
n
 
a
n
d
 
S
e
l
e
c
t
i
o
n
C
o
n
f
o
u
n
d
i
n
g
B
l
i
n
d
i
n
g
D
a
t
a
 
c
o
l
l
e
c
t
i
o
n
W
i
t
h
d
r
a
w
a
l
s
I
n
t
e
n
t
i
o
n
-
t
o
-
c
o
m
p
a
r
a
t
o
r
a
l
l
o
c
a
t
i
o
n
t
r
e
a
t
F
i
r
s
t
-
g
e
n
e
r
a
t
i
o
n
 
L
V
A
D
s
H
e
a
r
t
M
a
t
e
 
L
V
A
D
E
l
 
B
a
n
a
y
o
s
y
 
e
t
 
a
l
.
,
 
2
0
0
0
8
0
b
C
C
T
M
o
d
e
r
a
t
e
W
e
a
k
 
S
t
r
o
n
g
 
W
e
a
k
 
W
e
a
k
 
S
t
r
o
n
g
 
C
a
n
n
o
t
 
t
e
l
l
(
N
o
v
a
c
o
r
 
L
V
A
D
)
A
a
r
o
n
s
o
n
 
e
t
 
a
l
.
,
 
2
0
0
2
8
2
C
A
 
M
o
d
e
r
a
t
e
W
e
a
k
W
e
a
k
W
e
a
k
 
W
e
a
k
N
/
A
N
o
(
i
n
o
t
r
o
p
i
c
 
d
r
u
g
s
)
B
a
n
k
 
e
t
 
a
l
.
,
 
2
0
0
0
8
3
C
A
 
M
o
d
e
r
a
t
e
W
e
a
k
W
e
a
k
W
e
a
k
W
e
a
k
N
/
A
N
o
(
i
n
o
t
r
o
p
i
c
 
d
r
u
g
s
)
M
a
s
s
a
d
 
e
t
 
a
l
.
,
 
1
9
9
6
8
1
C
A
 
M
o
d
e
r
a
t
e
 
W
e
a
k
W
e
a
k
 
W
e
a
k
 
W
e
a
k
 
N
/
A
 
C
a
n
n
o
t
 
t
e
l
l
(
m
e
d
i
c
a
l
 
c
a
r
e
)
F
r
a
z
i
e
r
 
e
t
 
a
l
.
,
 
1
9
9
2
8
5
C
 
(
h
i
s
t
o
r
i
c
a
l
)
W
e
a
k
 
W
e
a
k
 
W
e
a
k
 
W
e
a
k
 
W
e
a
k
 
S
t
r
o
n
g
N
o
 
(
m
e
d
i
c
a
l
 
c
a
r
e
)
F
r
a
z
i
e
r
 
e
t
 
a
l
.
,
 
1
9
9
4
8
6
C
 
(
h
i
s
t
o
r
i
c
a
l
)
W
e
a
k
W
e
a
k
W
e
a
k
 
W
e
a
k
 
W
e
a
k
W
e
a
k
 
N
o
 
(
m
e
d
i
c
a
l
 
c
a
r
e
)
G
r
a
d
y
 
e
t
 
a
l
.
,
 
2
0
0
1
8
4
C
 
(
b
e
f
o
r
e
 
a
n
d
 
a
f
t
e
r
)
W
e
a
k
 
M
o
d
e
r
a
t
e
 
N
/
A
W
e
a
k
 
S
t
r
o
n
g
 
S
t
r
o
n
g
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
N
o
v
a
c
o
r
 
N
1
0
0
 
L
V
A
D
T
r
a
c
h
i
o
t
i
s
 
e
t
 
a
l
.
,
 
2
0
0
0
8
7
C
A
M
o
d
e
r
a
t
e
W
e
a
k
 
N
/
A
W
e
a
k
 
W
e
a
k
 
N
/
A
 
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
T
o
y
o
b
o
 
L
V
A
D
M
a
s
a
i
 
e
t
 
a
l
.
,
 
1
9
9
5
8
8
C
a
s
e
 
s
e
r
i
e
s
W
e
a
k
W
e
a
k
N
/
A
W
e
a
k
W
e
a
k
N
/
A
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
T
h
o
r
a
t
e
c
 
L
V
A
D
H
o
l
m
a
n
 
e
t
 
a
l
.
,
 
1
9
9
5
8
9
C
a
s
e
 
r
e
p
o
r
t
W
e
a
k
 
W
e
a
k
 
N
/
A
W
e
a
k
W
e
a
k
 
N
/
A
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
M
a
y
 
a
n
d
 
A
d
a
m
s
,
 
1
9
8
7
9
0
C
a
s
e
 
r
e
p
o
r
t
W
e
a
k
W
e
a
k
N
/
A
W
e
a
k
W
e
a
k
N
/
A
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
S
e
c
o
n
d
-
g
e
n
e
r
a
t
i
o
n
 
L
V
A
D
s
J
a
r
v
i
k
 
2
0
0
0
 
L
V
A
D
F
r
a
z
i
e
r
 
e
t
 
a
l
.
,
 
2
0
0
1
9
4
c
C
a
s
e
 
s
e
r
i
e
s
W
e
a
k
W
e
a
k
N
/
A
W
e
a
k
W
e
a
k
N
/
A
N
/
A
(
N
o
 
c
o
m
p
a
r
a
t
o
r
)
c
o
n
t
i
n
u
e
dHealth Technology Assessment 2005; Vol. 9: No. 45
29
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
T
A
B
L
E
 
1
5
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
q
u
a
l
i
t
y
 
a
n
d
 
q
u
a
l
i
t
y
 
o
f
 
r
e
p
o
r
t
i
n
g
 
o
f
 
s
t
u
d
i
e
s
 
a
s
s
e
s
s
i
n
g
 
t
h
e
 
c
l
i
n
i
c
a
l
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
o
f
 
L
V
A
D
s
 
a
s
 
a
 
B
T
T
 
f
o
r
 
p
e
o
p
l
e
 
w
i
t
h
 
E
S
H
F
a
(
c
o
n
t
’
d
)
R
e
f
e
r
e
n
c
e
S
t
u
d
y
 
d
e
s
i
g
n
 
a
n
d
 
D
e
s
i
g
n
 
a
n
d
 
S
e
l
e
c
t
i
o
n
C
o
n
f
o
u
n
d
i
n
g
B
l
i
n
d
i
n
g
D
a
t
a
 
c
o
l
l
e
c
t
i
o
n
W
i
t
h
d
r
a
w
a
l
s
I
n
t
e
n
t
i
o
n
-
t
o
-
c
o
m
p
a
r
a
t
o
r
a
l
l
o
c
a
t
i
o
n
t
r
e
a
t
F
r
a
z
i
e
r
 
e
t
 
a
l
.
,
 
2
0
0
3
1
0
0
c
C
a
s
e
 
s
e
r
i
e
s
W
e
a
k
W
e
a
k
N
/
A
W
e
a
k
W
e
a
k
 
N
/
A
N
/
A
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
M
i
c
r
o
M
e
d
 
D
e
B
a
k
e
y
 
L
V
A
D
N
o
o
n
 
e
t
 
a
l
.
,
 
2
0
0
1
9
1
C
 
(
b
e
f
o
r
e
 
a
n
d
 
a
f
t
e
r
)
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
W
e
a
k
 
W
e
a
k
 
N
/
A
W
e
a
k
W
e
a
k
 
W
e
a
k
C
a
n
n
o
t
 
t
e
l
l
P
o
t
a
p
o
v
 
e
t
 
a
l
.
,
 
2
0
0
0
9
3
C
 
(
b
e
f
o
r
e
 
a
n
d
 
a
f
t
e
r
)
W
e
a
k
 
W
e
a
k
 
N
/
A
W
e
a
k
W
e
a
k
S
t
r
o
n
g
Y
e
s
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
W
i
e
s
e
l
t
h
a
l
e
r
 
e
t
 
a
l
.
,
 
2
0
0
0
9
2
C
 
(
b
e
f
o
r
e
 
a
n
d
 
a
f
t
e
r
)
W
e
a
k
 
M
o
d
e
r
a
t
e
N
/
A
W
e
a
k
W
e
a
k
 
S
t
r
o
n
g
Y
e
s
(
n
o
 
c
o
m
p
a
r
a
t
o
r
)
C
,
 
c
o
h
o
r
t
;
 
C
A
,
 
c
o
h
o
r
t
 
a
n
a
l
y
t
i
c
;
 
C
C
T
,
 
c
o
n
t
r
o
l
l
e
d
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
;
 
N
/
A
,
 
n
o
t
 
a
p
p
l
i
c
a
b
l
e
.
a
T
h
e
 
d
i
f
f
e
r
e
n
t
 
c
r
i
t
e
r
i
a
 
w
e
r
e
 
r
a
t
e
d
 
f
o
l
l
o
w
i
n
g
 
t
h
e
 
g
u
i
d
e
l
i
n
e
s
 
p
r
o
v
i
d
e
d
 
b
y
 
T
h
o
m
a
s
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
7
7
w
i
t
h
 
s
o
m
e
 
a
d
a
p
t
a
t
i
o
n
s
 
(
s
e
e
 
A
p
p
e
n
d
i
x
 
1
1
)
.
 
W
h
e
r
e
 
c
r
i
t
e
r
i
a
 
a
r
e
 
r
a
t
e
d
 
a
s
 
w
e
a
k
,
m
o
d
e
r
a
t
e
 
o
r
 
s
t
r
o
n
g
,
 
i
t
 
r
e
l
a
t
e
s
 
t
o
 
t
h
e
 
s
t
u
d
y
’
s
 
m
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
n
t
r
o
l
 
o
f
 
t
h
e
 
c
r
i
t
e
r
i
a
.
 
A
s
 
s
u
c
h
,
 
i
f
 
a
 
s
t
u
d
y
 
i
s
 
r
a
t
e
d
 
a
s
 
s
t
r
o
n
g
 
i
t
 
i
n
d
i
c
a
t
e
s
 
t
h
a
t
 
t
h
e
r
e
 
i
s
 
a
 
l
o
w
 
r
i
s
k
 
o
f
 
b
i
a
s
 
f
o
r
 
t
h
e
 
p
a
r
t
i
c
u
l
a
r
c
r
i
t
e
r
i
a
.
 
W
h
e
r
e
 
a
 
c
o
m
p
o
n
e
n
t
 
i
s
 
c
o
n
s
i
d
e
r
e
d
 
n
o
t
 
t
o
 
b
e
 
r
e
l
e
v
a
n
t
 
t
o
 
a
 
s
t
u
d
y
 
d
e
s
i
g
n
,
 
i
t
 
i
s
 
r
e
f
e
r
r
e
d
 
t
o
 
a
s
 
n
o
t
 
a
p
p
l
i
c
a
b
l
e
 
(
N
/
A
)
.
b
A
l
t
h
o
u
g
h
 
t
h
e
 
s
t
u
d
y
 
b
y
 
E
l
 
B
a
n
a
y
o
s
y
 
a
n
d
 
c
o
l
l
e
a
g
u
e
s
8
0
c
o
m
p
a
r
e
d
 
t
h
e
 
N
o
v
a
c
o
r
 
N
1
0
0
 
a
n
d
 
H
e
a
r
t
M
a
t
e
 
V
E
 
L
V
A
D
s
,
 
t
h
e
 
r
e
s
u
l
t
s
 
a
r
e
 
d
i
s
c
u
s
s
e
d
 
a
s
 
p
a
r
t
 
o
f
 
t
h
e
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
t
h
e
 
H
e
a
r
t
M
a
t
e
L
V
A
D
s
.
c
T
h
e
r
e
 
m
a
y
 
b
e
 
s
o
m
e
 
o
v
e
r
l
a
p
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
s
t
u
d
i
e
s
,
 
a
l
t
h
o
u
g
h
 
t
h
i
s
 
w
a
s
 
n
o
t
 
f
o
r
m
a
l
l
y
 
i
d
e
n
t
i
f
i
e
d
.were rated as strong80,84,85 and one as weak86 on
methodological quality of reporting of withdrawals
or drop-outs from the different groups. Three
studies were not assessed on the criteria for
withdrawals as they were considered not applicable
for retrospective studies.81–83 In addition, none of
the studies either reported results using an
intention-to-treat analysis82,83,85,86 or it was unclear
how results were reported,80,81 providing the
possibility for the studies to be affected by attrition
bias. Intention-to-treat analysis was considered not
applicable for the study by Grady and
colleagues.84 One retrospective cohort analytic
study comparing heart transplant patients
supported with an LVAD or usual care reported
selected outcomes for an additional group who
had an LVAD implanted.82 Although the LVAD
implanted group included the patients who had
had a heart transplant following support from an
LVAD, it included patients with an LVAD who did
not have a heart transplant. As no information was
provided on the characteristics of this group, they
were excluded from assessment in the systematic
review.
Novacor
Of the two studies assessing the Novacor LVAD,
one compared the LVAD with the HeartMate VE
LVAD and the methodological quality is discussed
in the section on the HeartMate device above.80
The other study, a cohort analytic study assessing
the clinical effectiveness of short- and long-term
use of the Novacor LVAD, was judged to be of
weak methodological quality (see Appendix 13).87
Although the study design limited the possible
effects of allocation bias, the risk of selection bias
was high owing to the poor reporting of the
characteristics of the different patient groups.
Similarly, there was no description of blinding of
the assessment of outcomes with the possibility of
the study being affected by measurement bias.
Although there was limited discussion of the
methods of data collection, outcomes focused on
reasonably objective measures of survival and
adverse events. The study was not judged on the
criteria assessing confounding, withdrawals and
intention-to-treat analysis. 
Toyobo
The methodological quality of the case series
study assessing the Toyobo LVAD was weak
(Appendix 14).88 The study provided limited
information on the selection of the participants
and whether they were representative of the target
population or on the methods of data collection
and blinding of outcome assessment. As a
retrospective case series, the criteria judging
confounding, withdrawals and the intention-to-
treat analysis were considered not relevant.
Thoratec
The two case reports89,90 of the Thoratec device
were judged to be of weak methodological quality
(Appendix 15). The risk of selection bias was high
in both studies, a consequence of the very limited
information provided about the patients. Neither
study blinded the assessment of outcomes
providing the opportunity for ascertainment bias.
Although limited information was provided on the
tools and methods of data collection, objective
outcome measures were assessed limiting the
possibility for bias. The criteria for confounding,
blinding, withdrawals and the intention-to-treat
analyses were not strictly applicable to these types
of study design.
Second-generation LVADs
Jarvik
Two case series studies evaluating the Jarvik 2000
LVAD were judged to be methodologically
weak,94–100 with poor reporting of the selection
criteria for participants and the methods of data
collection (Appendix 16). Outcome assessment was
not blinded, providing the opportunity for
ascertainment bias. The criteria judging
confounding, withdrawals and intention-to-treat
analysis were thought not to be relevant to assess
the studies given their study designs.
MicroMed DeBakey
The methodological quality of the three before
and after cohort studies evaluating the MicroMed
DeBakey device91–93 was judged to be weak
(Appendix 17). These studies are subsets of a
multicentre study and are therefore likely to
include some repeat observations in their
publications. Although the authors of these studies
were contacted to establish the possible overlap,
they were unable to clarify the position. There was
a moderate92 to high91,93 risk of selection bias in
the studies as they provided limited information
on the selection of patients. None of the studies
discuss the blinding of outcome assessment or the
validity and reliability of data collection tools and
are considered to be methodologically weak.
Withdrawals and drop-outs were discussed and
patients are analysed on an intention-to-treat basis
in two studies, limiting the effects of attrition
bias.92,93 In the other study, limited information is
provided on withdrawals and whether the patients
were assessed as intention-to-treat.91 The criteria
judging confounding were not assessed as they
were thought not to be relevant to before and after
cohort studies.
Systematic review of the clinical effectiveness of LVADs for people with ESHF
30Generalisability 
The generalisability or external validity of the
studies was assessed through a comparison of the
key characteristics of the patient groups (Table 16).
Unfortunately, the lack of information provided in
the studies limits any comparisons. The six studies
comparing the HeartMate IP and/or VE LVAD
with inotropes or usual medical care tended to
focus on patients who were male (range 66.7–97%)
with a mean age between 40 and 53 years,
classified as NYHA Class IV or in United Network
for Organ Sharing (UNOS) status group 1 and
with an ischaemic aetiology (29–75%). The study
comparing the HeartMate VE with the Novacor
N100 LVAD was mainly focused on males (95%),
with a mean age of 55 years with idiopathic
(45–65%) or ischaemic cardiomyopathy
(30–50%).80 Similarly, the study of the Novacor
LVAD included male patients (100%) with a mean
age of 47–51 years with ischaemic aetiology
(40–80%), whereas the study of the Toyobo LVAD
was of males (100%) with a mean age of 40 years
and idiopathic dilated cardiomyopathy. One study
of the Jarvik 2000 LVAD focused on males (66%)
with a mean age of 47 years and suffering from
ischaemic aetiology,94 whereas in the other case
study patient ages ranged from 30 to 70 years,
73% were male and 50% suffered from dilated
cardiomyopathy and 50% from ischaemic
cardiomyopathy.94–100 The patients in the
MicroMed DeBakey studies range in age from 33
to 65 years and were predominantly male. The
case studies of the Thoratec LVAD each reported
male patients. In one,90 the patient was a 24-year-
old male with a 2-year history of cardiomyopathy.
In the second study,89 the patient was a 45-year-
old male admitted post-MI.
Assessment of the clinical effectiveness
of LVADs as a bridge to heart
transplantation
Survival
First-generation LVADs
HeartMate. The CCT by El Banayosy and
colleagues80 compared the survival of patients
supported with the HeartMate VE LVAD (n = 20)
with those supported with the Novacor N100
(n = 20) through implantation of the LVAD and
heart transplantation (Table 17 and Appendix 12).
All patients survived implantation of the LVAD
devices. El Banayosy and colleagues80 reported
that 60% of the patients with the HeartMate VE
LVAD and 65% of the patients with the Novacor
LVAD survived to heart transplantation (p not
stated). Although 70% (14 patients) of the
HeartMate and 75% (15 patients) of the Novacor
patients were discharged from hospital to home
with the device in place to await transplant, nine
patients with the HeartMate and 10 patients with
the Novacor had to be readmitted with
complications. Three patients with the Novacor
LVAD and two patients with the HeartMate LVAD
were awaiting transplantation. Four patients with
the Novacor LVAD and six patients with the
HeartMate LVAD died while on LVAD support. 
Two cohort analytic studies82,83 assessed the effect
on patient survival of the use of HeartMate IP
and/or VE LVAD compared with the use of intropic
agents (Table 17). The study by Aaronson and
colleagues82 found a limited difference in survival
to heart transplantation for patients receiving a
HeartMate LVAD [73% (9% still on waiting list), n
= 66] compared with those patients receiving
inotropic agents (74%, n = 38) (p not stated).
Similarly, actuarial survival to heart transplant was
not significantly different (p = 0.2) between the
patients receiving an LVAD and those receiving
inotropic agents at 1 month (81% versus 78%) or
at 3 months (81% versus 64%). Differences were
evident in survival of the groups following heart
transplantation. Post-transplantation actuarial
survival was significantly (p = 0.007) higher for
those receiving the HeartMate LVAD compared
with those on inotropic agents at 1 year (98%
versus 74%), 3 years (95% versus 65%) and 4 years
(95% versus 65%). As a consequence, overall
actuarial survival from the onset of bridging
support was significantly (p = 0.03) higher for
patients receiving the LVAD (80% at 1 year and
77% at 3 and 4 years) than for those receiving
inotropes (56% at 1 year and 44% at 3 and
4 years). In reporting the differences in survival,
Aaranson and colleagues82 noted the disparity
between the groups of patients selected for the
study and the potential effects on the outcomes
assessed. As a consequence, Aaranson and
colleagues82 undertook a subgroup analysis
comparing the patients receiving inotropic agents
who were eligible for placement of an LVAD and
those considered ineligible owing to the severity of
their illness. Analysis of survival to heart
transplantation showed that there was no
significant (p = 0.18) difference between the
groups. In addition, Aaronson and colleagues82
reported data on a second comparison group
(n = 60) who were classified as UNOS status 2
patients, that is, patients who are less severely ill
than those receiving the LVAD or inotropic agents.
When compared with those receiving a HeartMate
LVAD, the UNOS status 2 patients had a lower
post-transplant actuarial survival rate at 1 year
(98% versus 86%), 3 years (95% versus 77%) and
4 years (95% versus 77%), although the difference
Health Technology Assessment 2005; Vol. 9: No. 45
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swas not significant (p = 0.1). In a comparison of
the HeartMate IP LVAD (n = 20) and inotropic
agents (n = 20), Bank and colleagues83 found a
higher but not significant survival at 6 months
post-heart transplantation for those receiving an
LVAD (88.9%, n = 18) than for those on inotropes
(73.7%, n = 19) (p not stated). In addition,
patients supported with an LVAD were
significantly (p < 0.05) more likely to have
survived 6 months post-heart transplantation
without major complications (55.6%) compared
with those supported by inotropes (15.8%).
Three studies, one cohort analytic81 and two cohort
with historic controls,85,86 compared patient
survival following receipt of a HeartMate LVAD
with that from usual care (Table 17 and Appendix
12). In the study by Massad and colleagues,81 the
comparison of survival to transplant,
transplantation rates and post-heart transplant
survival for patients who had received a HeartMate
LVAD (n = 53) with those who were not given an
LVAD (n = 203) showed no statistically significant
difference. Eighty per cent of patients receiving a
HeartMate LVAD and 84% of the patients who
were not given an LVAD underwent transplantation
[p = not significant (ns)]. Post-operative mortality
at 30 days was 3.8% for those receiving an LVAD
and 4.4% for those who did not have an LVAD (p =
ns). Some 91% of patients receiving an LVAD
survived following heart transplantation compared
with 86% of patients who were not given the LVAD
after a mean follow-up of 22 months (17 months
LVAD group, 23 months non-LVAD group;
p = 0.01). Similarly, there was no statistically
significant difference in actuarial survival at 1-year,
94% of patients receiving the LVAD and 88% of
patients who were not given the LVAD survived
(p = ns). In addition, Massad and colleagues81
compared the actuarial survival of patients
receiving an LVAD with subgroups of patients who
did not receive an LVAD based on their UNOS
status [i.e. UNOS status 1 (n = 126) and status 2 (n
= 74)]. At 1 year, patients not receiving an LVAD
and who had a UNOS status 1 had an actuarial
survival of 91% compared with 86% for UNOS
status 2 patients and 94% for patients receiving an
LVAD. At 3 years the differences between the
groups had decreased, with actuarial survival rates
of 85.8% for UNOS status 1 patients, 82.5% UNOS
status 2 patients and 84.9% for the patients
receiving LVADs (p not stated). Although Massad
and colleagues81 found no statistically significant
difference in measures of survival between the
different treatment groups, the poor
methodological quality of the study suggest that
the results should be interpreted with caution.
Significant differences in the two groups’ baseline
characteristics, particularly their UNOS status and
underlying diagnosis, may affect the survival rates
(Table 17 and Appendix 12). 
Frazier and colleagues85 retrospectively studied
patients with HeartMate IP LVADs (n = 34) and
compared these with historical controls who
received usual care (n = 6). In the LVAD group,
eight patients did not meet the study inclusion
criteria but received an LVAD and were included
in the analysis of patient survival (Table 17 and
Appendix 12). Sixty-four per cent of all patients
who received an LVAD survived to heart
transplantation (excludes three patients awaiting
transplantation) compared with 50% of patients
receiving usual care. Of the 20 LVAD patients
transplanted, 17 patients met the eligibility
criteria for receipt of an LVAD and three did not.
Three patients with an LVAD were still waiting for
heart transplantation at the end of the study.
Survival of patients for over 60 days post-heart
transplant differed significantly between the two
groups (p < 0.05), with 52% (n = 31) of
transplanted patients with an LVAD surviving
compared with 17% (n = 6) of those on usual care.
Among the 23 patients who met the criteria for
and received an LVAD, 65% survived for >60 days
after receiving their heart transplant compared
with 13% of the eight patients not meeting the
criteria. The survival rate of the LVAD patients was
significantly greater than that for the patients
receiving usual care (p < 0.05).
In another cohort study comparing HeartMate IP
LVAD patients (n = 19) with historical medical
controls (n = 12), Frazier and colleagues86
reported higher survival rates among patients with
the LVADs (Table 17 and Appendix 12). Eighty-
four per cent of patients with an LVAD underwent
heart transplantation with 11% of patients dying
during support. In contrast, 25% of patients
receiving usual medical care underwent heart
transplantation, with the remaining 75% dying
while awaiting transplant. None of the patients
receiving usual medical care survived
transplantation. One patient with an LVAD
remained on the heart transplant waiting list.
Actuarial survival rates at one and 2 years post-
transplant for patients receiving an LVAD were
100% (n = 16) compared with 0% (n = 3) for the
patients receiving usual medical care (p < 0.05). 
Novacor. One retrospective cohort analytic study
compared survival of patients supported with
Novacor N100 LVAD for <30 days (n = 5) with
those supported for >30 days (n = 5) (Table 17
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TABLE 17 Summary of evidence of patient survival following treatment of patients with ESHF as a BTT
Study Outcomes Intervention Comparison p-Value
First-generation LVADs
HeartMate LVAD
El Banayosy et al.,  HeartMate Novacor
200080 Survival to transplantation (%) 12/20 (65) 13/20 (60) Not stated
3 Novacor group and 2 HeartMate group are awaiting transplantation
Aaronson et al., 200282 HeartMate Inotropic agents
Survival to transplant (%) 48/66 (73) 28/38 (74) Not stated
Actuarial survival to transplant  1 month: 81 (SD 5) 1 month: 78 (SD 8) 0.2
(% ± SD) 3 months: 81 (SD 5) 3 months 64 (SD 11)
Median: 2.9 months Median: 2.9 months
No. alive post-transplantation (%) 0 days: 48 (78) 0 days: 28 (74) Not stated
30 days: 47 (71) 30 days: 24 (63)
1 year: 31 (47) 1 year: 17 (45)
3 years: 9 (14) 3 years: 6 (16)
Post-transplantation actuarial  1 year: 98 (SD 2) Inotrope: LVAD vs 
survival (% ± SD) 3 years: 95 (SD 4) 1 year: 74 (SD 9) inotrope, 
4 years: 95 (SD 4) 3 years: 65 (SD 10) 0.007
4 years: 65 (SD 10)
UNOS status 2: LVAD vs 
1 year: 86 (SD 4) Unos
3 years: 77 (SD 7) status 2, 0.1
4 years: 77 (SD 7)
Overall actuarial survival  1 year: 80 (SD 5) 1 year: 56 (SD 8) 0.03
(% ± SD) 3 years: 77 (SD 6) 3 years: 44 (SD 9)
4 years: 77 (SD 6) 4 years: 44 (SD 9)
Bank et al., 200083 HeartMate Inotropic agents
Survival 6 months post-transplant  16/18 (88.9) 14/19 (73.7) Not stated
(%) (n = 18 LVAD, 19 inotrope)
Survival to 6 months without major  10/18 (55.6)  3/19 (15.8) <0.05
complications post-transplant (%)
Massad et al., 199681 HeartMate Medical care
Transplant rate (%) 42/53 (80) 170/203 (84) ns
Survivors (%) 48/53 (91) 174/203 (86) ns
Actuarial survival at 1 year  94% 88% (all non-LVAD) ns
(Kaplan–Meier) UNOS 1: 91%
UNOS 2: 86%
36-month survival (Kaplan–Meier) 84.9% UNOS 1: 85.8%
UNOS 2: 82.5%
Frazier et al., 199285 HeartMate Medical care
Received transplant (%) Total with LVAD:  3/6 (50) Not stated
(3 remained on LVAD) 20/31 (64)
Subset with LVAD 
who meet study 
criteria: 17/23 (74)
Survival >60 days (%) Total with LVAD:  1/6 (17) Survival rate 
16/31 (52) of LVAD 
Subset with LVAD  group 
who meet study  greater than 
criteria: 15/23 (65) control,
<0.05
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TABLE 17 Summary of evidence of patient survival following treatment of patients with ESHF as a BTT (cont’d)
Study Outcomes Intervention Comparison p-Value
Frazier et al., 199486 HeartMate Medical care
Successful transplantation (%) 16/19 (84) 0/12 (0)
Actuarial survival 1and 2 years 16 with successful  0/3 (0) <0.05
transplant: 100%
Grady et al., 200184 Survival not assessed
Novacor N100 LVAD
Trachiotis et al., 200087 LVAD <30 days LVAD >30 days
Survival post-transplant or  100 100 Not stated
explant 30 days (%)
Survival post-transplant or explant  100 80 Not stated
1 year (%)
Survival post-transplant or explant  100 Not reported Not stated
2 year (%)
Survival post-transplant or explant  60 60 Not stated
3 year (%)
Toyobo LVAD
Masai et al., 199588 Survival Patient 1 supported  No comparison Not stated
for 119 days then 
transplanted.
Patient 2 still 
supported at 390 days.
Patient 3 supported 
for 64 days then died
Thoratec LVADs
Holman et al., 199589 Survival Patient survived for  No comparison Not stated
60 days and then 
transplanted
May and Adams, 198790 Survival Patient survived for  No comparison Not stated
3 weeks post-
transplant and was 
discharged home
Second-generation LVADs
Jarvik 2000 LVADs
Frazier et al., 200194a Successful transplant (%) 2/3 (67) No comparison Not stated
Frazier et al., 2003100a Survival Of 22 patients,  No comparison Not stated
13 underwent heart 
transplant; 7 died 
awaiting transplant, 
2 ongoing at 92 and 
105 days post-implant
MicroMed DeBakey LVADs
Noon et al., 200191 Probability of survival at 30 days 81% No comparison Not stated
Number transplanted (%) 11 of 32 patients (34) No comparison Not stated
Deaths on support (%) 10 of 32 patients (31) No comparison Not stated
continuedand Appendix 13).87 Survival at 30 days post-heart
transplant or explant of the LVAD (one patient was
explanted) was 100% in both groups. At 1 year
post-transplant, survival in those supported for
<30 days was still 100%, but had declined to 80%
in the group who had been supported for
>30 days. After 3 years, however, survival in both
groups was 60%. No statistical data analysis was
reported in the study. A CCT comparing the
Novacor N100 with the HeartMate VE LVAD
reported survival to transplant; results are
presented in the section discussing the HeartMate
LVADs.
Toyobo. One case series study reported survival as
the duration of support with the Toyobo LVAD for
three patients (Table 17 and Appendix 14).88 One
patient was supported for 119 days then
transplanted, one was still supported and awaiting
a transplant at 390 days and the final patient was
supported for 64 days but then died. 
Thoratec. Two case reports of the Thoratec LVAD
reported survival data (Table 17 and Appendix
15).89,90 In one a 45-year-old male patient survived
for 60 days and was then transplanted.89 In the
second case report,90 a 24-year-old male was
supported for 21 days and then transplanted; he
was discharged home 3 weeks after transplantation.
Second-generation LVADs
Jarvik. Two case series of the Jarvik 2000 LVAD
reported survival to transplantation (Table 17 and
Appendix 16).94–100 In a case series94 of three
patients, a successful heart transplant rate of 67%
was reported with one patient still awaiting
transplant. A multicentre case series study, which
also assessed patients supported long term with
LVAD (see the section ‘LVADs as a long-term
chronic support’ p. 58), reported survival to heart
transplantation for 22 patients with the indication
of BTT.95–100 Of these, 13 patients underwent
heart transplant, seven patients had died and two
patients continued to be supported by the device. 
MicroMed DeBakey. A multicentre before and
after cohort study of the MicroMed DeBakey
device has been undertaken in the USA and
Europe (Table 17 and Appendix 17). Some of the
centres involved in the study have published their
results separately.91–93 One paper reports data
from the first 32 of the 51 patients studied to date
and may include patients reported by the other
centres.91 Probability of survival in the 32 patients
at 30 days was 81%. Of these 32 patients, 11
received a heart transplant and 10 died. In the
reports from the Austrian centre,92,101–103 eight of
the 10 patients included survived to follow-up;
four of these were transplanted and four were
awaiting transplantation. In the study by the
German centre,93 five of the six patients included
survived to follow-up. Two of these received a
heart transplant. 
Functional status
First-generation LVADs
HeartMate. Two cohort studies with historical
controls report data on functional status of
patients using the NYHA functional classification
(Table 18 and Appendix 12).85,86 Frazier and
Health Technology Assessment 2005; Vol. 9: No. 45
39
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
TABLE 17 Summary of evidence of patient survival following treatment of patients with ESHF as a BTT (cont’d)
Study Outcomes Intervention Comparison p-Value
Wieselthaler et al., 200192 Survival (%) 8 (80) survived; 4  No comparison Not stated
(40) transplanted; 
4 (40) awaiting 
transplant; 2 (20) 
died
Deaths on support (%) 2 (20) patients  No comparison Not stated
(1 patient died from 
MOF after 25 days; 
1 patient died infectious 
complications leading 
to MOF 142 days 
post-operation)
Potapov et al., 200093 Number transplanted (%) 2 (34) No comparison Not stated
Deaths on support (%) 1 (17) No comparison Not stated
MOF, multiple organ failure.
a There may be some overlap between the two studies, although this was not formally identified.colleagues85 compared the change in the NYHA
functional class for patients receiving an LVAD
with those on usual medical care. Prior to
treatment 100% of patients in the LVAD group
(n = 34) were in NYHA Class IV, whereas 83% of
patients receiving usual medical care (n = 6) were
in Class IV and 17% were in Class III. Of the 16
patients with an LVAD surviving 60 days post-heart
transplantation, 94% were in Class I and 6% in
Class II. In contrast, the one patient in the control
group who survived heart transplantation was in
Class IV (p not reported). In another study, Frazier
and colleagues86 reported that all patients
receiving an LVAD were in NYHA Class IV prior to
implantation (n = 19), with 94% in NYHA Class I
following heart transplantation (although one
patient was unable to ambulate owing to the poor
position of the pneumatic drive line) (p not
reported). Change in NYHA classification was not
reported by Frazier and colleagues86 for the
historical control group who received usual care.
Second-generation LVADs
Jarvik. Only one study, a subset of patients in a
case series of the Jarvik 2000 LVAD,95 reported
changes in the functional status of patients
(Table 18 and Appendix 16). The 10 patients
included in the case series were in NYHA Class IV
prior to implantation of the Jarvik 2000 LVAD.
Post-implantation of the device, seven patients
improved to NYHA Class I and three patients died.
Quality of life
First-generation LVADs
HeartMate. One cohort study by Grady and
colleagues84 reported the QoL of 30 patients with
the HeartMate LVAD before and 1–2 weeks after
implantation on a range of indices (see Table 19
and Appendix 12). On the Quality of Life Index
(score from 0.00 = very dissatisfied to 1.00 = very
satisfied) the mean (SD) total QoL improved
significantly (p = 0.037) from 0.66 (0.14) before
implantation to 0.73 (0.13) 1–2 weeks after
implantation. There were significant
improvements in satisfaction on the subcategories
of significant others (before 0.84, after 0.90;
p = 0.002) and health functioning (before 0.51,
after 0.66; p = 0.001), but significant worsening of
satisfaction in the socio-economic subcategory
(before 0.72, after 0.50; p < 0.0001). In contrast,
there was no change in the psychological
subcategory (before 0.64; after 0.64; p = ns).
Patients were generally more satisfied than
dissatisfied with their lives before and after surgery
as all mean scores were found to be ≥0.50.
Similarly on the Heart Failure Symptom Checklist
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TABLE 18 Summary of evidence of patients’ functional status following treatment of patients with ESHF as a BTT
Study Outcomes Intervention Comparison p-Value
First-generation LVADs
HeartMate LVAD
Frazier et al., 199285 NYHA functional class HeartMate LVAD Usual medical care
LVAD implantation/time of meeting  34/34 (100) in  5/6 (83) Class IV Not stated
study criteria (for controls) (%) Class IV 1/6 (17) Class III
60 days after transplantation  15/16 (94) in Class I 1/1 (100) Class IV Not stated
(surviving patients) 1/16 (6) in Class II
Frazier et al., 199486 NYHA functional class HeartMate LVAD Usual medical care
Implantation All Class IV (n = 19) Not reported for  N/A
comparator
Transplant (%) 15/16 (94) Class I Not reported for  N/A
(1 patient unable to  comparator
ambulate owing to 
poor position of 
pneumatic drive line)
Second-generation LVADs
Jarvik 2000 LVAD
Westaby et al., 200295 NYHA functional class Jarvik 2000 No comparator
Baseline (n = 10) 10/10 in Class IV N/A
Post-implantation of LVAD (n = 10) 7/10 in Class I N/A
3/10 diedHealth Technology Assessment 2005; Vol. 9: No. 45
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TABLE 19 Summary of evidence of patients’ QoL following treatment of patients with ESHF as a BTT
Study Outcomes Baseline Follow-up p-Value
First-generation LVADs
HeartMate LVADs
Grady et al., 200184 Before implantation 1–2 weeks after 
implantation
QOL Index (0.00 very dissatisfied, 1.00 = very satisfied) (mean ± SD)
Significant others 0.84 (0.10) 0.90 (0.08) 0.002
Socio-economic 0.72 (0.21) 0.50 (0.25) <0.0001
Psychological 0.64 (0.22) 0.64 (0.24) ns
Health functioning 0.51 (0.18) 0.66 (0.17) 0.001
Total score 0.66 (0.14) 0.73 (0.13) 0.037
Rating Question Form (mean ± SD)
Stress level (1 = no stress,  6.2 (2.5)  4.9 (2.9) ns
10 = very much stress)
Coping ability (1= very poorly,  7.7 (2.0) 6.6 (2.6) 0.026 (ns)a
10 = very well)
Health (1 = very poor,  4.0 (3.1) 6.2 (2.4) 0.012 (ns)a
10 = very good)
QoL (1 = very poor,  3.5 (2.5) 5.9 (2.7) 0.002
10 = very good)
How well will do/doing after  8.7 (1.3) 7.1 (2.1) 0.001
LVAD (1 = very poorly, 
10 = very well)
How well will do/doing after HT  9.3 (0.9) 9.3 (1.1) ns
(1= very poorly, 10 = very well)
Heart Failure Symptom Checklist (0.00 = not bothered at all, 1.00 = very bothered) 
(mean ± SD)
Cardiopulmonary 0.37 (0.18) 0.23 (0.18) 0.002
Gastrointestinal 0.26 (0.12) 0.19 (0.14)  0.004
Psychological 0.25 (0.20) 0.20 (0.19) ns
Genitourinary 0.23 (0.15) 0.14 (0.13) 0.002
Neurological 0.22 (0.12) 0.17 (0.11) 0.017 (ns)
Dermatological 0.08 (0.08) 0.06 (0.08) ns
Physical (all except psychological) 0.22 (0.09) 0.16 (0.09) 0.001
Total score 0.23 (0.10) 0.16 (0.10) 0.002
Functional disability from the Sickness Impact Profile (0.00 = least disability to 1.00 =
most disability) (mean ± SD)
Recreation 0.54 (0.30) 0.46 (0.30) ns
Home management 0.49 (0.32) 0.43 (0.39) ns
Work 0.48 (0.09) 0.50 (0.00) ns
Sleep/rest 0.40 (0.29) 0.43 (0.29) ns
Social interaction 0.35 (0.20) 0.34 (0.25) ns
Mobility 0.34 (0.24) 0.29 (0.27) ns
Ambulation 0.30 (0.17) 0.35 (0.22) ns
Alertness 0.23 (0.33) 0.20 (0.24) ns
Self-care 0.20 (0.15) 0.30 (0.15) 0.002
Eating 0.17 (0.11) 0.14 (0.11) ns
Emotional behaviour 0.12 (0.15) 0.17 (0.22) ns
Communication 0.10 (0.18) 0.17 (0.25) ns
Psychological disability 0.24 (0.16) 0.25 (0.19) ns
Physical disability 0.34 (0.13) 0.35 (0.14) ns
Total score 0.30 (0.13) 0.32 (0.14) ns
Second-generation LVADs
No studies of second-generation devices
a Grady and colleagues state that the differences were not statistically significant as p > 0.01.(0.00 = not bothered at all, 1.00 = very bothered),
the mean total score improved significantly
(p = 0.002) from 0.23 (0.10) before to 0.16 (0.10)
after implantation of the LVAD. The subcategories
of cardiopulmonary (before 0.37, after 0.23;
p = 0.002), gastrointestinal (before 0.26, after
0.19; p = 0.004), genitourinary (before 0.23, after
0.14; p = 0.002), neurological (before 0.22, 
after 0.17; p = 0.017) and physical (before 
0.22, after 0.16; p = 0.001) improved significantly
from pre- to post-implantation of the LVAD.
Improvements in the subcategories of
psychological (before 0.25, after 0.20; p = ns) and
dermatological (before 0.08, after 0.06; p = ns)
improved but not significantly. Patients were
generally ‘less bothered’ than ‘more bothered’ by
symptoms both before and after device implant as
scores were all below the mean of 0.50.
The mean (SD) total score on functional disability
from the Sickness Impact Profile (0.00 = least
disability to 1.00 = most disability) worsened in
patients following implantation of the LVADs with
an insignificant increase (p = ns) in the index from
0.30 (0.13) before implant and 0.32 (0.14) after
implant. Only the self-care subcategory was found
to worsen significantly (p = 0.002), increasing
from 0.20 (0.15) before to 0.30 (0.15) after LVAD
implantation. Similarly the subcategories of work
(before 0.48, after 0.50), sleep/rest (before 0.40,
after 0.43), ambulation (before 0.30, after 0.35),
emotional behaviour (before 0.12, after 0.17),
communication (before 0.10, after 0.17),
psychological disability (before 0.24, after 0.25)
and physical disability (before 0.34, after 0.35)
worsened, although not significantly (p = ns). In
contrast, the subcategories of recreation (before
0.54, after 0.46), home management (before 0.49,
after 0.43), social interaction (before 0.35, after
0.34), mobility (before 0.34, after 0.29), alertness
(before 0.23, after 0.20) and eating (before 0.17,
after 0.14) improved but not significantly (p = ns).
On the global ratings of different areas of QoL
from the Rating Question Form there were
significant improvements in the mean (SD) QoL
(1 = very poor, 10 = very good) [before 3.5 (2.5),
after 5.9 (2.7); p = 0.002] and health (1 = very
poor, 10 = very good) [before 4.0 (3.1), after 6.2
(2.4); p = 0.012]. In contrast, patients’ response to
‘How well will do/doing after LVAD’ (1 = very
poorly, 10 = very well) worsened significantly
[before 8.7 (1.3), after 7.1 (2.1); p = 0.001], as it
did for coping ability (1 = very poorly, 10 = very
well) [before 7.7 (2.0), after 6.6 (2.6); p = 0.026].
Stress levels (1 = no stress, 10 = very much stress)
improved [before 6.2 (2.5), after 4.9 (2.9); p = ns]
but not significantly. Patients’ response to ‘How
well will do/doing after heart transplant’ (1 = very
poorly, 10 = very well) did not change [before 9.3
(0.9), after 9.3 (1.1); p = ns].
Second-generation LVADs
None of the studies of the second-generation
devices reported changes in the QoL of patients
on recognised outcome measures. 
Adverse events
First-generation LVADs
HeartMate. Adverse events were reported by the
CCT comparing the HeartMate VE LVAD with the
Novacor N100 LVAD,80 and also the three cohort
analytic studies81–83 and the three cohort studies84–86
assessing the HeartMate LVAD compared with
inotropic agents or usual medical care (Table 20
and Appendix 12), focusing on survival of patients
without major complications, mortality from
adverse events, rates of infections and mechanical
failures associated with the different devices. 
Mortality from adverse events El Banayosy and
colleagues80 reported deaths from adverse events
of patients while supported by either the
HeartMate VE LVAD (n = 20) or the Novacor
N100 LVAD (n = 20). Six patients with HeartMate
LVADs died [multiorgan failure (MOF)/sepsis, five
patients; cerebral bleeding, one patient] compared
with four patients supported by the Novacor N100
LVAD (MOF/sepsis, three patients; cerebral
bleeding, one patient) (p not stated). 
Patients receiving the HeartMate LVAD were less
likely to suffer or die from major complications
either before or after heart transplantation than
those patients on inotropic agents or usual
medical care. Bank and colleagues83 reported a
significantly (p < 0.05) higher proportion of
patients with LVADs (55.6%, n = 18) surviving to
6 months without major complications post-
transplant than for patients receiving inotropic
agents (15.8%, n = 19). In comparing the use of
LVADs with inotropic agents, Aaronson and
colleagues82 found a higher pre- (LVADs 18%,
inotropes 26%; p not stated) and post- (LVADs 4%,
inotropes 32%; p = 0.045) heart transplant
mortality among those patients receiving inotropic
agents. The underlying causes of pre-heart
transplant mortality were cerebrovascular accident
(LVADs 1, inotropes 1), device failure (LVADs 1),
haemorrhage (LVADs 1), MOF and/or sepsis
(LVADs 5, inotropes 4), right-sided circulatory
failure (LVADs 4), sudden death (inotropes 2) and
refractory cardiogenic shock (inotropes 3), whereas
the cause of post-transplant mortality was
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TABLE 20 Summary of evidence of adverse events following treatment with first-generation LVADs of patients with ESHF as a BTT
Study Outcome Intervention Comparison p-Value
HeartMate LVADs
El Banayosy et al., 200080 Novacor 100N HeartMate LVAD
Death (%) 4/20 (20) 6/20 (30) Not stated
MOF/sepsis: 3 MOF/sepsis: 5
Thromboembolism: 1 Cerebral bleeding: 1
Neurological complications and device-related infections: (events/patient/month, 95% CI):
Thromboembolic event (%) 4 (20) (0.026, 0.001  0 0.1
to 0.051)
(on days 14–67, 
mean 29 days)
Driveline infection (%) 4 (20) (0.026, 0.01  9 (45) (0.078, 0.029  0.09
to 0.051) to 0.127)
Pocket infection (%) 2 (10) (0.013, –0.005  5 (25) (0.044, 0.006  0.1
to 0.031) to 0.082)
Device-related infections  4 (20) (0.025,  11 (55) (0.096,  0.02
(days 30–111, mean 58 days) (%) 0.001 to 0.051) 0.042 to 0.15)
Controller exchange (technical) (%) 2 (10) (0.013,  14 (70) (0.122,  <0.001
–0.005 to 0.031) 0.062 to 0.182)
Driveline crack (%) 3 (15) (0.019,  2 (10) (0.017,  0.6
–0.003 to 0.041) –0.007 to 0.041)
Pump failure (%) 0 4 (20) (0.035,  0.3
0.001 to 0.069)
Other complications
Bleeding 8 (40%) 7 (35%) 0.7
Reoperation for bleeding 6 (30%) 4 (20%) 0.5
Systemic infection 4 (20%) 9 (45%)
Right heart failure necessitating  1 (5%) 1 (5%)
RVAD support
Right heart failure with medical  4 (20%) 2 (10%) 0.4
treatment
Massad et al., 199681 Post-heart transplant HeartMate LVAD Medical control
30-day operative mortality (%) 2 (3.8) 9 (4.4) ns
Re-exploration for bleeding (%) 3 (5.7) 9 (4.4) ns
Septicaemia (%) Successful BTT:  Not stated Not stated
27/53 (51)
Septicaemia from device-related  Successful BTT:  Not stated Not stated
infection (%) 21/53 (40)
Abdominal complications  ~15% Not stated Not stated
necessitating operative intervention
Adverse events at 1 year
CMV infection 20% (n = 53) 17% (n = 203) Kaplan– 
Meier ns
Vascular rejection rate 15% (n = 53) 12% (n = 203) Kaplan–
meier ns
Moderate and severe rejection free 12% (n = 53) 22% (n = 203) ns
Transplant CAD free 90% (n = 53) 88% (n = 203) ns
Mean no. of moderate and severe  At 12 weeks: 1.68 At 12 weeks: 1.47 ns
rejection episodes At 1 year: 2.53 At 1 year: 1.99
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TABLE 20 Summary of evidence of adverse events following treatment with first-generation LVADs of patients with ESHF as a BTT
(cont’d)
Study Outcome Intervention Comparison p-Value
Aaronson et al., 200282 HeartMate LVAD Inotropic agent
Pre-transplant mortality, cause  12/66 (18) 10/38 (26) Not stated
of death (%) Cerebrovascular  Cerebrovascular 
accident 1 accident 1
Device failure 1 MOF/sepsis 4
Haemorrhage 1 Sudden death 2
MOF/sepsis 5 Refractory 
Right-sided cardiogenic 
circulatory failure 4 shock 3
All occurred by 
19 days after LVAD 
implant
Post-transplant mortality, cause  2/48 (4) 9/28 (32) 0.045
of death (%) Cerebrovascular  Cerebrovascular 
accident 1 accident 1
Rejection (acute) 1 Infection 3
Haemorrhage 1
Primary allograft 
dysfunction 1
Rejection (acute) 3
Bank et al., 200083 HeartMate LVAD Inotropic agents
Death before transplant 1/20 (sepsis)  1/20 Not stated
1/20
None 8/20 (40%) 11/20 (55%) Not stated
Acute renal failure 0 0 Not stated
Right heart failure 0 0 Not stated
Reoperation 1/20 (5) 0/20 Not stated
Mechanical device failure 4/20 (20)  N/A Not stated
Infection 9/20 (45)  8/20 (40)  Not stated
Stroke 1/20  (5) 0/20 Not  stated
Adverse effects post-transplant (%) (n = 18 LVAD, n = 19 control)
None 11 (61.1) 3 (15.8) Not stated
Acute renal failure 3 (16.7) 10 (52.6) <0.05
Right heart failure 1 (5.6) 6 (31.6) <0.05
Reoperation 3 (16.7) 7 (36.8) ns
Rejection 1 (5.6) 3 (15.7) ns
Disability 2 (11.1) 4 (21.0) ns
Infection 3 (16.7) 8 (42.1) ns
Stroke  1 (5.6) 1 (5.2) ns
Death 2 (11.1) 5 (26.3) ns
Frazier et al., 199285 HeartMate LVAD Medical care
Bleeding requiring return to  0 N/A N/A
operating room
Patient-related bleeding, e.g.  11 (39) N/A N/A
cardiac tamponade (%)
Haemolysis (before and after LVAD  1 (4) N/A N/A
implantation) (%)
Haematocrit After implant: mean  N/A N/A
34%
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TABLE 20 Summary of evidence of adverse events following treatment with first-generation LVADs of patients with ESHF as a BTT
(cont’d)
Study Outcome Intervention Comparison p-Value
Platelet count After implant: mean  N/A N/A
249,000/ml
Free plasma haemoglobin (n = 26) After implant: mean  N/A N/A
8.7 mg/dl
Haemoglobin conc. 
11 g/dl
Infection (%) 7 (25) 2 (33) Not stated
(6 underwent 
transplantation, 
4 long-term 
survivors).
Infected vs 
non-infected: 
p > 0.05 for 
outcome
Renal or hepatic dysfunction or  24/26 LVAD group  N/A N/A
both before or during LVAD  (92.3)
(not considered device-related) 
(%)
Right heart failure (required right  6 (21) N/A N/A
ventricular assistance or exhibited 
symptoms of serious right 
ventricular dysfunction after LVAD 
implantation) (%)
Thromboembolism device related 0 N/A N/A
Related to mechanical aortic valve  1 (4) (successful 
in natural heart (%) transplantation)
Bowel adhesions to drive line (%) 2 (7) N/A N/A
Mechanical failure (loose outflow  1 (4) N/A N/A
connector) (%)
Frazier et al., 199486 HeartMate LVAD Medical care 
(unless stated 
otherwise)
Mortality (%) 2 (10) (during  3 (25) Not stated
extended support)
Possible device related axillary  1 (5) N/A Not stated
artery thromboembolus plus 
transient ischaemic attack 
(no long-term sequelae) (%)
Episodes of rejection per patient  0.71 episodes  No data for  Not stated
up to 6-months post-transplant (SD 0.98) control group
General transplant 
population: 
1.19 episodes 
(SD 1.0)
Severe rejection  0.13 episodes  No data for control  Not stated
(SD 0.087) group
General transplant 
population: 
0.35 episodes 
(SD 0.02)
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TABLE 20 Summary of evidence of adverse events following treatment with first-generation LVADs of patients with ESHF as a BTT
(cont’d)
Study Outcome Intervention Comparison p-Value
Patients with ≥1 infectious episodes during 6 months after transplant (no information is
provided about the number of patients on which percentages are based) (%)
Bacterial 40 36 Not  stated
Viral 7 44
Fungal 7 20
Protozoal 0 7
Grady et al., 200184 HeartMate LVAD 1–2 weeks after 
before implantation implantation
Post-implant complications 30 days postoperation
Mechanical device 23% Not stated Not stated
Infection 83% Not stated Not stated
Psychiatric complications 40% Not stated Not stated
Novacor LVADs
Trachiotis et al., 200087 Novacor LVAD  Novacor LVAD 
<30 days >30 days
Infection 5 (100) 4 (80) Not stated
Pancreatitis 1 (20) 0 Not stated
Reoperation (bleeding) 3 (60) 0 Not stated
Thromboembolism 1 (20) 4 (80) Not stated 
Neurological dysfunction 2 (40) 3 (60) Not stated 
Renal failure/dialysis 1/0 (20/0) 2/1 (40/20) Not stated
Right heart failure 0 0 Not stated
Toyobo LVADs
Masai et al., 199588 Adverse events were not reported separately for LVAD patients and BiVAD patients
Thoratec LVADs
Holman et al., 199589 Adverse events from Thoratec LVAD No comparator
On second postoperative night an episode of VT.  N/A
VAD output during this was 3.6–3.8 litres/minute and 
systolic blood pressure was 80–90 mmHg. Cardioverted 
and intravenous amiodarone was continued. 
Episodes of paroxysmal VT and occasional VF recurred 
and became more frequent during the ensuing days
May and Adams, 198790 Adverse events from Thoratec LVAD No comparator
Severe respiratory distress after 2.5 days post-LVAD  N/A
implant, and developed adult respiratory distress syndrome. 
Intubated and placed on 100% O2 and 12–15 cm of 
positive end-expiratory pressure but was only able to 
maintain an arterial partial pressure of oxygen of 50 mmHg. 
Blood cultures showed Legionella bacteria, treated with 
antibiotics. Haemolysis which stabilised in 1 week
CAD, coronary artery disease; CMV, cytomegalovirus; VF, ventricular fibrillation; VT, ventricular tachycardia.cerebrovascular accident (LVADs 1, inotropes 1),
acute rejection (LVADs 1, inotropes 3), infection
(inotropes 3), haemorrhage (inotropes 1) and
primary allograft dysfunction (inotropes 1). Bank
and colleagues83 reported two deaths (10%)
among patients receiving LVADs (one patient died
of sepsis and one of ventricular fibrillation
following device removal) and one death (5%)
among those on inotropes [refractory ventricular
tachycardia (VT)] prior to heart transplantation.
After heart transplantation, Bank and colleagues83
noted that two patients (10%) with LVADs died
compared with five patients (25%) receiving
inotropes; the causes of death are not discussed.
In the comparison of LVADs and usual medical
care, Massad and colleagues81 reported similar 
30-day operative mortality following heart
transplantation with 3.8% (n = 53) of patients with
LVADs and 4.4% (n = 203) of patients receiving
usual medical care dying (p = ns). 
Frazier and colleagues’86 cohort study noted lower
mortality rates prior to heart transplantation
among the 19 patients with LVADs (10%) than for
the 12 patients receiving usual medical care (25%).
Mortality among the LVAD patients was from
MOF associated with systemic lupus from the 
pre-implantation period (one patient) and from a
massive thromboembolic embolism (one patient).
None of the patients with an LVAD died post-heart
transplantation, whereas the three patients with
usual medical care who received a heart transplant
died (two patients immediately postoperation from
massive bleeding and donor heart failure and one
patient from lymphoma-related rejection).
Infection Five studies reported the occurrence of
infections following implantation of the HeartMate
LVAD.80,81,83–85 El Banayosy and colleagues80
reported higher rates of infection for patients
supported by the HeartMate VE LVAD (n = 20)
compared with the Novacor N100 LVAD (n = 20).
The occurrence of driveline infections was
significantly (p = 0.09) higher among patients
receiving a HeartMate VE LVAD [nine patients;
0.078 events/patient/month (95% CI 0.029 to
0.127)] than with the Novacor N100 LVAD [four
patients; 0.026 events/patient/month (95% CI 0.01
to 0.051)]. Similarly, El Banayosy and colleagues
reported a higher occurrence of pocket infections
(HeartMate five patients, Novacor two patients)
and systemic infections (HeartMate nine patients,
Novacor four patients) among patients with a
HeartMate VE LVAD than with a Novacor N100
LVAD, although differences were not significant
(p = 0.1). Infection was the cause of readmission to
hospital. Six patients (five pocket infections; one
driveline infection) with the HeartMate VE LVAD
and four patients (two pocket infections; two
driveline infections) with the Novacor N100 LVAD
were readmitted to hospital owing to infection
(differences were not statistically significant). Bank
and colleagues83 found similar rates of major
infection among patients with LVADs (45%, n = 20)
and with inotropic agents (40%, n = 20) prior to
heart transplantation (p not stated). Among the
group of LVAD patients, the major infections were
driveline infections (five patients), pneumonia
(three patients) and bacterial sepsis (one patient),
wheareas those among the inotrope group of
patients were line sepsis (seven patients) and
pneumonia (one patient). The occurrence of major
infections following heart transplantation were
higher among the patients on inotropes (42%,
n = 19) compared with the LVAD patients (16%,
n = 18) (p = ns). No details are provided of the
causes of infections following heart transplantation.
Similarly, Frazier and colleagues85 found higher
rates of infection among patients receiving usual
medical care (33%, n = 6) compared with those
with an LVAD (25%, n = 28). Frazier and
colleagues85 note that all the infections suffered by
the LVAD patients were device related. This study
used a historical control group. In their comparison
of LVADs with usual medical care, Massad and
colleagues81 reported the occurrence of septicaemia
in patients with an LVAD. Of the 53 patients
successfully bridged to heart transplantation, 51%
had septicaemia with 40% from device-related
infection. Grady and colleagues84 noted that 83%
of patients with an LVAD who completed an
assessment before and after device implantation
(n = 30) suffered infection during the 30 days
following the operation.
Mechanical failure Mechanical device failures
were reported in four of the studies of the
HeartMate LVAD.80,83–85 El Banayosy and
colleagues80 reported several device-related
failures in their comparison of the HeartMate VE
LVAD and the Novacor N100 LVAD. Significantly
(p < 0.001) more patients required the controllers
for their HeartMate VE LVAD (14 patients)
exchanging than did patients with Novacor LVAD
(two patients). Driveline cracks were found in the
devices of two HeartMate LVAD and three
Novacor LVAD patients (p = 0.6). Whereas there
were no pump failures among patients with
Novacor N100 LVADs, four patients with
HeartMate LVADs suffered pump failure
(p = 0.3).80 As a consequence of the device-related
failures, three patients with a HeartMate LVAD
and one Novacor patient were readmitted to
hospital (p = 0.3). Bank and colleagues83 noted a
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20 patients receiving a HeartMate LVAD,
including one patient each suffering a broken
console, loss of sensor function, torn inflow
housing structures and inflow valve dysfunction
due to pannus growth. Grady and colleagues84
reported that 23% of patients receiving a
HeartMate LVAD incurred device failure (n = 30);
no details were provided on the cause. Frazier and
colleagues85 reported one patient with a loose
connector flow from the 34 patients with an LVAD.
Bleeding, reoperation and thromboembolic
events El Banayosy and colleagues80 reported that
35% of patients with a HeartMate LVAD (n = 20)
and 40% of patients with a Novacor LVAD
(n = 20) suffered from bleeding (p = 0.7). Some
20% of HeartMate patients (n = 20) and 30% of
Novacor patients (n = 20) required reoperation as
a consequence of bleeding (p = 0.5). El Banayosy
and colleagues80 reported that four patients with
Novacor LVADs suffered a thromboembolic event
compared with none of the HeartMate LVAD
patients (p = 0.1). Massad and colleagues81 found
similar proportions of patients (p = ns) requiring
re-exploration due to bleeding in the LVAD group
(5.7%, n = 53) and the group receiving usual
medical care (4.4%, n = 203). Following LVAD
implantation, Frazier and colleagues85 found that
39% (n = 34) of patients suffered bleeding,
although none required reoperation. In addition,
one patient suffered from haemolysis before and
after LVAD implantation and one patient was
found to have a thromboembolism related to the
mechanical aortic valve in the natural heart and
not associated with the LVAD. In another study by
Frazier and colleagues,86 one patient had a
possible device-related axillary artery
thromboembolus plus transient ischaemic attack.
Bank and colleagues83 reported that one patient
within an LVAD required reoperation prior to
heart transplantation; details were not provided.
Other adverse events El Banayosy and
colleagues80 reported that three patients with a
HeartMate LVAD (n = 20) and five patients with a
Novacor LVAD (n = 20) suffered right heart failure
necessitating support with either a RVAD or
medical treatment. Frazier and colleagues85 noted
that 21% (n = 34) of patients with an LVAD
suffered right heart failure requiring right
ventricular assistance or exhibited symptoms of
serious right ventricular dysfunction after LVAD
implantation. Also, Frazier and colleagues85 found
two patients who suffered from bowel adhesions to
the driveline. Bank and colleagues83 reported that
one patient with an LVAD suffered a stroke prior to
heart transplantation, and Grady and colleagues84
found that 40% of patients (n = 30) receiving an
LVAD suffered from psychiatric complications.
Adverse events after heart transplantation Three
studies examined adverse events among the
different patient groups following heart
transplantation.81,83,86 Bank and colleagues
reported that 28.9% of patients with an LVAD
(n = 18) suffered adverse events after heart
transplantation compared with 84.2% of those
receiving inotropic agents (n = 19). Significantly
more of the patients undergoing treatment with
inotropic agents suffered acute renal failure
(52.6% versus 16.7%; p < 0.05) or right heart
failure (31.6% versus 5.6%; p < 0.05) than patients
with an LVAD. Similarly, more patients receiving
inotropic agents required reoperation (36.8%
versus 16.7%), suffered rejection (15.7% versus
5.6%), incurred disability (21.0% versus 11.1%) or
infections (42.1% versus 16.7%) than patients with
an LVAD, although these differences did not differ
significantly.83 In addition, one patient in each
treatment group suffered a stroke following heart
transplantation. Massad and colleagues81 reported
adverse events 1 year following heart
transplantation, with no significant difference
(p = ns) between patients with an LVAD (n = 53)
compared with those on usual medical care
(n = 203) respectively for cytomegalovirus (CMV)
infection (20% versus 17%), vascular rejection
(15% versus 12%), moderate and severe rejection
free (12% versus 22%), transplant coronary artery
disease (CAD) free (90% versus 88%) and
moderate and severe rejection episodes (2.53
versus 1.99). Frazier and colleagues86 compared
the adverse events following heart transplantation
suffered by patients receiving an LVAD (n = 19)
with those in the general transplant population
(n = 12). Up to 6 months after heart
transplantation, patients with an LVAD suffered
0.71 episodes of rejection per patient compared
with 1.19 episodes in the general transplant
population. Similarly, patients with LVADs suffered
fewer episodes of severe rejection than the general
transplant population with 0.13 compared with
0.35 rejection episodes.86 In addition, episodes of
infection 6 months after heart transplantation
tended to be more evident among those patients
receiving usual medical care than an LVAD,
whether viral (44% versus 7%), fungal (20% versus
7%) or protozoal (7% versus 0%) infections.
Bacterial infections affected 40% of LVAD patients
and 36% of the general transplant population.
Novacor. In the cohort analytic study comparing
patients supported with a Novacor LVAD for
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than 30 days (n = 5) (Table 20 and Appendix 13 ).
Trachiotis and colleagues87 reported the
occurrence of infection (5 versus 4), pancreatis
(1 versus 0), reoperation due to bleeding (3 versus
0), thromboembolism (1 versus 4), neurological
dysfunction (2 versus 3), and renal failure/dialysis
(1/0 versus 2/1). In addition, Trachiotis and
colleagues87 reported two late deaths from
malignancy and two deaths from sepsis and MOF
and one patient had the LVAD removed (reason
not stated).
Toyobo. Adverse effects were reported in the case
series by Masai and colleagues88 of the Toyobo
LVAD (Table 20 and Appendix 14). Unfortunately,
the adverse events data provided aggregate data
for three patients with an LVAD and one patient
who was supported with a BiVAD and it is unclear
which events relate specifically to the LVAD
patients. As a consequence, the adverse events
data on cardiovascular accident, postoperative
bleeding and mechanical device failure have been
excluded from the analysis.
Thoratec. Adverse events were reported in the two
case studies of the Thoratec LVAD (Table 20 and
Appendix 15).89,90 A 45-year-old male patient had
an episode of VT 2 days post-implantation.
Following that, episodes of paroxysmal VT and
occasional ventricular fibrillation (VF) recurred
and became more frequent during the ensuing
days.89 A 24-year-old male patient showed severe
respiratory distress after 2.5 days and developed
adult respiratory distress syndrome. In addition,
this patient had haemolysis which stabilised after
1 week, and was found to have blood cultures
positive to Legionella bacteria.90
Second-generation LVADs
Jarvik. The two case series of the Jarvik 2000
LVAD examined adverse events (Table 21 and
Appendix 16).94–100 Frazier and colleagues’94 case
series of three patients with a Jarvik 2000 LVAD as
a BTT found localised infection of the power-
cable exit site in one patient. There were no
device-related medical problems. The second case
series95–100 of the Jarvik 2000 LVAD reported
adverse events for a subset of 10 patients, finding
abdominal power cable infections in two patients;
a major haemorrhage in one patient, which was
from a gastric ulcer and a separate ateriovenous
malformation in the small intestine; and technical
problems with the LVAD in two patients where the
power-cable connectors were broken by the
operator in one and one connector pin was bent
by the patient. No thromboembolisms in the
devices were noted, nor were any device infections
or any significant haemolysis.
MicroMed DeBakey. Two cohort studies assessing
the MicroMed DeBakey VADs assessed adverse
events (Table 21 and Appendix 17).91,93 Potapov
and colleagues93 reported that one of the six
patients with a MicroMed DeBakey LVAD died
from sepsis. Noon and colleagues91 noted that one
patient with the LVAD died from a device-related
adverse event, although no details are provided. 
Summary of clinical effectiveness of
LVADs as a bridge to heart
transplantation for ESHF
Quantity of Studies
Sixteen studies assessed LVADs as a BTT, with 11
studies of first-generation devices and five studies
of second-generation devices. Of the 11 studies of
first-generation devices, seven assessed the
HeartMate VE/IP LVAD, one the Novacor LVAD,
one study the Toyobo LVAD and two the Thoratec
LVAD. Direct comparisons were limited to studies
of the HeartMate LVAD with alternatives of the
Novacor LVAD,80 inotropic agents82,83 or
undefined medical care.81,85,86 Of the five studies
of second-generation devices, three assessed the
MicroMed DeBakey LVAD and two the Jarvik 2000
LVAD. None of these studies included a
comparator.
Methodological quality
The methodological quality of studies was judged
to be weak when appraised against criteria that
assess the rigor of studies and the opportunities
for bias. In many instances this was inevitable
given that most studies were observational studies,
but the experimental and quasi-experimental
studies were also affected by methodological
weaknesses that may limit the strength and
reliability of the evidence presented.
Generalisability
Most studies focused on male patients aged
between 40 and 60 years who suffered from either
dilated or ischaemic cardiomyopathy and were in
NYHA Class IV.
Survival
There was limited difference shown in the CCT of
the survival to heart transplantation of patients
receiving the HeartMate LVAD (60% survived, 10%
died) compared with the Novacor LVAD (65%
survived, 15% died).80 When compared with
inotropic agents in two cohort analytic studies,82,83
patients receiving the HeartMate LVAD
experienced some benefit in actuarial survival to
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support (actuarial survival: 1 month 78% versus
81%; 3 months 64% versus 81%, respectively). The
benefit in survival for those receiving a HeartMate
LVAD compared with inotropic agents increased
post-heart transplantation (survival: 6 months
88.9% versus 73.3%; actuarial survival: 1 year 98%
versus 74%; 4 years 95% versus 65%, respectively).
Differences in survival when comparing patients
who had received the HeartMate LVAD with those
on usual care were more equivocal. Whereas a
retrospective cohort analytic study found no
difference between patients with the HeartMate
LVAD and usual care in survival to transplant and
following transplantation at 22 months, two
retrospective cohort studies with historic controls
found an advantage for patients who received an
LVAD compared with those on usual care in
survival to transplant (64% versus 50%85 and 84%
versus 25%,86 respectively) and survival post-
transplantation (60 days: 52% versus 17%85;
actuarial survival 1 and 2 years: 100% versus
0%86). The studies of the other devices did not
include a comparator intervention and, as a
consequence can only provide an indication of the
additional survival the patients gained through the
specific intervention compared with the assumed
outcome of the condition. The retrospective
cohort analytic study of the Novacor LVAD
compared post-transplantation survival of groups
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TABLE 21 Summary of evidence of adverse events following treatment with second-generation LVADs of patients with ESHF as a BTT
Study Outcome Intervention Comparison p-Value
Jarvik 2000 LVADs
Westaby et al., 200295 Jarvik 2000 LVAD No comparator
Abdominal power cable infection 2 patients N/A
Major haemorrhage  1 patient N/A
Device thromboembolism 0 patients N/A
Device infection  0 patients N/A
Significant haemolysis 0 patients N/A
Power-cable connector broken  2 patients N/A
by patient
Connector pin bent by patient 1 patient N/A
Frazier et al., 200194 Jarvik 2000 LVAD No comparator
Intraoperative blood loss (average) 1.5 litres N/A
Postoperative bleeding Minimal  N/A
(amount not stated)
Complications associated with  0/3  N/A
implant surgical procedure
Free from adverse events  1/3 (34%) N/A
throughout support
Localised infection of power-cable  1/3 (34%) N/A
exit site (responded to antibiotic 
therapy and local treatment)
Gastrointestinal bleeding from  1/3 (34%) N/A
duodenal ulcer
Device-related medical problems 0/3 N/A
Thromboembolism 0/3 N/A
MicroMed DeBakey LVADs
Potapov et al., 200093 MicroMed No  comparator
DeBakey LVAD
Deaths from sepsis 1/6 N/A
Noon et al., 200191 MicroMed No  comparator
DeBakey LVAD
Deaths from device-related  1/32 N/A
adverse eventssupported for <30 days with those supported for
≥ 30 days, with no difference at 3 years (60%
survival). A case series study of three patients with
the Toyobo device showed one patient surviving to
64 days before dying, another patient surviving
119 days to transplantation and a third still alive
on the transplant waiting list at 390 days. Two case
reports of the Thoratec LVAD showed two patients
surviving 21 and 60 days before transplantation. 
A cohort study of the MicroMed DeBakey LVAD
showed that 81% of patients survived to 30 days
post-implantation of the device, 34% received a
heart transplant and 31% died. In two case series
of the Jarvik 2000 LVAD, ~70% had successfully
been bridged to transplant with around 30%
having died (one patient was still on support). 
Functional status
Two cohort studies with historical controls of the
HeartMate LVAD showed that patients receiving
an LVAD were more likely to improve their
functional status than those on usual care when
assessed on the NYHA functional classification
(before LVADs, 100% NYHA Class IV, usual care
84% NYHA Class IV; after LVADs, 94% NYHA
Class I, usual care 100% NYHA Class IV,85 and
before LVADs, 100% NYHA Class IV; after LVADs,
94% NYHA Class I).86 Similar improvements in
functional status were experienced by patients
receiving a second-generation Jarvik 2000 LVAD
(before LVAD, 100% NYHA Class IV; after LVAD,
70% NYHA Class IV, 30% dead).95
Quality of life
A cohort study of the HeartMate LVAD provided
the only evidence of the effect of first-generation
LVADs on QoL. It showed that patients receiving
the HeartMate LVAD had statistically significant
improvements on some elements of the Quality of
Life Index, the Heart Failure Symptom Checklist
and the global ratings from the Rating Question
Form. However, there was significant worsening of
elements of the Quality of Life Index, Rating
Question Form and functional disability. No
studies of the second-generation LVADs assessed
changes in QoL.
Adverse events
Comparison of the HeartMate and Novacor
LVADs showed limited difference in the rates of
mortality from adverse events. The HeartMate
LVAD appeared to have a higher rate of device-
related complications, including technical
problems with controllers, device-related infections
and driveline infections. Other studies of the
HeartMate device showed ~20% of patients
having mechanical device failures.83,84 Patients
with the Novacor LVAD suffered slightly higher
rates of bleeding (40% versus 35%), reoperation
(30% versus 20%) and thromboembolic events
(20% versus 0%) than those with a HeartMate
LVAD.80 Other studies have shown lower rates of
thromboembolic events for the HeartMate device,
but higher rates of bleeding (39% of patients).85
Several studies showed that implantation of the
HeartMate device resulted in right heart failure
among ~20% of patients80,85 and one study found
that 40% patients suffered psychiatric
complications.84 Studies of the HeartMate LVAD
showed lower rates of adverse events following
heart transplantation than for those receiving
usual care, with fewer patients suffering end organ
failure, reoperation, rejection, disability or
infection. Although the adverse events
experienced by recipients of other LVADs were less
clearly reported, it was evident that patients with
the Novacor and Thoratec devices suffered from
infection and thromboembolism and required
reoperations as a consequence. Studies of the
Jarvik 2000 LVAD reported technical problems
with power-cable connections breaking and
incurring infections, but thromboembolic events,
significant device infections or haemolysis were
not significant problems. The two cohort studies
of the MicroMed DeBakey LVAD reported two
device-related deaths from sepsis and an
unspecified adverse event.
Conclusion
LVADs appear to provide some benefit to patients
awaiting heart transplantation with an increased
chance of surviving both to, and following, the
transplantation. Benefits are evident through
improvements in the functional status and QoL of
patients with an LVAD and appear to outweigh
those experienced by patients receiving inotropic
agents or usual care. There are risks associated
with the use of LVADs with adverse events related
to device failures, infections and thromboembolic
events. Evidence on the effectiveness of different
devices is sparse. Of the first-generation devices
only the HeartMate LVAD has evidence comparing
it with different alternatives. This shows greater
benefits than usual care and inotropic drugs but
similar effectiveness when compared with the
Novacor LVAD. For the second-generation devices,
the early evidence suggests that the Jarvik 2000
and the MicroMed DeBakey LVADs are similar in
terms of measures of clinical effectiveness.
Although these devices appear to show
improvements in the adverse events associated
with first-generation devices, experiencing lower
rates of infection and thrombolembolism, it is still
early in their development to identify whether
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associated with the change in the nature of the
circulatory support.
LVADs as a bridge to recovery
Quantity of research
Seven studies considering the clinical effectiveness
of LVADs as a BTR met the inclusion criteria for
the systematic review (see Table 22 and
Appendices 18–22). All the studies assessed first-
generation devices with one case report of the
Abiomed LVAD,104 one case report of the
HeartMate LVAD,105 one case report of the
Novacor LVAD106, two case reports of the Thoratec
LVAD,107,108 and two case series evaluations of the
Toyobo LVAD.109,110 There were no studies of
second-generation devices included in the
systematic review.
Methodological quality of research
First-generation LVADs
The methodological quality and the quality of
reporting of the seven studies were poor (Table 22
and Appendices 18–22). As all the studies were
retrospective observational studies with no
comparator, there was considerable opportunity
for bias. Limited details were provided in the
studies concerning patient selection and with the
small samples it is unlikely that the patients were
representative of the target population. Although
the outcomes assessed included survival, mortality
and organ function and adverse effects, no details
were provided as to the methods of data
collection. The quality criteria assessing
confounding, blinding and withdrawals/drop-outs
were not applicable to these study designs,
indicating the opportunity for bias.
Generalisability
The external validity of the studies was assessed
through the key characteristics of the patients
assessed (Table 23). As there were very few studies of
the different devices, it was unlikely that there would
be a representative patient group for any one device.
However, it was evident that the patients included
were predominantly male (77%), aged between 16
and 73 years and mainly suffering from dilated
cardiomyopathy (40%) or acute MI and shock (23%).
Assessment of the clinical effectiveness
of LVADs as a bridge to recovery
Survival
First-generation LVADs
Abiomed. One case study assessed survival in one
patient supported with the Abiomed BVS 5000
until recovery (Table 24 and Appendix 18).104 The 
16-year-old patient with cardiogenic shock
secondary to acute myocarditis was weaned after
7 days of support and was discharged home. The
patient did not require listing for transplantation
during the short-term follow-up (duration not
known).
HeartMate. The survival of one patient supported
with the HeartMate LVAD (no details of type of
device) until recovery was reported by Kjellman
and colleagues105 (Table 24 and Appendix 19). The 
19-year-old patient with acute left ventricular
heart failure during an exacerbation of multiple
sclerosis was supported for 83 days and was then
successfully weaned from support. Cardiac
function was reported to have normalised. At
follow-up at 1 year after explantation, the patient
was reported to be in excellent clinical condition
without the support of pharmacological therapy
for heart failure; cardiac function remained
normal and NYHA functional class was I.
Novacor. A case study reported survival of one
patient supported with a Novacor LVAD until
recovery of heart function (Table 24 and Appendix
20).106 The 54-year-old man with cardiac failure
refractory to medical therapies and
contraindicated to heart transplant was well
enough to be transferred to a partial outpatient
status 6 weeks after implant and 3 months later
was successfully weaned from the device. The
patient was discharged home after 6 weeks and
was alive and well at 6 months follow-up.
Toyobo. Two case series studies reported survival
of patients supported with the Toyobo LVAD
(Table 24 and Appendix 22).109,110 Nakatani and
colleagues109 reported survival for five patients
supported for up to 11 months. Two of these
patients were successfully weaned after 95 days
and 50 days of support, respectively. The two
patients were still alive at 1 year 6 months and
3 years 9 months, respectively, after explantation
of their LVADs. The heart function of the three
other patients did not improve and they died at 7,
9 and 11 months post-LVAD implantation. Noda
and colleagues110 report survival outcomes for two
male patients supported for 12 days. The first
patient was weaned at 12 days but then died
149 days later from infection and cerebral
haemorrhage. The second patient died from
respiratory failure following 12 days of support
from the device.
Thoratec. Two case studies reported survival 
of patients supported with a Thoratec LVAD 
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s(Table 24 and Appendix 21).107,108 Joharchi and
colleagues107 report survival for one 17-year-old
patient with acute myopericarditis. The 
patient was successfully weaned from support 
after 46 days, and was alive 6 months following
explantation. Ueno and colleagues108
reported survival for a 34-year-old male 
patient, also with acute myopericarditis. He 
was successfully weaned after 5 weeks of 
support, and was alive at 3 months of 
follow-up.
Functional status
First-generation devices
None of the studies of the Abiomed BVS 5000,
HeartMate, Novacor or Toyobo LVADs reported
changes in functional status.104–106,109,110 One
patient supported with a Thoratec LVAD was
reported to be in NYHA Class I at follow-up (6
months) in the case report by Joharchi and
colleagues.107 This patient had recovered from
acute myopericarditis and had been weaned from
her LVAD after 46 days.
Quality of life
First-generation devices
None of the studies of the Abiomed BVS 5000,
HeartMate, Novacor or Toyobo LVADs reported
changes in QoL.104–106,109,110
Adverse events
First-generation devices
Abiomed. The case study of the Abiomed BVS
5000 LVAD did not report adverse events.104
HeartMate. The one patient supported with a
HeartMate LVAD105 suffered a drive line
infection 3 weeks after device implantation 
(Table 25 and Appendix 19). This patient, who
also had her diagnosis of multiple sclerosis
confirmed while on the device, had persistent
infection problems with repeated periods of
sepsis despite antibiotic treatment until the
device was explanted.
Novacor. The case study of the Novacor LVAD did
not report adverse events.106
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TABLE 24 Summary of evidence of patient survival following treatment of patients with ESHF as a BTR
Study Outcomes Intervention
First-generation LVADs
Abiomed LVADs
Marelli et al., 1997104 Survival Weaned at 7 days and discharged home in good condition
HeartMate LVAD
Kjellman et al., 2000105 Survival Patient alive 1 year after explantation, cardiac function normalised and in
NYHA Class 1. Not taking any pharmacological of therapy for heart failure
Novacor
Pietsch et al., 1998106 Survival Patient transferred to a partial outpatient status 6 weeks after implant.
2 months later cardiac recatheterisation. Device removed 4 weeks after
revascularisation. Discharged home after a further 6 weeks. Alive at
6 months post-discharge
Thoratec LVAD
Joharchi et al., 2002107 Survival Survived to 6 months follow-up. Supported for 46 days when weaned from
LVAD
Ueno et al., 2000108 Survival Survived to 3 months of follow-up
Toyobo LVAD
Nakatani et al., 1998109 Survival 2 patients survived 3 months and weaned: 1 had LVAD removed at 95 days
and alive at 18 months; 1 had LVAD removed at 50 days and alive at
45 months. 3 patients died at 7, 9 and 11 months after insertion of LVAD
Noda et al., 1989110 Survival 1 patient survived and was weaned after 12 days but died 149 days after
removal from infection and cerebral haemorrhage, 1 patient died of
respiratory failure whilst on the LVAD (12 days)
Second-generation LVADs
No studiesToyobo. Adverse events were reported in the two
case series of the Toyobo LVAD (Table 25 and
Appendix 22).109,110 Nakatani and colleagues109
noted that three of the five patients died following
adverse events. One patient’s death was attributed
to a cerebral haemorrhage caused by infectious
aneurysm 5 months after LVAD implantation,
leading to death through sepsis 2 months after
discontinuation. The other two patients developed
cerebral embolism 3 and 5 months after
implantation of the LVAD, which led to MOF. In
the case series by Noda and colleagues,110 limited
details are provided about the complications
suffered by the patients. The first patient had lung
and kidney complications requiring special
treatments, and also liver and infectious
complications not requiring special treatments.
The second patient had kidney complications
requiring special treatments and lung, infection,
brain and disseminated intravascular coagulation
complications that did not require special
treatments. Special treatments were reported to
include high-frequency oscillated ventilation for
lung complication, peritoneal dialysis for kidney
failure and plasmapheresis for liver failure.
Thoratec. The case studies of the Thoratec LVAD
did not report any adverse events.107,108
Summary of clinical effectiveness 
of LVADs as a bridge to recovery 
for ESHF
Quantity of evidence
Seven studies (12 patients) assessed LVADs as a
BTR. All studies examined first-generation devices
and were either case series or case reports with no
comparator intervention.
Methodological quality
All seven studies were judged to be
methodologically weak when assessed against
criteria examining rigour and the opportunities
for bias.
Generalisability
The studies included a wide range of patients.
Patients were predominantly male (77%), aged
from 16 to 73 years and suffered from differing
underlying conditions including dilated
cardiomyopathy (40%) and acute MI and shock
(23%).
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TABLE 25 Summary of evidence on adverse events following treatment of patients with ESHF as a BTR
Study Outcomes Intervention
First-generation LVADs
HeartMate LVAD
Kjellman et al., 2000105 Adverse events 8 weeks after implantation: relapse of neurological symptoms and
diagnosis of multiple sclerosis confirmed. Infectious problems with
repeated periods of sepsis despite antibiotic treatment, therefore device
was explanted 83 days after implantation
Toyobo LVAD
Nakatani et al., 1998109 Adverse events 1 patient LVAS was stopped because of cerebral haemorrhage caused by
infectious aneurysm 5 months after the start of the LVAS; this patient
died of sepsis 2 months after discontinuation. 
The other two patients developed cerebral embolism following 3 and
5 months of LVAS support and died at 9 and 11 months from MOF
Noda et al., 1989110 Adverse effects  Patient 1: massive transfusion before LVAD. Lung and kidney 
defined by body  complications requiring special treatments,a liver and infection 
organ not specific  complications not requiring special treatments
complication Patient 2: kidney complications requiring special treatments,a lung,
infection, brain, DIC (not defined by authors, probably disseminated
intravascular coagulation) not requiring special treatments. Special
treatments include high-frequency oscillated ventilation for lung
complication, peritoneal dialysis for kidney failure, plasmapheresis for
liver
Second-generation LVADs
No studies
a See Appendix 22 for definition of special treatment.Survival
The case studies for the Abiomed, HeartMate,
Novacor and Thoratec LVADs reported that
patients were supported with the respective
devices for periods ranging from 7 days to
3 months, with all patients recovering to be
discharged home and still alive at further follow-
up between 3 months and 1 year later. The case
series for the Toyobo LVAD reported survival for
seven patients supported from 12 days to
11 months, with two patients alive at 18 and
45 months of follow-up and five patients who died
following support for between 12 days and
11 months.
Functional status
None of the studies of the Abiomed BVS 5000,
HeartMate, Novacor or Toyobo LVADs assessed
the functional status of patients. One case study of
the Thoratec LVAD noted that the patient was in
NYHA Class I following support with the LVAD,
but provided no baseline assessment.
Quality of life
None of the studies assessed QoL.
Adverse events
The case studies of the Abiomed, Novacor and
Thoratec devices did not report adverse events.
The case study of the HeartMate LVAD reported a
drive line infection and repeated periods of sepsis
despite antibiotic treatment, until the device was
explanted. One of the case series of the Toyobo
LVAD reported that three patients died following
adverse events including cerebral haemorrhage
following an infectious aneurysm and death from
sepsis for one patient and cerebral embolism after
LVAD implantation and MOF for two patients.
The second case series of the Toyobo LVAD
reported lung, kidney, liver and infectious
complications in the two patients.
Conclusion
The evidence of the clinical effectiveness of LVADs
as a BTR is limited and of poor methodological
quality. The systematic review shows that LVADs
do appear to provide benefit to patients who
would be likely to die from their condition. There
was no evidence to judge the effects on the
patients’ QoL or functional status. Adverse events
associated with the devices provide a risk to the
patient. Although information was limited from
the studies, infections and bleeding associated
with the LVADs are the main concern, which when
considered with the poor health of the patient
may lead to MOF. The studies provided
insufficient good-quality comparative evidence to
identify whether any of the LVAD was more
clinically effective than another LVAD or form 
of care.
LVADs as a long-term chronic
support
Quantity of research
Six studies assessing the clinical effectiveness of
LVADs as LTCS for patients with ESHF met the
inclusion criteria for the systematic review, four
studies of first-generation LVADs and two studies
of a second-generation LVAD (Table 26 and
Appendices 23–27). Of the four studies of first-
generation devices there was one RCT of the
HeartMate VE LVAD,111 one series of case reports
of the LionHeart LVAD,112 one case report of the
Novacor LVAD113 and one case report of the
Toyobo LVAD.114 The two studies of the second-
generation LVAD were a case report94 and a case
series investigating the use of the Jarvik LVAD for
LTCS.95–100
Methodological quality of research
First-generation LVADs
HeartMate
The methodological quality and the quality of
reporting in the study assessing the clinical
effectiveness of the HeartMate VE LVAD was
judged to be moderate (Table 26 and Appendix
23).111 The study, the REMATCH trial, was
considered to have a strong study design. It was a
multicentre RCT that appeared to use an
appropriate method of allocation, randomising
patients centrally through a Data and Clinical
Coordinating Centre overseen by a clinical
‘gatekeeper’ with stratification by centre and
blocked to try to ensure equal numbers of patients
in the arms of the trial. However, as the actual
method of randomisation was not described, its
method of allocation was rated as moderate. The
REMATCH study attempted to select patients that
would be representative of those likely to require
LTCS using a priori inclusion and exclusion
criteria. Modification of the inclusion criteria
during recruitment to ensure adequate sample size
may have affected the process of selecting a
representative sample. As a consequence, selection
was judged to be weak. Although it is not clear
from the study whether the patients agreed to
participate, it is likely given that the study had to
adhere to FDA requirements. The study
demonstrated that there were no significant
differences between the study groups, reducing the
risk of confounding. Blinding of patients and the
treating surgeons to the interventions compared in
Systematic review of the clinical effectiveness of LVADs for people with ESHF
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.the REMATCH trial was impossible. To try to limit
the effects of observational bias, the study used
independent blinded observers who had not
treated patients to judge outcomes. Although the
validity and reliability of the data collection tools
received limited discussion, the primary outcome
used was death from any cause verified by an
independent assessor. Other outcome measures
included objective measures of physical
functioning using the NYHA classification, 
6-minute walk test and maximal oxygen
consumption and subjective measures of QoL
including the Minnesota Living with Heart Failure
questionnaire, the Short Form with Items (SF-36)
36 Health Survey and EuroQoL. The REMATCH
trial was judged to be methodologically strong on
withdrawals and drop-outs from the study,
identifying the numbers of and reasons for
withdrawal in addition to undertaking an
intention-to-treat analysis.
LionHeart
The series of case reports of the LionHeart LVAD
was judged to be weak in its methodological
quality (Table 26 and Appendix 24).112 Limited
information was provided about the selection of
participants, blinding or methods of data
collection. As the study was a retrospective series
of case reports assessment of confounding,
withdrawals and intention-to-treat analyses were
considered not to be relevant.
Novacor
The case report assessing the clinical effectiveness
of the Novacor LVAD was judged to be of poor
methodological quality (Table 26 and Appendix
25).113 The risk of selection bias and observer bias
was high. Although objective outcome measures
such as survival, NYHA classification and organ
function measures were used, limited details were
provided on the validity and reliability of the
methods of data collection. As a consequence of
the study design, assessment of confounding,
withdrawals and intention-to-treat analysis were
considered not to be relevant.
Toyobo
The methodological quality of the case report
evaluating the Toyobo LVAD was poor (Table 26
and Appendix 26).113 Limited details were given
in the case report as to how the patients were
selected and as to blinding of the assessment of
outcomes, providing the possibility for selection
and observer bias. Although objective outcome
measures such as survival and mortality were used,
no details were given of the methods of data
collection used and as a consequence it is difficult
to determine whether the data collection was valid
or reliable. Other quality criteria were considered
not to be relevant.
Second-generation LVADs
Jarvik
The case report and case series assessing the
Jarvik 2000 LVAD were considered to be weak
methodologically (Table 26 and
Appendix 27).94–100 Although the studies
described their selection criteria for participants,
its was difficult to judge if the small samples were
representative of patients requiring LTCS. Limited
information was provided on the methods of data
collection and on blinding of outcome assessment.
With no comparator group, the quality criteria
assessing confounding and withdrawals were of
limited applicability. 
Generalisability
The generalisability of the studies was judged on
the characteristics of the study participants
(Table 27). The REMATCH trial111 specified
inclusion/exclusion criteria thought to characterise
patients requiring LTCS. It was felt likely that the
study was representative, characterised by
participants who were male (78% LVADs, 82%
medical), with a mean age between 66 and
68 years, classified as NHYA Class IV, with left
ventricular ejection fraction (LVEF) of 17% and an
ischaemic aetiology (LVAD 78%, medical 69%). It
is more difficult to judge the generalisability of the
case reports of the LionHeart,112 Novacor113 and
Toyobo114 LVADs and the case series of the Jarvik
2000 LVAD owing to the samples.94–100 The series
of case reports on the LionHeart LVAD included
males aged 55–69 years who suffered from dilated
or ischaemic cardiomyopathy, were in NYHA
Class IV and were ineligible for heart
transplantation.112 The study of the Novacor
LVAD included a male patient aged 54 years with
dilated cardiomyopathy and contraindicated to
heart transplantation, while the study of the
Toyobo LVAD focused on a male aged 44 years
with idiopathic cardiomyopathy. The case report
and case series assessing the Jarvik 2000 LVAD
included males (100%), with a mean age between
61 and 64 years and suffering, predominantly,
from dilated cardiomyopathy.
Assessment of the clinical effectiveness
of LVADs as a long-term chronic support
Survival
First-generation LVADs
HeartMate. The multicentre REMATCH RCT
assessed the effect on patient survival of the use of
the HeartMate VE LVAD (n = 68) compared with
Systematic review of the clinical effectiveness of LVADs for people with ESHF
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soptimal medical management (n = 61) (Table 28
and Appendix 23).111 Differences were evident in
the survival of the groups. Rose and colleagues111
reported that there was a 48% reduction in the
risk of death from any cause for those patients
receiving the HeartMate VE LVAD compared with
those on optimal medical management (RR 0.52;
95% CI 0.34 to 0.78; p = 0.001). Actuarial survival
rates were significantly higher for those patients
receiving a HeartMate VE LVAD compared with
those patients on optimal medical treatment at
1 year (52% versus 25%, p = 0.002) and 2 years
(23% versus 8%, p = 0.09) follow-up. The
difference in survival was reflected in the median
length of survival of the groups, with patients in
the LVAD group surviving for 408 days compared
with 150 days for those in the optimal medical
management group. The REMATCH trial assessed
the influence of the patient’s age on survival
undertaking subgroup analysis of 1-year actuarial
survival rates in those aged <60 years and those
aged 60–69 years. One-year survival rates for
patients aged <60 years were significantly higher
(p = 0.05) for patients with a HeartMate VE LVAD
(74%, n = 13) than those on optimal medical
management (33%, n = 9). Similarly, patients aged
60–69 years with a HeartMate VE LVAD (47%,
n = 29) had significantly (p = 0.009) higher 1-year
survival rates than patients receiving optimal
medical management (15%, n = 20).
LionHeart LVAD. One study describing a series of
case reports on six patients reported survival
following surgery to implant with the LionHeart
LVAD and survival at 18 months post-operative
follow-up (Table 28 and Appendix 24).112 All six
patients survived implantation of the LVAD. Three
(50%) of the six patients survived to 18 months
follow-up, three died of MOF at 17, 31 and
112 days following implantation of the LVAD.
Novacor. A case study reported survival of one
patient supported with a Novacor N100 LVAD
(Table 28 and Appendix 25).113,115 The 54-year-old
male with dilated cardiomyopathy and
contraindications for heart transplantation was
supported for 1342 days (3.8 years) when the
pump was changed. He then survived an
additional 172 days to 1514 days of support when
he died of causes unrelated to the pump.
Toyobo. A case study reported survival in a 44-
year-old male with idiopathic dilated
cardiomyopathy supported with a Toyobo LVAD
(Table 28 and Appendix 26).114 The patient
survived until 190 days after implantation. No
further details were reported.
Second-generation LVADs
Jarvik. Westaby and colleagues95,96,98,100 and
Siegenthaler and colleagues99 reported survival of
seven patients receiving a Jarvik 2000 LVAD as
part of a multicentre case series (Table 28 and
Appendix 27). Six patients had been discharged
from hospital with five continuing to undergo
support with the Jarvik 2000 LVAD. Two patients
from the UK centre had died after 95 and
382 days. The four patients at the UK centre
survived for a mean of 502 days (range
95–889 days)100 and the three patients from the
German centre for 93 days (range 66–145 days).
In a separate case report, Frazier and colleagues94
reported that a 61-year-old man survived to
discharge 6 weeks post-implantation of the device.
Functional status
First-generation LVADs
HeartMate. Functional status was assessed in the
REMATCH trial using the NYHA functional
classification (Table 29 and Appendix 23).111 At
baseline assessment Rose and colleagues111 found
that all patients entering the REMATCH trial were
in NYHA Class IV. At the 12-month follow-up
patients receiving a HeartMate VE LVAD had
improved to NYHA Class II, significantly
(p < 0.001) better than those patients on optimal
medical management who remained in NHYA
Class IV. It should be noted that the assessment of
NYHA classification at 12 months is limited to a
proportion of those patients surviving and able to
be assessed (HeartMate VE LVAD 24 of 68 patients;
medical management seven of 61 patients).
LionHeart. The series of case reports of the
LionHeart LVAD did not assess functional status.112
Novacor. The case study of the Novacor LVAD
reported that the patient was in NYHA Class I
following implantation of the LVAD, but did not
provide any baseline assessment (Table 29 and
Appendix 25).113,115
Toyobo. The case study of the Novacor LVAD did
not assess functional status.114
Second-generation LVADs
Jarvik. Westaby and colleagues95,96,98,100 and
Siegenthaler and colleagues99 reported the
functional status of seven patients undergoing
LTCS with the Jarvik 2000 LVAD (Table 29 and
Appendix 27). In the UK study by Westaby and
colleagues,95,96,98,100 three surviving patients
(n = 4) had improved from NYHA Class IV at
baseline to NYHA Class I (two patients) or II 
(one patient) within 4 weeks of implantation. 
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TABLE 28 Summary of evidence of patient survival following treatment of patients with ESHF as an LTCS
Study Outcomes LVAD Comparison p-Value
First-generation LVADs
HeartMate LVAD
Rose et al., 2001111 Survival at 1 year (actuarial) 52% 25% 0.002
Survival at 2 years (actuarial) 23% 8% 0.09
Median survival  408 days  150 days
Death from any cause  Reduction of 48% in the risk of death from any cause in 
(Kaplan–Meier analysis over  LVAD group: RR 0.52 (95% CI 0.34 to 0.78), p = 0.001
30 months)
1-year survival in patients  74% (n = 13) 33% (n = 9) 0.05
under 60 years (n = 22)
1-year survival inpatients  47% (n = 29) 15% (n = 20) 0.009
60–69 years (n = 49)
LionHeart LVAD
El Banayosy et al.,  Operative mortality 100% survived  N/A N/A
2003112 implantation (n =6 )
Survival at 18 months  50% survived (n = 6). N/A N/A
post-implantation 3 patients died at 17, 
31 and 112 days
Novacor LVAD
Dohmen et al.,  Survival Survived to 1342 days  N/A N/A
2001,113 1999115 (3.8 years) when pump 
changed.
Then survived to 
1514 days until died 
of causes unrelated 
to the pump
Toyobo LVAD
Seki et al., 1995114 Survival Died 190 days  N/A N/A
after surgery
Second-generation LVADs
Jarvik 2000 LVAD
Frazier et al., 200194 Survival post-transplant 1 patient survived for  N/A N/A
6 weeks until 
discharged, no 
further details
Westaby et al., 200295 Survival UK study (n = 4): N/A N/A
and Frazier et al.,  3 patients left hospital 
2003100 within 4 weeks (one 
report states that 
three patients left 
hospital within 
3–8 weeks), 2 patients 
died at 95 and 
382 days. The 
surviving 2 patients 
were still supported 
after 642 and 889 days. 
German study (n = 3): 
3 patients surviving 
at follow-upA subsequent update report by Frazier and
colleagues100 stated that one patient subsequently
died. Siegenthaler and colleagues99 noted that all
three patients were classified as NYHA Class I or
II at follow-up (range 14–93 days postoperatively),
but provided no baseline assessment. Frazier and
colleagues94 did not assess functional status.94
Quality of life
First-generation LVADs
HeartMate. The REMATCH trial111 reported the
QoL of patients with the HeartMate LVAD
compared with those on optimal medical
management at baseline and at 12 months’ follow-
up on a range of measures (Table 30 and 
Appendix 23). All patients entering the RCT
completed the baseline assessment on Minnesota
Living with Heart Failure score, the physical
function and emotional role subscales of the SF-36
and on the Beck Depression Inventory, with no
significant difference between the groups. At the
12-month follow-up only a limited proportion of
the patients included at allocation to treatment
groups had survived and were able to complete
the assessments of QoL. On the Minnesota Living
with Heart Failure score (total score 0–105, higher
score equates to worse QoL) patients with the
HeartMate VE LVAD [mean 41 (SD 22), n = 23]
had better QoL at 12 months than those patients
receiving medical management [mean 58 (SD 21),
n = 6], although the difference was not statistically
significant (p = 0.11). Comparison on the SF-36
[physical function and emotional role, scored 0
(worst) to 100 (best)] showed that patients
receiving the HeartMate VE LVAD had
significantly better QoL on the physical function
[mean 46 (SD 19), n = 23 versus mean 21 (SD 21),
n = 6; p = 0.01] and emotional role [mean 64
(SD 45), n = 23 versus mean 17 (SD 28), n =6 ;
p = 0.03] subscales than patients on optimal
medical management. Depression was assessed on
the Beck Depression Inventory (score 0–9 normal,
10–18 mild to moderate depression, 19–29
moderate to severe depression, 30–64 severe
depression). Patients on optimal medical
management suffered from significantly (p = 0.04)
worse depression than those with a HeartMate VE
LVAD [13 (SD 7), n = 22 versus 8 (SD 7), n = 5].
LionHeart. The series of case reports of the
LionHeart LVAD did not assess QoL.112
Novacor. The case study of the Novacor LVAD did
not assess QoL.113,115
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TABLE 29 Summary of evidence of patient functional status following treatment of patients with ESHF as an LTCS
Study Outcomes Intervention Comparison p-Value
First-generation LVADs
HeartMate LVAD
Rose et al., 2001111 Median NYHA class No. assessed: 24/24  No. assessed: 7/11  <0.001
(100%) (64%)
Score: II Score: IV
LionHeart LVAD
El Banayosy et al., Not  assessed
2003112
Novacor LVAD
Dohmen et al.,  Not assessed at baseline
2001,113 1999115
Toyobo LVAD
Seki et al., 1995114 Not assessed
Second-generation LVADs
Jarvik 2000 LVAD
Frazier et al., 200194 Not assessed
Westaby et al., 200295 NYHA functional 
classification
Baseline (n = 3) 3/3 in Class IV No comparator
Post-implantation of LVAD  2/3 in Class I No comparator
(4 weeks): 1/3 in Class IIToyobo. The case study of the Novacor LVAD did
not assess QoL.114
Second-generation LVADs
Jarvik. The multicentre case series of the Jarvik
2000 LVAD95,96,98,100 reported the QoL of seven
patients undergoing LTCS (Table 30 and 
Appendix 27). In the UK, Westaby and
colleagues98 noted that the QoL improved for the
three surviving patients on the Minnesota Living
with Heart Failure Questionnaire following
implantation of the LVAD. An updated report by
Frazier and colleagues100 does not provide
additional information on the long-term QoL of
these patients other than to report that one of the
three patients died and one of the remaining two
long-term survivors was travelling extensively and
participating in physical challenges. Siegenthaler
and colleagues99 reported that the mean QoL
score for the three patients at the German centre
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TABLE 30 Summary of evidence of QoL following treatment of patients with ESHF as an LTCS
Study Outcomes Intervention Comparison p-Value
First-generation LVADs
HeartMate LVADs
Rose et al., 2001111 Quality of life/function at 
12 months
Physical function No. assessed: 23/24  No. assessed: 6/11  0.01
(96%) (55%)
Score: 46 (SD 19) Score: 21 (SD 21)
Emotional role No. assessed: 23/24 No. assessed: 6/11  0.03
(96%) (55%)
Score: 64 (SD 45) Score: 17 (SD 28)
Minnesota Living with  No. assessed: 23/24  No. assessed: 6/11  0.11
Heart Failure (96%) (55%)
Score: 41 (SD 22) Score: 58 (SD 21)
Beck Depression Inventory No. assessed: 22/24  No. assessed: 5/11  0.04
(92%) (45%)
Score: 8 (SD 7) Score: 13 (SD 7)
LionHeart LVAD
El Banayosy et al., Not  assessed
2003112
Novacor LVAD Not assessed
Dohmen et al., 
2001,113 1999115
Toyobo LVAD
Seki et al., 1995114 Not assessed
Second-generation LVADs
Jarvik 2000 LVAD
Frazier et al., 200194 Not assessed
Westaby et al., 200295 Minnesota Living with  UK study (n = 4) N/A N/A
Heart Failure score  Patient 1: pre-LVAD 89, 
post-LVAD 24
Patient 2: pre-LVAD 76, 
post-LVAD died
Patient 3: pre-LVAD 83, 
post-LVAD 38
Patient 4: pre-LVAD 87, 
post-LVAD 45
German study (n =3 )  
Pre-LVAD 75.2 (SD 11.4); 
2 months post-implant: 
30.0 (SD 18.6)improved from the preoperative score of 75.2
(SD 11.4) to the postoperative 2-month score of
30.0 (SD 18.6). Frazier and colleagues94 did not
assess QoL.94
Adverse events
First-generation devices
HeartMate. Rose and colleagues111 compared the
incidence of serious adverse events in the
REMATCH trial for the patients in the HeartMate
VE LVAD group and the medical therapy group, in
addition to reporting serious adverse events
related specifically to the LVAD (Table 31 and
Appendix 23). These were reported as event rates
per patient-year with comparison through the rate
ratio (95% CIs). Patients receiving a HeartMate VE
LVAD were more than twice as likely to suffer a
serious adverse event (an accumulation of all
adverse events reported) than patients receiving
medical therapy [rate ratio: 2.35 (95% CI 1.86 to
2.95]. Of the specific adverse events reported,
patients with a HeartMate VE LVAD were
significantly more likely to suffer from non-
neurological bleeding [rate ratio 9.47 (95% CI
2.30 to 38.90)] or neurological dysfunction
(includes stroke, transient ischaemic attacks and
toxic or metabolic encephalopathy) [rate ratio
4.35 (95% CI 1.31 to 14.50)] than patients
receiving medical therapy. Patients with an LVAD
suffered higher rates of supraventricular
arrhythmias, peripheral embolic events, sepsis,
local infection, renal failure, miscellaneous adverse
events, syncope and serious psychiatric disease
than patients receiving medical therapy, although
the differences were not statistically significant. In
contrast, patients on medical therapy reported
significantly higher rates of ventricular
arrhythmias than patients with an LVAD [rate ratio
0.45 (95% CI 0.22 to 0.90)]. Also, patients on
medical therapy incurred higher rates of cardiac
arrest and non-perioperative MI than patients
with an LVAD. The serious adverse events related
specifically to the use of an LVAD included:
suspected malfunction of LVAD (rate per patient-
year 0.75); perioperative bleeding (0.46); infection
of the drive-line tract or pocket (0.41); infection of
pump interior, inflow tract or outflow tract (0.23);
right heart failure (0.17); failure of LVAD system
(0.08); and thrombosis in LVAD (0.06). Rose and
colleagues111 reported the cause of death of
patients during the REMATCH trial. Of the 41
patients with an LVAD who died, 17 were due to
sepsis, seven to LVAD failure, five to miscellaneous
noncardiovascular causes and four to
cerebrovascular disease. In contrast, 50 of the 54
deaths of patients in the medical therapy group
were due to left ventricular dysfunction.
LionHeart. El Banayosy and colleagues112
reported adverse events for six patients who
received the LionHeart LVAD (Table 31 and
Appendix 24). Of the six patients, three suffered
from temporary haemolysis, three reported
bleeding and two had an early arrhythmia. Other
adverse events included reoperation for bleeding
(one patient), tamponade (one patient),
gastrointestinal ischaemia (one patient), outflow
graft kink (one patient), low pump output (one
patient), cerebrovascular accident (one patient)
and controller change (one patient). In addition,
the three surviving patients were readmitted to
hospital on three occasions for urinary tract
infection, renal calculi and battery change (one
patient), controller change (one patient) and
spontaneous bleeding from femoral haematoma
and late haemolysis after 6 months (one patient).
There were no admissions for infection,
thromboembolic complications or arrhythmias.
Novacor. In the case study of the Novacor
device,113,115 the patient suffered from transient
renal failure during the postoperative period
(Table 31 and Appendix 25). In addition, the
recovery of the patient was complicated by
bronchopneumonia and the need for a
tracheostomy due to prolonged ventilation. Once
discharged home on support, the patient suffered
from febrile episodes that were traced to an
infection of the inflow and outflow valve conduits,
which were then replaced.
Toyobo. Adverse effects were reported in the one
patient being supported by the Toyobo LVAD
(Table 31 and Appendix 26).114 A cerebral
embolism which resulted in a hemiparesis was
noted on the ninth postoperative day, and
following this the patient suffered from multiple
cerebral embolisms on the 57th and 175th
postoperative days. These led to a left hemiplegia,
aphasia and loss of consciousness. The pump’s
electromagnetic valve was exchanged at day 91,
and the blood pump was exchanged on the 141st
postoperative day owing to thrombi attaching to
the pump surface.
Second-generation LVADs
Jarvik. Westaby and colleagues95,96,98 reported
that one patient suffered dyspnoea at 4 months,
one patient had ventricular tachycardia at
11 months, one patient experienced three power
supply problems with the LVAD and one patient
suffered an infection following a blood transfusion
(Table 31 and Appendix 27). It was noted that
none of the three surviving patients suffered from
infection of the skull-mounted percutaneous
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TABLE 31 Summary of evidence on adverse events following treatment of patients with ESHF as an LTCS
Study Outcome Intervention Comparison p-Value
First-generation LVADs
HeartMate LVAD
Rose et al., 2001111 Deaths at time of final analysis  41 (60%) 54 (88%)
Cause of death
Left ventricular dysfunction 1 (1%) 50 (82%)
Sepsis 17/41 (41% of  1 (2%)
deaths)
Failure of LVAD 7/41 (17% of  0
deaths)
Miscellaneous non-cardiovascular  5 (7%) 0
causes
Cerebrovascular disease 4 (6%) 0
Miscellaneous cardiovascular  2 (3%) 1 (2%)
causes
Pulmonary embolism 2 (3%) 0
Acute MI 0 1 (2%)
Cardiac procedure 0 1 (2%)
Perioperative bleeding 1 (1%) 0
Unknown 2 (3%) 0
Incidence of serious adverse  n =6 0 n =6 7
events (rate/patient-year)
Any serious adverse event 6.45 2.75 Rate ratio 2.35
(95% CI 1.86 to
2.95)
Non-neurological bleeding 0.56 0.06 Rate ratio 9.47
(95% CI 2.30 to
38.90)
Neurological dysfunction  0.39 0.09 Rate ratio 4.35 
(stroke, transient ischaemic  (95% CI 1.31 to 
attack, toxic or metabolic  14.50)
encephalopathy)
Supraventricular arrhythmia 0.12 0.03 Rate ratio 3.92
(95% CI 0.47 to
32.40)
Sepsis 0.60 0.30 Rate ratio 2.03
(95% CI 0.99 to
4.13)
Local infection 0.39 0.24 Rate ratio 1.63
(95% CI 0.72 to
3.70)
Renal failure 0.25 0.18 Rate ratio 1.42
(95% CI 0.54 to
3.71)
Miscellaneous adverse events 1.37 0.98 Rate ratio 1.41
(95% CI 0.93 to
2.12)
Syncope 0.04 0.03 Rate ratio 1.31
(95% CI 0.12 to
14.40)
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TABLE 31 Summary of evidence on adverse events following treatment of patients with ESHF as an LTCS (cont’d)
Study Outcome Intervention Comparison p-Value
Serious psychiatric disease 0.04 0.03 Rate ratio 1.31
(95% CI 0.12 to
14.30)
Cardiac arrest 0.12 0.18 Rate ratio 0.65
(95% CI 0.21 to
2.00)
Non-perioperative MI  0.02 0.03 Rate ratio 0.65 
(95% CI 0.04 to
10.30)
Ventricular arrhythmia 0.25 0.56 Rate ratio 0.45
(95% CI 0.22 to
0.90)
Hepatic failure 0.02 0.0
LVAD-related events 
(rate/patient year)
Suspected malfunction of LVAD 0.75
Perioperative bleeding 0.46
Infection of drive-line tract or  0.41
pocket
Infection of pump interior,  0.23
inflow tract or outflow tract
Right heart failure 0.17
Failure of LVAD system 0.08
Thrombosis in LVAD 0.06
Perioperative MI 0.0
LionHeart LVAD
El Banayosy et al., 2003112 Patients suffering from adverse  No comparator
events (n =6 )
Haemolysis (temporary)  3 patients
Bleeding 3  patients
Early arrhythmia 2 patients
Reoperation for bleeding 1 patient
Tamponade 1 patient
Gastrointestinal ischaemia 1 patient
Outflow graft kink 1 patient
Low pump output 1 patient
Cerebrovascular accident 1 patient
Controller change 1 patient
Readmission to hospital
Urinary tract infection, renal  1 patient
calculi and battery change
Controller change 1 patient
Spontaneous bleeding from  1 patient
femoral haematoma and late 
haemolysis after 6 months
Readmissions for infection,  none
thromboembolic complications 
or arrhythmias
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TABLE 31 Summary of evidence on adverse events following treatment of patients with ESHF as an LTCS (cont’d)
Study Outcome Intervention Comparison p-Value
Novacor LVAD
Dohmen et al., 2001,113 Postoperative period complicated  No comparator
1999115 by transient renal failure
Recovery complicated by 
bronchopneumonia
Tracheostomy required due to 
prolonged ventilation
Febrile episodes while at home, 
traced to Staphylococcus aureus 
infection of the inflow and 
outflow valve conduits (replaced)
Toyobo LVAD
Seki et al., 1995114 On ninth postoperative day patient  No comparator
had cerebral embolism resulting in 
hemiparesis. Multiple 
cerebralembolisms on 57th and 
175th postoperative days. Developed 
left hemiplegia, aphasia and loss of 
consciousness. Died 190 days after 
surgery. No other major complications 
such as infection, bleeding, hepatic 
or renal dysfunction. Electromagnetic 
valve exchanged at day 91. Blood 
pump exchanged on 141st 
postoperative day owing to thrombi 
attaching to pump surface
Second-generation LVADs
Jarvik 2000 LVAD
Frazier et al., 200194 Not assessed
Westaby et al., 200295 Adverse events No comparator
UK study (n =4 )
Significant haemolysis 0; dyspnoea 
1 patient at 4 months; VT 1 patient 
at 11 months; thrombus 0
Device-related complications
1 patient suffered 3 power supply 
problems; 1 patient suffered an 
infection from a blood transfusion
German study (n =3 )
Transient ischaemic attack 1; ventricular 
arrythmia 1
Minor events: 
1 episode of loss of consciousness while 
battery changed
1 knee effusion after vigorous ergometry 
training
1 large skin abrasion from adhesive tape
1 hospital readmission due to dehydration
2 patients required postoperative 
psychological therapypower delivery system. A further update by Frazier
and colleagues100 provided no additional
information on adverse events, although it was
noted that patients received serious patient-related
complications including postoperative bleeding,
left ventricular thrombus, coronary thrombosis,
subdural haematoma and gastrointestinal
bleeding. There were no system failures but there
were technical difficulties with batteries and
connectors. Siegenthaler and colleagues99
reported no infections, device-related
complications or reoperations. Minor adverse
events were reported. Frazier and colleagues94 did
not assess adverse events suffered by the patient
undergoing LTCS.
Summary of clinical effectiveness for
LVADs as a long-term chronic support
for ESHF
Quantity of evidence
Six studies assessed the clinical effectiveness of
LVADs as an LTCS, with four studies of the
HeartMate, LionHeart, Novacor and Toyobo first-
generation LVADs and two of the Jarvik 2000
second-generation LVAD. 
Methodological quality
The methodological quality of the studies varied.
Only the RCT of the HeartMate LVAD was judged
to be moderate to strong in its methodological
rigour. The studies of the other devices were
observational in design and were considered to be
weak in the methodology adopted in terms of
preventing opportunities for bias.
Generalisability
The RCT of the HeartMate LVAD was felt to
represent those most likely to benefit from LTCS.
Patients were predominantly male (~80%), aged
over 65 years, with an ischaemic underlying cause
(70–80%) and contraindicated for heart
transplantation. The case series of the Jarvik 2000
was also thought to be fairly representative of
those who may benefit, including males aged
59–72 years, suffering predominantly from dilated
cardiomyopathy. The other studies of the Jarvik,
LionHeart, Novacor and Toyobo devices included
male patients, aged 44–69 years and suffering
dilated or ischaemic cardiomyopathy.
Survival
The HeartMate LVAD was shown to lead to a
statistically significant 48% reduction in the risk of
death from any cause compared with optimal
medical management. Actuarial survival was
significantly higher for patients with the
HeartMate LVAD compared with optimal medical
management at 1 year (52% versus 25%) and
2 years (23% versus 8%) of follow-up. The
significant difference in 1-year survival was evident
for patients aged <60 years and those aged
60–69 years. The case reports of the LionHeart
LVAD found that 50% of patients survived to
18 months of follow-up. The case reports of the
Novacor and the Toyobo LVADs showed patients
were supported for over 4 years and 190 days,
respectively. The multicentre case series of seven
patients with the Jarvik 2000 LVAD showed that
six patients have survived for between 66 to
455 days of support, with one patient dying after
94 days. A case study of the Jarvik 2000 LVAD
reported survival to discharge of a patient at
6 weeks post-implantation.
Functional status
The functional status of a subset of patients
receiving HeartMate LVAD and who were well
enough to be assessed improved significantly from
NYHA Class IV at baseline to NYHA Class II at
12 months of follow-up compared with those
patients on optimal medical management who
remained in NYHA Class IV. The functional status
of patients receiving the Jarvik 2000 LVAD
improved from NYHA Class IV to either Class I or
II following implantation. Functional status was
not assessed at baseline and follow-up for the
LionHeart, Novacor and Toyobo LVADs.
Quality of life
QoL was not assessed for the LionHeart, Novacor
and Toyobo LVADs. The RCT comparing the
HeartMate LVAD with optimal medical
management found that QoL for those with the
LVAD improved compared with those on optimal
medical management on a range of measures,
significantly for SF-36 subscales on physical
function and emotional role and on the Beck
Depression Inventory. The case series of the Jarvik
2000 LVAD showed that patients’ QoL on the
Minnesota Living with Heart Failure
Questionnaire improved following implantation of
the device.
Adverse events
Patients receiving a HeartMate LVAD were twice as
likely to suffer a serious adverse event than those
on optimal medical management, with
significantly higher rates of non-neurological
bleeding and neurological dysfunction. In
addition, patients with a HeartMate LVAD had
higher rates of supraventricular arrhythmias,
peripheral embolic events, sepsis, local infection,
renal failure, miscellaneous adverse events,
syncope and serious psychiatric disease than
Health Technology Assessment 2005; Vol. 9: No. 45
71
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.patients receiving medical therapy. Patients on
optimal medical therapy had higher rates of
ventricular arrhythmias, cardiac arrest and non-
perioperative MI. Of the HeartMate patients who
died, 41% were due to sepsis, 17% to LVAD failure
and 10% to cerebrovascular disease, whereas 93%
of optimal medical management patients died
from left ventricular dysfunction. The case study
of the Novacor device found that the patient
suffered from transient renal failure,
bronchopneumonia and febrile episodes due to
device-related infection. Patients with the
LionHeart LVAD suffered temporary haemolysis
(50%), bleeding (50%), early arrhythmia (40%)
and other adverse events. It was reported that 
no patients with the LionHeart were admitted 
with infection, thromboembolic complications 
or arrhythmias. With the Toyobo LVAD the 
patient suffered from multiple cerebral embolisms
and thrombi within the pump. The case series 
of the Jarvik 2000 reported cases of dyspnoea, 
VT, power supply problems and infection. No
other device-related malfunctions or infections
were reported.
Conclusion
There is good-quality evidence that LVADs provide
benefit to patients as a long-term support,
lengthening the patient’s life and its quality when
compared with optimal medical therapy. Adverse
events associated with the use of LVADs include
device malfunctions, infection and bleeding
associated with their use. Evidence of the clinical
effectiveness of the different devices indicates that
the HeartMate LVAD appears to be effective when
compared with optimal medical management. For
the second-generation devices, the early evidence
suggests that the Jarvik 2000 shows promise, but
further research is needed to assess whether there
will be any long-term consequences associated with
the change in the nature of the circulatory
support.
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A systematic review was conducted to identify
economic studies or costing papers evaluating the
use of LVADs for people with ESHF for the three
indications of BTT, BTR and LTCS. For each
indication, the quantity and quality of research
evidence available for the different LVADs are
discussed and the outcomes assessed. This
detailed approach was undertaken for all studies
which included a cost analysis. In contrast to the
systematic review of clinical effectiveness, this
review did not restrict the assessment to specific
LVADs. This approach was taken owing to the
apparent scarcity of evidence on the cost-
effectiveness of this technology and the need for
data to develop and populate an economic
evaluation for the UK. Although such an approach
involves some uncertainty about the
appropriateness of such data, its effects may be
evaluated through sensitivity analyses. For the
purpose of this systematic review, the economic
studies retrieved were placed into four groupings:
cost summation; cost-minimisation analysis; cost-
effectiveness analysis and cost–utility analysis.
Studies which reported utilities for patients with
LVADs or with ESHF were reviewed with the aim
of populating an economic model for the UK. Full
details of the research methods for the systematic
review are discussed in Chapter 2.
Quantity of research
Nineteen studies were identified which evaluated
the costs or cost-effectiveness of LVADs for people
with ESHF. In 15 studies the LVAD studied was
identified as a first-generation LVAD. Although the
remaining four studies did not specify the LVAD
used, it is likely that they were first-generation
devices. A summary of the key characteristics of
these studies, in terms of country, device,
indication, sample size and method of economic
analysis, is provided in Table 32 with additional
details provided in Appendices 28 and 29. 
The majority of published research in the area
constituted simple cost summation or cost
minimisation analyses conducted in poorly
controlled samples of LVAD patients, primarily
based in the USA. A number of limitations apply
to the usefulness of such data outside its specific
context. First, the generalisability of cost data from
one healthcare system to another is very
limited.116 This is of particular concern in the
USA where the majority of ‘costs’ are presented in
the form of insurance charges which are fixed
reimbursements and do not specify the actual
amount of resource used for a given centre.
Second, US research must be viewed in the light 
of the strict FDA regulations, which were initially
in place in the USA with regard to the treatment
protocols surrounding the use of LVADs. Prior to
1995, LVADs were restricted to inpatient use for
BTT. Thereafter some limited outpatient use was
indicated.117 Following a further update of FDA
regulations in 1998, there has been increasing
opportunity for LVAD support to be managed on
an outpatient basis, and in 2002 LVADs were
licensed for use as a permanent alternative to
transplantation (referred to as LTCS in this
study).118 Costs collected in the different time
periods are therefore not comparable owing to 
the increased costs associated with FDA-mandated
length of stay (LOS). To combat these problems,
focus was directed on papers where resource use
was presented in natural units (e.g. number of
follow-up appointments) alongside estimates of
cost. 
Three studies were identified eliciting utilities.
One was specific to LVADs,138 with the remaining
two reporting utilities for ESHF patients139,140
The studies are summarised in Table 33. A fuller
discussion of these studies is presented in the
section ‘Cost–utility analyses’, p. 80.
Methodological quality of research
The methodological quality and quality of
reporting of the studies was assessed using an
adapted version of the criteria outlined by
Drummond and Jefferson.116 Although all studies
were assessed, only the quality of those reported as
full papers are discussed in detail as those
Health Technology Assessment 2005; Vol. 9: No. 45
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TABLE 32 Summary of studies of costs and cost-effectiveness of LVADs for people with ESHF
Study (listed alphabetically Country Device Indication Type of analysis  Sample size
with abstracts at the end)
Full studies
Arabia et al., 1996119 USA Novacor BTT CMA 4
CETS, 2000120 Canada Novacor  BTT/LTCS CEA: cost per LYG Modelled data
Christopher and Clegg, 1999121 UK HeartMate/Novacor BTT CUA Modelled data
Cloy et al., 1995122 USA HeartMate BTT CMA 13
Couper et al., 1999123 USA Centrifugal VAD
Abiomed BVS 5000  BTT/LTCS CMA 22
BiVAD/LVAD/RVAD
Gelijns et al., 1997124 USA HeartMate VE/ LTCS Cost summation 62
pneumatic
Loisance et al., 1991125 France Not specified BTT CMA, CEA: cost  37
per survivor
Mehta et al., 1995126 USA Pierce–Donachy LVAD BTT CMA 43
Morales et al., 2000127 USA HeartMate VE BTT/BTR Cost summation 90
Moskowitz et al., 2000128 USA Not specified BTT/LTCS CUA Modelled data
Oz et al., 1997129 USA Not specified LTCS Cost 68
Schiller and Reichart, 2000130 Germany Novacor N100P LVAS BTT Cost 23
Skinner et al., 2000131 USA HeartMate/Thoratec BTT CMA 36
Abstracts
Christensen et al., 1999132 USA Not specified CMA 12
Kolbye et al., 2000133 Denmark HeartMate/Biomedicus BTT CEA: cost per LYG Not reported
Miller et al., 2002134 USA HeartMate VE  LTCS Cost 45
Mir et al., 1997135 USA HeartMate BTT CMA 23
Petty and Ormanza, 1997136 USA HeartMate BTT CMA 15
Schulze et al., 2000137 Germany Novacor LTCS CMA 40
CEA, cost-effectiveness analysis; CMA, cost-minimisation analysis; CUA, cost–utility analysis; LYG, life-year gained.
TABLE 33 Summary of studies of eliciting utilities for LVAD and ESHF patients
Study Country Device Indication Derivation  of  Sample 
utilities size
Moscowitz et al., 1997138 USA HeartMate BTT: before, during and  Patient-based,  29
post-transplant SG
Havranek et al., 1999139 USA N/A ESHF as waiting list  Patient-based,  50
(outpatients) TTO, VAS
Lewis et al., 2001140 USA N/A ESHF advanced heart  Patient-based,  99
failure, 75% are  SG, TTO
inpatients
SG, standard gamble; TTO, time trade-off; VAS, visual analogue scale.published only as abstracts provided such limited
information as to render any discussion of their
methods or results of limited value. Assessment of
the quality of the 13 full studies showed variability
in their methodological quality and quality of
reporting (see Table 34). Six studies were designated
as being of ‘higher quality’,120,121,124,126,127,141 with
only one achieving close to a full quality rating.120
This is not unexpected given the findings of
previous large-scale reviews regarding the general
quality of economic studies.142
The study question was well defined in all but one
of the studies.125 However, four of the 13
economic studies did not clearly state the
perspective of the analysis,123,125–127 thus limiting
the interpretation of the results. Three studies did
not clearly state the time horizon over which costs
and consequences were assessed, making
interpretation of daily costs difficult.122,126,129,131
Of the 13 studies, only three had sample sizes
>50.124,127,129 Small sample sizes do not produce
robust findings; they suggest that studies were not
powered to detect differences in outcomes, so any
findings of difference should be interpreted with
caution.
Four studies did not provide a full description of
the competing alternatives, making it difficult to
interpret whether the findings of the studies would
be applicable in a particular setting.122,123,129,141
Of the remaining eight studies that fully described
the competing alternatives, four did not identify
all the relevant costs and consequences associated
with either the LVAD or comparator
arm.119,121,125,131 Out of all 13 papers, only three
studies reported quantities of resources separately
from the costs.121,122,127 This means that the
generalisability of the other 10 studies is limited.
Nine studies reported both costs and
effects,120,121,123,125–128,130,131 but only five of these
studies established the effectiveness of the
programmes in a transparent manner.120,121,126–128
Only four calculated an incremental cost-
effectiveness ratio (ICER).120,125,128,130 Of these,
only one detailed the calculation to the extent that
it could be replicated.120 This lack of transparency
makes accurate interpretation difficult.
Misleading presentation of results was common to
two studies.124,126 Mehta and colleagues126 derive a
cost per day for the LVADs against comparator (a
legitimate approach to costing), and conclude that
LVADs, although more costly, are actually more
cost-effective if considered in terms of cost per
day. However, the period considered for the LVAD
intervention appears to be greater than that
considered for the comparator, meaning that like
is not being compared with like. The presentation
of cost per day is therefore misleading. In the
resource trend analysis by Gelijns and
colleagues,124 the reporting of probability values
implies a greater significance than is strictly the
case. Statistically significant does not necessarily
equate with clinically significant and presentation
of probability values can be misleading.
Seven of the studies did not present credible
conclusions,119,122–126,130 in so far as the claims
that were made in the conclusions were not fully
supported by the results described in the text. Two
of these studies made claims of cost-effectiveness
or improved QoL where an effectiveness outcome
had not been reported.122,123 In the study by
Couper and colleagues,123 the LVAD intervention
was deemed to be less costly over a period relative
to a comparator, and so was deemed the ‘cost-
effective’ option. This is a misuse of the term. In
the study by Cloy and colleagues,122 it was claimed
that there was lower cost and improved QoL but
QoL was not actually measured. The studies by
Arabia and colleagues,119 Loisance and
colleagues125 and Schiller and Reichart130 all
present conclusions that go beyond the scope of
their results. The first claimed support for early
intervention (intuitively reasonable but not
demonstrated in the study findings), Loisance and
colleagues125 claimed improved outcome with
prophylaxis (without inclusion of a no prophylaxis
option) and Schiller and Reichart130 concluded
that long-term costs of LVADs were equivalent to
costs associated with other chronic organ diseases
but did not include any of these costs for
comparison. The two remaining studies overstated
the significance of their results in their
conclusions. Gelijns and colleagues124 overstated
the significance of a correlation between
programme experience and intensive care unit
(ICU) stay (the magnitude of the correlation is
actually very small) and Mehta and colleagues126
drew on their results to promote early use of
LVADs (again not wholly supported given the
findings and the sample size of their study). 
Six studies were available in abstract form only
and as a consequence provided very limited
information on their methodological quality.132–137
These abstracts are included in the quality
assessment table for completeness of reporting.
The results from the abstracts are reported, along
with those from the full studies, in the subsequent
sections of the review. Caution should be exercised
when interpreting the results of the studies
published as abstracts.
Health Technology Assessment 2005; Vol. 9: No. 45
75
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.The quality assessment of the utility studies
(Table 35) used the checklist devised by
Drummond and Jefferson.116 All three of the
studies derived patient-based utilities using
validated economic instruments such as the
standard gamble (SG) and time trade-off
(TTO).143 The studies were conducted in the USA,
which raises questions over generalisability to the
UK, especially given the likely different protocol-
driven treatment regimens. Sample sizes were
small and no information was provided describing
how the sample sizes were calculated. 
The wording of the questions used was also
examined for offering respondents realistic
alternatives that they could quantify. In the study
by Moskowitz and colleagues,138 the SG asked
patients told to compare (1) a hypothetical pill
which would return them to full health versus (2)
loss of their candidacy for transplantation or
LVAD/relief of current symptoms (post-transplant
group). In the study by Havrenak and
colleagues,139 TTO patients traded off their
current health state with a return to full health;
in the visual analogue scale (VAS) they were
asked to rate their current health on a 10-cm line
between 0 (death) and full health (1). In their
TTO, Lewis and colleagues140 asked patients to
trade off a 2-year life expectancy in their current
health state versus a range of shorter durations
in full health. The SG asked them to choose
between their current health and a probability of
return to full health. 
LVADs as a bridge to heart
transplantation for people with
ESHF
Simple cost analyses
HeartMate
Morales and colleagues127 followed a cohort of 90
consecutive patients in the USA undergoing LVAD
implantation with HeartMate VE LVADs over the
period from implant to transplantation. Resource
use data were collected retrospectively over a 
6-year period in order to assess the impact of
discharge to home during the period of LVAD
support. Costs were presented in 1998–99 US$.
The study was made possible due to the relaxation
of FDA regulations for LOS following
implantation, and the increasing acceptance of the
use of LVADs in a rehabilitation-enhancing
capacity (as opposed to a last-resort therapeutic
option). Out of the cohort of 90 patients, 44
patients (49%) met the criteria for hospital
discharge to home (see Table 36).
The non-discharge group included both inpatients
and those patients released on a day-trip/one-
night stay basis or to a rehabilitation
centre/medically supervised housing. Outcomes
measured in the study (across the n =9 0
population) were successful BTT, planned
explantation or death. On each of these three
outcomes the patients in the discharge group had
improved outcomes relative to those patients in
the non-discharged LVAD group. Some 96% of the
discharged LVAD patients went on to receive
transplants compared with 44% in the non-
discharged group. The extra benefit associated
with the discharge group is not surprising given
the criteria for discharge, but still represents an
important finding. 
The additional benefit was achieved at
considerably lower costs relative to the non-
discharged arm. Table 37 indicates the key cost
components associated with maintenance of a
healthy outpatient, relative to the daily cost of an
inpatient. The daily cost of an inpatient stay was
of a much greater magnitude than the average
monthly charge attached to a healthy discharged
patient, indicating an increased cost-effectiveness
of LVAD use in an appropriate subgroup of
patients who are well enough to be discharged
following implantation. The authors observe that
the proportion of patients meeting the criteria for
discharge (49%) could be taken as a proxy for the
proportion of patients eligible to benefit from
home-based LVAD support as the figure was based
on the activities of a cohort of consecutive patients
over a 6-year period. However, the sample size is
small, which may inhibit generalisability. 
The cost estimates include FDA-mandated weekly
visits, which are no longer a requirement. If these
visits were reduced to one per month, the routine
costs associated with the LVAD patients who were
discharged (excluding readmissions) would fall to
~US$600 per month. It is appropriate to consider
the outpatients as being ‘healthy’ as 95% of
outpatient time was spent at home. Cost
components seemingly not accounted for are the
cost attached to the training course undertaken by
patients and their carers on the care and
operation of the LVAD device and patient
transportation costs. The completion of this
training course was a stipulation for discharge and
so the cost of the course should ideally be
included in the cost calculations. No indirect costs
or QoL estimates were reported. Inclusion of such
costs is unlikely to reverse the findings of the
study, but it should be remembered that this
analysis considers the post-implantation period
Systematic review of the costs and cost-effectiveness of LVADs for people with ESHF
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TABLE 34 Methodological quality and quality of reporting of the studies assessing the costs and cost-effectiveness of LVADs for
people with ESHF
Quality criteria 116 Full study Abstract
Was the study question clearly                  
defined?
What was the sample size of the  4 N/A 72 26 2 a 37 43 90 N/A 68 23 36b 12 45 23 15 40
study?
Was the perspective of the analysis                
clearly stated?
Was the time horizon of costs and              
consequences clearly stated?
Was a comprehensive description of           N/A       
the competing alternatives given?
Was the effectiveness of the  N/A    N/A N/A     N/A N/A   
programmes or services (appropriately) 
established in a transparent manner?
Were all the relevant costs and          
consequences for each alternative 
identified?
Were costs and consequences valued                  
credibly?
Were quantities of resources reported        
separately from costs?
Were costs and consequences adjusted  N/A    N/A N/A N/A N/A N/A
for differential timing?
Was an incremental analysis of costs  N/A   N/A      N/A  
and consequences of alternatives 
performed?
Was the calculation of the ICER  N/A   N/A N/A N/A N/A N/A N/A N/A N/A N/A
transparent?
Was allowance made for uncertainty   
in the estimates of costs and 
consequences?
Sensitivity analysis        
Confidence intervals  
Were credible conclusions drawn                 
from the results?
Ticks mean criteria satisfied; N/A, not applicable.
a In the Geljins study, only 12 patients were used for the main cost analysis; a further 50 were used only for derivation of the
resource trend data.
b The Skinner study assesses the impact of antifungal prophylaxis during LVAD support. The cost analysis focuses on this
parameter but the analysis is included for fullness.
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TABLE 35 Methodological quality and quality of reporting of utilities studies for LVADs and ESHF
Moskowitz et al., 1997138 Havranek et al., 1999139 Lewis et al., 2001140
Was an economic measure of      
preference of elicitation used? SG TTO, VAS  SG, TTO
(psychometric scale)
Subjects from whom valuations      
were obtained Patients at 3 stages of LVAD  Patients in cardiology  Patients in cardiology 
implantation (before  clinic hospital ward
support, during support, 
after heart transplantation)
Sample size 29 50 99
Reporting on what subjects  ?    
asked to value?
Is this reasonable or appropriate?  Lacks description of  Yes, patients trading-off  Yes, patient value current 
consequences of candidacy  current health state health state. Estimated 
although patients may be  survival related to life 
expected to be familiar expectancy
How was the sample size derived? ✕✕ ✕
No information. Poorer  No information. Retest in  No information
health patients too impaired  subsample (n = 12) 
for interview indicated stability
Generalisability to UK context? ? US population ? US population ? US population
 , Satisfied; ✕, not satisfied; ?, unclear.
TABLE 36 Discharge criteria127
Criteria for discharging LVAD patients
1 Patient must be hospitalised for at least 30 days post-transplantation
2 Patient must currently be NYHA Class I
3 There must be echocardiographic evidence indicating that the patient’s native heart has sufficient contractility to open the
arterial valve and maintain an arterial pressure with the LVAD operating at its lowest rate
4 Patient must have passed the required training course in the care and operation of the device
5 Patient must be accompanied by a trained companion who has passed the required training course in the care and
operation of the device
6 Patient must have in the immediate vicinity required primary and backup equipment at all times
TABLE 37 BTT costs (outpatient versus inpatient)127
Type of cost Unit cost (US$) Frequency Weekly cost (US$) Monthly cost per healthy
outpatient (US$)
Professional fees 50 Weekly 50 200
Laboratory fees 76 Weekly 76 304
Dressing changes 5 Daily 36 151
Medications 3 Daily 23 99
Readmissions 25,653 0.0040/day 718 –
Inpatient cost  1,600 Dailya 11,200 –
Total  754
a Daily charge for non-acute room and board.and does not consider the acute costs associated
with LVAD implantation.
Novacor
Schiller and Reichart’s130 cost-effectiveness
analysis calculated costs associated with the use of
the Novacor LVAD as a BTT in a German
healthcare setting for 23 patients with rapidly
deteriorating CHF refractive to medical treatment.
Costs were calculated from the perspective of both
hospital and health insurer, with the overall
outcome being cost (to the hospital) per day
survived. Costs were presented in 1997 €. The
mean stay in the ICU was 33.1 days with a further
35.7 days of inpatient stay in a normal ward. The
largest part of the expense was due to the device
itself. Acute costs, excluding the costs of heart
transplant, amounted to €131,117. When
including the costs of heart transplant, these costs
rose to €175,278 per patient. In the absence of a
comparator group, it was found that for each
patient there was a deficit of approximately
€25,500 with regard to the amount paid out by the
hospital and amount reimbursed by the health
insurer. Schiller and Reichart130 calculate the
average cost per day survived over a number of
time periods. It is unclear which perspective these
costs are calculated from (i.e. cost to hospital or
cost of the deficit), but the 3-year cost per day
survived is calculated at €184, the 5-year cost at
€122 and the 10-year cost at €68.
Cost-minimisation analyses
HeartMate
A cost-minimisation study in the USA by Cloy and
colleagues122 reported savings accrued due to
outpatient release of LVAD patients relative to
those patients undergoing conventional hospital-
based medical care while waiting for transplant.
The year of costing was not specified in the
analysis but costs are assumed to be presented in
1995 US$. Cloy and colleagues122 assessed the use
of the HeartMate device in a sample of six
patients relative to six patients undergoing
conventional medical care. Natural resource units
were not reported. Cost savings were calculated
based upon the difference between the duration
and costs of inpatient and outpatient maintenance
associated with the two treatment regimens. The
savings associated with the discharged group
relative to the non-discharged group were
calculated at US$76,191 per patient (n = 6). The
authors conclude that the use of LVADs is cost
saving in those patients who can be rehabilitated
during the period of LVAD support. However,
careful patient selection for home discharge
patients in this study may have confounded results.
A further two studies from the USA were reported
as abstracts.135,136 These were cost-minimisation
analysis of the HeartMate LVAD as a BTT for
status 1 patients at single treatment centres and
were based on relatively small numbers of patients
(n = 38, total).135,136 The year of costing was not
presented but both abstracts were published in
1997. Status I patients are defined as either
inpatients in the ICU receiving inotropic or
mechanical support or patients who have received
an LVAD. In each abstract, the HeartMate led to
higher hospital charges than patients on inotropic
therapy.135,136 Results were similar across the two
studies: the LVAD groups had average total
hospital charges of US$291,651–294,087 whilst
inotropic therapy was US$183,233–194,132.135,136
Novacor
Arabia and colleagues119 assessed the use of the
Novacor LVAD in the USA in three patients in
comparison to one control patient who refused the
device. The year of costing is not specified but
costs appear to be presented in 1995 US$. Natural
resource units were not presented. Cost savings
were calculated based upon the difference between
the duration and costs of inpatient and outpatient
maintenance associated with the two treatment
regimens. The savings associated with the
discharged group relative to the non-discharged
group were calculated as US$46,893 per patient
(n = 3). The authors conclude that the use of
LVADs is cost saving in those patients who can be
rehabilitated during the period of LVAD support.
However, the sample size of this study is extremely
limited and results should be viewed with caution.
Pierce Donachy
Mehta and colleagues126 reviewed all status I
patients on the cardiac transplant waiting list 
(12 Pierce Donachy LVAD patients, Group 1, and
31 patients maintained on optimal medical
management, Group 2) at a hospital in the USA.
Costs were calculated over the period of the
review, 1991–1994, and it is assumed that they are
presented in 1994 US$. Cost-minimisation
analysis revealed a significant difference in the
mean cost/charge associated with each group
(p < 0.001) with Group 1 at US$186,131/$302,048
and Group 2 at US$100,115/$165,219. However,
when these figures were calculated on a daily basis,
there was a trend towards lower costs/charges in
Group 1 (p > 0.1), with Group 1 cost/charge per
day calculated as US$2859/$1808 and Group 2 as
US$3371/$2071. There was also a trend toward
increased discharge rates post-transplant in the
LVAD group, but this did not reach statistical
significance.
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The study by Oz and colleagues,129 described as a
cost-minimisation analysis in 68 patients in the
USA (21 unspecified LVAD devices and 47 heart
transplants), presents its methodological approach
to the costing, but does not provide actual costs.
Another study in the USA by Christensen and
colleagues,132 presented as an abstract only,
evaluates the maintenance costs for an unspecified
LVAD as a BTT. The year of costing is not
reported. The average cost per day of inpatient
LVAD support was compared against the average
costs of outpatient support, where the outpatient
setting was a specially developed assisted living
facility (not the patient’s own home). The average
cost per day for the first group (n = 5) was
calculated as US$3441 and for the second (n =7 )
as US$1357. Christensen and colleagues132
concluded that an average saving of US$2084 per
day was realised by discharging patients to the
assisted-living facility with total accrued savings
amounting to US$1,469,220 across the patient
group. These calculations did not include the costs
of laboratory or professional fees.
Several other cost-minimisation analyses were
retrieved but either focused on the effects of
prophylaxis or failed to draw a distinction between
the type of devices used. In the USA, Skinner and
colleagues131 compared antifungal prophylaxis in
LVAD patients receiving either the HeartMate or
Thoratec LVADs but failed to identify the different
devices in their analysis. Couper and colleagues123
undertook a study in the USA (n = 22) comparing
an unspecified centrifugal VAD with the use of the
Abiomed BVS 5000 as a BiVAD, LVAD or RVAD.
No analysis was presented separately for the LVAD
subgroup. Similarly, the study in France by
Loisance and colleagues,125 comparing the costs
and cost-effectiveness of mechanical against
pharmacological BTT, grouped together TAHs,
BiVADs and LVADs in the costing exercise. Further
details of these studies are presented in
Appendices 28 and 29. 
Cost-effectiveness analyses
HeartMate
A cost-effectiveness study undertaken in Denmark
by Kolbye and colleagues133 reported that the
HeartMate LVAD was more cost-effective than a
Biomedicus (an extracorporeal blood pump)
device as a BTT. The HeartMate LVAD cost a
reported DKK270,000 per life-year gained (LYG)
(approximately €37,800). This was a retrospective
study that incorporated costs of devices and
hospitalisation, including drug costs. The year of
costing was not stated.
Novacor
The study by the Conseil d’Évaluation des
Technologies de la Santé du Québec (CETS)120 in
Canada examined the cost-effectiveness of the
Novacor LVAD for the three indications of BTT,
BTR and LTCS.120 Costs were presented in 1998
Can$. The analysis utilised costs from a number of
sources, specifically Gelijns and colleagues124 and
the ‘Quebec’ transplant study.144 These were then
applied to estimates of LYGs in the LVAD support
group relative to the non-LVAD group to estimate
the ICER of the LVAD intervention. The approach
of the analysis is marginal in that it does not
consider any of the costs which are equal across
the two groups. The analysis is based on clearly
defined hypothetical treatment scenarios. Costs
and benefits are assessed over a 12-year period.
This time frame is driven by extrapolation of 
3-year post-transplant survival rates which assumes
that the average survival post-transplantation is
12 years. The costs and benefits associated with
transplant following routine care are taken as the
baseline, with the expected additional costs and
benefits associated with 100 patients undergoing
transplantation following a period of LVAD support
representing the marginal costs and benefits used in
determining the cost-effectiveness of the BTT
scenario (see Tables 38 and 39). The authors state
that it was not possible to calculate the cost-
effectiveness ratio in an emergency implant BTT
scenario, as owing to the shortage of donor hearts
no additional lives would be saved by the use of the
LVAD technology (just different ones).
The ICER is calculated as Can$91,332 per life-
year gained (~€56,000) with LVAD support
relative to routine care (Can$117,197 discounted
at 5%; most costs are accrued in year 1 with the
benefits accrued over the 12-year period)
(Table 39). A sensitivity analysis looked at the
impact of assuming that a proportion (0.75) of
patients would have lived for 1 year in the absence
of LVAD support (thus reducing the LYGs by
procedure to 185). The resultant ICER in this
scenario was calculated as Can$126,304 per life-
year saved (~€77,000).
Cost–utility analyses
HeartMate
No cost–utility studies were identified in the
international literature for the BTT indication.
However, Moskowitz and colleagues138 conducted
a study which assessed the utilities of patients
undergoing LVAD implantation as BTT. It was a
comprehensive but small (n = 29) study conducted
across all adult patients undergoing LVAD
implantation at Columbia Presbyterian Medical
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duration of heart disease prior to implantation
was 3.3 years (mean 6.5, SD 8.4, range 0.1–40.9).
Patients were interviewed at three points in their
treatment, prior to implantation (while in
intensive care), post-implantation, during LVAD
support (while hospitalised), and post-
transplantation (interviews conducted in both
hospital and home settings). Utilities were derived
via an SG exercise, with scenarios constructed by
the authors, and are summarised in Table 40.
Different numbers of patients were interviewed at
each point as not all patients were available for
interview at each of the time periods (owing to
impairment, drop-out or death). However, in
order to address potential bias, the authors also
conducted binary and three-way comparisons
amongst those patients available for interview at
the different time periods (reported below).
Moskowitz and colleagues138 calculated the
reported utilities using binary comparisons (i.e.
considering the responses of the same patients at
two of the health states) to measure relative
improvements. Significance of the difference
between them was tested via paired-data analysis
on 11 patients who were interviewed both before
and during LVAD and 10 patients who were
interviewed both during LVAD and after
transplant. In each comparison, the difference
between average scores varied significantly from
zero even after correcting for multiple
comparisons (p = 0.008, 0.003). A further analysis
was conducted based on the six patients who
underwent all three interviews. 
Moskowitz and colleagues138 undertook another
analysis to address the issue of discarded data. In
this analysis, the authors imputed data for the
missing utility values during the LVAD support
period and recalculated the utility associated with
this period as 0.699. The authors pointed out that
this is still considerably higher than the 0.548
associated with the pre-implantation period, a
figure which subsequent analyses have used as a
proxy for the utility associated with non-LVAD
support prior to heart transplantation. It is worth
noting that the CI around the point estimate for
this period is large, implying that less confidence
can be attached to the accuracy of this figure.
Two other studies that examined the utilities in
ESHF patients were assessed.139,140 The two studies
were designed to review the suitability of the use of
a utility measure in the heart-failure population.
Havranek and colleagues139 conducted a study in
an outpatient setting (n = 50) with the study
population including patients awaiting cardiac
transplantation (unfortunately there was no
breakdown of the proportion of these patients or
any further information on the NYHA
classification of participants). In the study, a battery
of measures were used on the patients, including
TTO, SF-36 physical and mental health
component scores, MLHFQ, VAS and the 6-minute
walk distance. The explanation for the 0.30
difference between the TTO and VAS scores in the
study by Havranek and colleagues is unclear given
the transparent wording employed in each exercise
(see above). In the study by Lewis and
colleagues,140 participants (n = 99) were patients
with advanced heart failure (mean LVEF 24%), the
majority (75%) of whom were inpatients. Table 41
summarises the utility scores derived in these two
studies and these appear to corroborate those
reported by Moskowitz and colleagues.138
The only economic evaluation based in the UK
was undertaken by Christopher and Clegg121 as
Health Technology Assessment 2005; Vol. 9: No. 45
81
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
TABLE 38 CETS benefits calculation120
Calculation component Input
Initial cohort (n) 143
Percentage proceeding to transplant 70
Number proceeding to transplant (n) 100
Increased survival (%)a 20
Additional survivors (n)2 0
Time on LVAD support (days) 100
Survival time post-transplant (years)b 13
Health benefit (life-years) 260
a Based on a 20% improvement in the 5-year survival
rate found by Jouveshomme and colleagues.145
b Based on a projected estimate of 74% survival at
3 years.
TABLE 39 CETS cost calculation (BTT)120
Cost component Cost (Can$)
Cost of LVAD device 90,000
Cost of LVAD implant/heart transplant 48,883
Cost of support (per day) 3,800
Annual maintenance cost 10,000
Marginal cost LVAD 138,883 × 143
Marginal cost of LVAD supporta 3,800 × 100
Marginal cost of transplant 48,443 × 20
Marginal cost of maintenance  10,000 × 20 × 13
Total marginal cost 23,746,209
Cost per life-year  91,332
Cost per life-year (discounted at 5%) 117,197
a Assumed to be Can$38/day based on Gelijns and
colleagues’124 estimate.part of a systematic review of clinical and cost-
effectiveness of LVADs for ESHF. The study
models the cost–utility associated with the use of
the HeartMate and Novacor LVADs in the UK for
the BTT indication. The study presents a
systematic review of the literature up to early 1999
and the cost–utility model bases its efficacy
estimates on the data from the cohort study by
Frazier and colleagues146 and its utility estimates
on the study by Moskowitz and colleagues.138 The
year of costing is not reported but it can be
assumed that costs were presented in 1998 UK£.
The model follows a hypothetical cohort of 100
HeartMate LVAD and 100 non-LVAD patients
from pre-transplant to 20 years post-transplant.
The number of patients surviving to transplant
was taken from the study by Frazier and
colleagues,146 where 71% of the LVAD group and
36% of the non-LVAD group survived to
transplant. The duration between LVAD
implantation and heart transplant is assumed to
be 76 days for the LVAD group and 12 days for
the non-LVAD group146 The QoL (utility)
associated with the pre-transplant period was
taken from the baseline estimates from the study
by Moskowitz and colleagues,138 assumed to be
constant at 0.548 for the non-LVAD group and
0.809 for the LVAD group. Post-transplant utility
was 0.964 for both groups.
The time frame used in the analysis was 20 years
with the authors assuming a linear decline in the
death rate between the known values of post-
transplant survival at 1 (75%) and 5 years (64%)
(based on robust statistics from the National
Transplant Database) and 10 years (50%) (based
on findings from one UK Transplant Centre). The
quality-adjusted life-year (QALY) gain over the
study period was calculated as 430 for the LVAD
group and 212 for the non-LVAD group. Survival
at 20 years is therefore assumed to be zero. It was
assumed that both groups gain the same benefits
after heart transplant. This is a conservative
assumption since improved rehabilitation post-
transplantation is to be expected in the LVAD arm
and this may be associated with additional gain in
utility in this patient group. Costs over the period
were assumed to be as shown in Table 42.
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TABLE 40 Summary of Moskowitz and colleagues’ utilities138
Patient condition Method of utility  Utility score (SD) Sample size for comparisons (n)
derivation
Before LVAD implantation SG 0.548 (0.276) (overall score) 14
0.566a (0.236) 11
0.704b (0.133) 6
During LVAD support SG 0.809 (0.136) (overall score) 20
0.804a (0.102) 11
0.826c (0.149) 10
0.828b (0.126) 6
Post-transplantation SG 0.964 (0.089) (overall score) 11
0.990c (0.015) 10
0.995b (0.005) 6 
a Binary comparisons of before implantation with during LVAD support.
b Three-way comparisons.
c Binary comparison of during LVAD support with post-transplantation.
TABLE 41 Summary of patient-derived ESHF mean utility scores
Patient condition Method of utility  Utility score (SD) Study description 
derivation
Waiting list (outpatients) TTO  0.77 (SD 0.28)a Patient-based
VAS 0.47 (SD 0.21) n = 50; Havranek et al.139
Advanced heart failure (75% as inpatients) SG 0.64 Patient-based
TTO 0.65b n = 99; Lewis et al.140
a 1-week retest 0.78 (SD 0.25), p = ns, n = 12.
b 0.3–0.65 subset of NYHA Class III–IV, no SD reported.Based on 100 patients going through each arm, the
discounted (costs discounted at 6%, benefits at
1.5%) the incremental cost per QALY for the LVAD
group was estimated at £39,790 relative to the non-
LVAD group (over a projected 20-year period). This
means that in order to gain an additional QALY in
the LVAD arm relative to the non-LVAD arm, an
additional £39,790 would be required. The analysis
notably did not include any costs associated with
the period of LVAD support (an omission for which
this study has been criticised); the problems with
this exclusion are discussed in more detail below.
The study further attached no cost to the 12-day
period of pre-transplant; as shown in the CETS
analysis,120 inclusion of this figure would improve
the cost-effectiveness of the LVAD arm. 
The utility values chosen for use in the analysis
could also be challenged. In each case the study by
Christopher and Clegg121 uses the average overall
(as opposed to binary or three-way comparison)
utility values derived by Moskowitz and
colleagues.138 These utilities were collected while
patients were in the ICU and those values
collected following LVAD implantation and heart
transplantation may well be artificially inflated as
patients have not yet had time to adjust to their
new health state and are merely glad to be alive
(cf. heroic intervention effect). Moskowitz141 uses
an adjusted utility estimate in the calculation of
cost-effectiveness: 0.75 for the period of LVAD
support rather than 0.809. This would be the
conservative approach to take in this analysis, as
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TABLE 42 Christopher and Clegg cost-effectiveness calculations121
LVAD group Non-LVAD group
(HeartMate/Novacor devices)
Number of patients a 100 100
LVAD device (Trust Finance Dept) b £52,880 –
LVAD procedure (Trust Finance Dept) c £9,600 –
LVAD costs (device and procedure) per patient d = b + c £62,480 –
Total LVAD procedure and device costs  e = a × d £6,247,900 –
(100 patients)
Number of patients undergoing heart  f 71 36
transplants (i.e. surviving to transplant)
Heart transplant procedure (ref. costs) g £23,950 £23,950
Heart transplant follow-up costs  h £3,500 £3,500
(Trust Finance Dept)
Immunosuppressant drug costs  i £2,890 £2,890
(Trust protocol/BNF)
Total first year heart transplant first (per patient) j = g + h + i £30,340 £30,340
Total heart transplant costs k = j x f £2,154,107 £1,092,223
Annual follow-up heart transplant costs  l £3,500
(Trust Finance Dept)
Annual follow-up immunosuppressant drug  m £3,161
costs (Trust protocol/BNF)
Total annual follow-up costs per person n = l + m £6,662
Number of patients followed up  o 53 27
(year 1 onwards)
Total discounted heart transplant follow-up  p £2,707,576 £1,372,855
costs (including drugs)
For calculation see report. Based on 0% 
20-year survival
Total discounted costs (LVAD + heart  q = p + e + k £11,109,583 £2,465,079
transplant)
QALYs (discounted) r 430 212
Incremental cost s £8,644,504 –
Incremental QALYs t 218 –
Incremental cost per QALY u = s/t £39,654a –
a Rounding error present: the study itself reports £39,787.although sensitivity analyses do address this issue
(by calculating the ICER under minimum and
maximum utility assumptions), the baseline
calculation may well overestimate benefit. 
Summary of costs and cost-
effectiveness of LVADs as BTT for
patients with ESHF
  A number of studies consider LVADs in a BTT
indication, although only one study was based
in the UK.
  There were no data on second-generation
devices.
  The quality of these studies is mixed, although
the study in the UK was of high quality.
  The studies are in different settings and
conducted in different years, hence it is difficult
to make credible comparisons.
  The majority of studies reviewed the use of the
HeartMate device.
  No studies were found on the Jarvik, Toyobo or
MicroMed DeBakey second-generation 
devices.
HeartMate
  One study127 found that 49% of LVAD patients
were eligible for discharge during the period of
support. Healthy outpatient costs were
significantly lower than inpatient costs.
  One study conducted a cost-effectiveness
analysis in a Danish setting133 and generated a
cost per LYG of ~€37,800. It is not clear
whether this includes a period of outpatient
support or whether all LVAD support patients
are maintained as inpatients.
  Cost–utility analysis of the use of HeartMate as
BTT estimates the cost per QALY at £39,790
over a 20-year period.121 Threshold analysis
indicated that an LVAD device and procedure
cost of <19,000 would lead to a cost per QALY
of <£20,000.
Novacor
  The CETS cost-effectiveness analysis generates
a cost per LYG of €56,000. This analysis
assumed that patients were maintained as
outpatients during the period of LVAD 
support.
  Schiller and Reichart130 calculate a less
transparent cost-effectiveness analysis of 
3-year cost per day survived at €184 (10-year
cost €68).
Pierce Donachy
  Mehta and colleagues126 conclude a trend
towards lower cost/day in the LVAD group
relative to optimal medical management.
LVADs as a bridge to recovery for
people with ESHF
No costing studies or economic evaluations were
found that examined the use of LVADs as a BTR
for people with ESHF. The study by CETS120
highlighted the potential cost-effectiveness of
LVADs as a BTR, but insufficient data were
available to undertake an analysis.
LVADs as a long-term chronic
support for people with ESHF
Simple cost analyses
HeartMate
Gelijns and colleagues124 (also reported in
Moskowitz and colleagues117) conducted a simple
analysis of the costs associated with an LVAD
programme conducted at their institution (the
Columbia Presbyterian Medical Center). Costs
were presented in 1995 US$. In the main 
analysis, Gelijns and colleagues124 retrospectively
reviewed the episodic and projected 1-year 
costs related to the initial hospitalisation 
and outpatient follow-up for 12 patients who
received HeartMate VE LVADs. The authors 
used the ratio of cost to charges method to
measure the direct costs associated with 
treatment (hospital and physician time). Given 
the FDA regulations in place at the time 
of the analysis (minimum LOS set to 30 days),
Gelijns and colleagues calculated ‘clinically
sufficient’ average costs alongside ‘actual’ 
average costs.124
In the analysis, the clinically sufficient costs were
derived by adjusting the actual LOS to that
considered clinically sufficient. Estimates of the
clinically sufficient LOS were based on review 
of criteria such as general health status, blood
results, echocardiographic evidence and evidence
of appropriate management of the device on the
part of patients and their companions. The
average actual cost of LVAD support over 
a 9.5-month period (including outpatient 
and readmission costs) was calculated at
US$221,313; calculations based on clinically
sufficient LOS reduced this estimate to
US$201,148. The focus of the study was derivation
of the costs associated with the long-term use 
(i.e. LTCS) of the LVAD technology. A projection
of the clinically sufficient 9-month cost estimated
the average predicted first-year cost at
US$219,139. The breakdown of the initial
hospitalisation costs for the clinically sufficient
scenario is detailed in Table 43.
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half of the total hospitalisation cost for
implantation, with the next largest cost drivers
being professional payments and special care days
(comprising days in ICU, cardiac care and
stepdown units). Gelijns and colleagues124 assessed
the trend in resource use over time associated with
implementation of the LVAD programme, with
particular reference to LOS in ICU. This analysis
was based on the data for 50 patients with
pneumatic LVADs. On the basis of a regression
analysis, the authors concluded that LOS in ICU
(a significant cost driver of the LVAD programme)
was inversely correlated with the time from
implementation of the programme. However, this
finding should be treated with some caution as,
although the result was statistically significant
(p < 0.05), the magnitude of the inverse
relationship was small (r2 = 0.964).
A recent abstract from the REMATCH trial
undertaking a cost-minimisation analysis,134
reported mean inpatient costs for 45 patients
(66% study population) HeartMate LVADs of
US$196,699 (median US$97,741). This excluded
the US$65,000 cost of the LVAD device.134 The
year of costing was not reported but the abstract
was published in 2002. These inpatient costs are
similar to those reported by Gelijns and
colleagues.124 As the data were presented as an
abstract with limited study details, caution should
be exercised in their interpretation. Although the
annual costs of the use of an LVAD as a BTT
appear high, they compare favourably with first-
year charges (including evaluation, candidacy,
organ procurement, hospitalisation, physician
charges, follow-up and immunosuppression) for
heart transplant patients (based on 1999 data) at
US$303,000.147
Novacor
One study published as an abstract examined the
costs of the use of the Novacor LVAD as a long-
term alternative to heart transplant in Germany.
Costs were presented in 1999 €. In a sample of 20
patients those receiving the Novacor LVAD had a
higher mean in-hospital costs compared with
those receiving a heart transplant (€62,142 vs
€46,874).137
Cost-effectiveness analyses
Novacor
In the application of LTCS, the CETS authors
calculate the cost-effectiveness of both emergency
and elective implantation of the LVAD
technology.120 The previous cost calculations are
used, and it is again assumed that 70% of patients
will survive LVAD implantation. Costs are
presented in 1998 Can$. A subsequent annual
mortality rate of 3% is assumed (based on the
International Society for Heart and Lung
Transplantation Sixteenth Annual Data Report,
available at http://www.ishlt.org/registry.html)
average post-transplant mortality rate of 3% per
year, and it is assumed that the LVAD will require
replacement every 4 years with a cost equal to that
of the initial implantation cost. 
In the LTCS scenario, by the end of year 12, the
total accumulated cost for a cohort of 100 patients
is calculated at Can$38.4 million with a gain of
641 life-years, or Can$59,842 per LYG (~€37,000)
(Can$57,628 discounted at 5%). Sensitivity
analysis assumes 11 days of short-term support for
the non-LVAD patients at Can$5000 per patient
(the baseline calculation assumes a rapid demise at
negligible cost), thus reducing the net marginal
cost of the LVAD arm by Can$50 million, resulting
in a cost per LYG of Can$52,043 (~€32,000),
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TABLE 43 LVAD implantation hospitalisation costsa
Resource category Average cost (SD) (US$) % of total cost
LVAD (HeartMate) 67,085 48%
Professional payment 23,935 ± 10,897 17%
Special care days  14,765 ± 10,874 10%
Regular floor days 7,071 ± 7,376 5%
Operating room 10,818 ± 1,725 8%
Diagnostics 3,900 ± 3,574 3%
Laboratory 3,407 ± 1,767 2%
Blood products 2,873 ± 2,562 2%
Drugs 3,257 ± 3,229 2%
Miscellaneous 3,235 ± 1,695 2%
Rehabilitation 670 ± 423 0%
Total 141,016
a Initial hospitalisation costs only, based on ‘clinically sufficient’ LOS of 17.5 days.(Can$50,075 discounted at 5%). The elective
implantation scenario assumes that some LVAD
patients would have survived in the absence of
LVAD support. Assuming an average of 1-year
survival, LYGs are reduced to 531 with a resultant
cost-effectiveness of Can$70,903 (~€43,000)
(Can$67,883 discounted at 5%) per LYG.
The authors stress that their calculations are based
on hypothetical scenarios and are not comparable
with the estimates in the report by Christopher
and Clegg.121 They also suggest that detailed 
data collection with matched controls should be
made a stipulation of acceptance of the device
onto Quebec’s reimbursement tariff in order 
that more robust calculations of cost-effectiveness
can be carried out. As yet there is no evidence of
any such data having been published. The 
authors also stress that a number of decisions 
need to be made prior to implementation with 
a clear understanding that limitation of use 
will be essential alongside plans for additional
funding.
Cost–utility analyses
HeartMate
In the study by Moskowitz and colleagues,138 the
authors conclude that if the utility rating
associated with the period of LVAD support can be
taken as a proxy for the utility associated with
long-term implantation (i.e. LTCS), then such use
would be acceptable on the basis of patient QoL.
However, it should be noted that no long-term
utility data have been collected to date and the
impact of regular LVAD replacement on QoL has
not been assessed. Other authors have assumed
that device replacement would be necessary
approximately every 4 years.120 Furthermore, the
utilities reported in the study by CETS represent a
point estimate derived very soon after
implantation during hospitalisation. This value
may therefore be an overestimate of the benefit
accrued over a longer term period as patients
begin to be aware of the limitations imposed by
the presence of the LVAD.
In an extension of the study by Gelijns and
colleagues,124 Moskowitz141 considered a
hypothetical LTCS cost-effectiveness scenario,
based on the findings of the original Gelijns and
colleagues’124 costing paper and Moskowitz and
colleagues’138 baseline utility estimates. Costs are
presented in 1995 US$. Moskowitz calculated the
cost–utility of (only) the LVAD support period.
The author highlights that there is an unusually
high utility value (0.809) attached to Moskowitz
and colleagues’ original estimate of utility and
suggests that this is likely to be an artefact of the
‘thank God I’m still alive’ feeling which LVAD
support patients may have. The utilities derived in
the study by Moskowitz were modified in order
that this ‘heroic intervention’ effect does not
confound the results, and in this instance a value
of 0.75 (arbitrarily chosen and reported to
approximate patients on haemodialysis) is used in
the calculations of cost–utility. The study is set in
the USA and, as with the original paper by Gelijns
and colleagues,124 works on the premise of actual
and clinically sufficient LOS driving two
independent cost-effectiveness scenarios (LOS of
43.5 and 17.5 days, respectively). 
In each case the cost-effectiveness ratio is
presented under two assumptions of efficacy
resulting in different values of cost per QALY (the
details are not presented in the paper). The
derivation of costs used in the exercise is unclear
but it is assumed that costs reflect those calculated
by Gelijns and colleagues.124 Moreover the
incremental analysis (see Table 5, p. 190, in
Moskowitz141) does not appear to use the utility
data presented in the accompanying text. Table 44
recalculates the cost-effectiveness analysis using
those values cited in the text.
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TABLE 44 Incremental cost-effectiveness of LVADs as an LTCS141 – corrected estimates
Strategy Incremental cost Incremental effectiveness  Incremental cost-effectiveness 
(US$) (QALYs) (years) (cost per QALY) (US$)a
Implantation LOS 17.5 days
LVAD – low efficacy 61,938 1.37 45,210
LVAD – high efficacy 87,013 2.40 36,255
Implantation LOS 43.5 days
LVAD – low efficacy 82,278 1.37 60,057
LVAD – high efficacy 107,353 2.40 44,730
a The original paper does not present a transparent calculation. Results have been recalculated here using corrected figures
but may contain rounding errors as the original underlying data were unavailable.These results show a cost per QALY of between
US$36,000 and 60,000, which is lower than the
estimates for BTT produced by Christopher and
Clegg.121 This analysis provides the only cost-
effectiveness data for LTCS.
Summary of evidence of costs and 
cost-effectiveness of LVADs as an LTCS
for people with ESHF
  There are limited data available in this
indication.
  The quality of the studies was mixed.
  Available data are necessarily based on
hypothetical scenarios or projected short-term
costs (no long-term data are as yet available for
this indication).
  There were no data on second-generation LVAD
devices.
HeartMate
  One study calculates the (projected) first-year
cost of use of the HeartMate device at
US$219,139.124
  Main cost drivers are found to be cost of the
LVAD, professional payment and special care
days (ICU, cardiac care and stepdown unit).
  One study calculates a cost per QALY of
between US$36,000 and 60,000 for the use of
HeartMate in this indication.138
Novacor
  The CETS analysis calculates a cost per LYG of
Can$57,628 based on a hypothetical scenario.120
Discussion
Although there are a number of simple costing
studies, this review has shown there is relatively
little published literature on the cost-effectiveness
of LVADs. A number of the costing studies
reported in this review had serious methodological
flaws. Even those in the ‘higher quality’ category
had limited applicability or generalisability. The
various restrictions of FDA mandated LOS for
LVAD patients pre-1998 further restricts the
generalisability of these studies. The major
limitation of the studies in this systematic review
was their limited sample size and the lack of
comparators against which to judge the
significance of the reported costs.
The key studies in the systematic review were the
two cost summations by Gelijns and colleagues124
and Morales and colleagues127 and the two
systematic reviews by CETS120 and Christopher
and Clegg.121 The two systematic reviews
presented primary cost-effectiveness analyses
based on modelled data. The CETS study used
costs derived from Gelijns and colleagues124 and a
previous study on the costs of heart
transplantation.148 The study by Christopher and
Clegg121 populated the model with costs based on
treatment protocols, data from individual NHS
trust finance departments and utilities derived in
the study by Moskowitz and colleagues.138 The
study by Christopher and Clegg121 provides the
only example of UK-specific literature in this area.
The benefit of the model by Christopher and
Clegg121 lies in its detailed consideration of
survival and its use of cost–utility analysis to
generate a cost per QALY figure. Rather than
assuming a blanket average survival time post-
transplant (as in the CETS model), the model
plots the survival curve for each arm of the model.
However, it should be noted that there is a
difference between the estimates of survival to
transplant used in the model (71 and 36% for the
LVAD and non-LVAD patients, respectively) and
the assumption of marginal gain used in the
model by CETs (20% additional survival to
transplant in the LVAD relative to the non-LVAD
patients).120 The study by Christopher and
Clegg121 cited the figures from Frazier and
colleagues,146 which includes an age range of
14–66 years in the patient group, and for 
that reason was excluded from the systematic
review of clinical effectiveness presented in
Chapter 3.
The calculations by Christopher and Clegg121
could be viewed in the light of current UK prices.
The current prices for HeartMate and Novacor
are £48,000 per device whereas the second-
generation implantable MicroMed DeBakey LVAD
has been priced at £35,000 per device (submission
by MicroMed DeBakey). Assuming comparable
efficacy, the lower of these estimates could yield
savings of £1.79 million (£17,880 savings × 100
patients) and the cost per QALY could fall to
£31,452. Christopher and Clegg121 used threshold
analysis to calculate that an LVAD device and
procedure cost of £19,300 would equate to a cost
per QALY of ≤ £20,000.
The model developed by CETs (Novacor LVADs)
was simple and transparent and provided a good
template for a marginal analysis. The benefits of
this model over that by Christopher and Clegg121
relate primarily to the consideration of costs
associated with the period of LVAD support. The
omission of these costs in the model by
Christopher and Clegg121 (although pointed out
Health Technology Assessment 2005; Vol. 9: No. 45
87
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.by the authors) represents a problem that needs to
be addressed.121 However, given that these costs
constitute only a very small proportion of the costs
associated with LVAD use, their omission, although
open to criticism on methodological grounds,
should not materially alter the results of any
calculations.
No studies to date have attempted to generate
utilities for LVADs as an LTCS, or for outpatient
LVAD support. Assuming that these states have the
same utility as that during LVAD BTT support
may be mistaken. 
The utility estimates by Moskowitz and
colleagues,138 used in the model by Christopher
and Clegg,121 represent the only source of patient-
based utility data for LVADs patients. Bias could
be introduced in terms of the small sample size
(especially in the pairwise comparisons), the
influence of a ‘heroic intervention’ effect (which
may explain the CETS reluctance to use them),
the fact the study was conducted between 1993
and 1995 and that the device was a first-
generation HeartMate LVAD. 
The analysis by Christopher and Clegg121 reports
cost per QALY values at the boundary of
acceptability given recent decision-making.149
Based on total treatment costs of both LVAD BTT
support and heart transplantation, the discounted
cost per QALY was ~£39,790 (range
£28,510–74,000). However, as discussed, the
assumptions underlying the costing and efficacy
estimates are open to question. Moskowitz and
colleagues generated acceptable threshold levels 
of cost-effectiveness (around US$36,000–60,000)
for the HeartMate IP LVAD as an LTCS. If this
value is converted to UK currency it would 
appear that LVADs are more cost-effective in the
LTCS indication. However, making comparisons
across the two studies is problematic given the
different settings, years and methodologies
employed.138
Economic evaluations for the use of LVADs as an
LTCS are in their infancy with good-quality trial
and observational data just beginning to emerge
(e.g. the REMATCH trial). 
To summarise, the level of available evidence is
surprisingly minimal given the serious nature of
ESHF and the consistent shortfall between the
number of donor organs and the number of
patients requiring transplant. There is, however, a
good basis for future research based on the
findings and methodologies of the studies by
CETS and Christopher and Clegg.121 Further
generation of utilities will allow for more robust
calculations of cost per QALY. 
Conclusions from the systematic
review of costs and cost-
effectiveness of LVADs for ESHF
  The findings from the literature review
highlight a paucity of data in this area,
particularly with regard to cost–utility 
analyses.
  Nineteen studies purporting to be economic
analyses were retrieved; five studies were
reported in abstract format only.
  The majority of the evidence was of poor
methodological quality and ungeneralisable.
  The majority of studies described experience
with the HeartMate device as a BTT, with
limited consideration of other devices.
  For the BTT indication a number of studies
(n = 14) have been published but the quality of
these studies is mixed. Comparisons between
studies are problematic owing to the different
settings, time periods and methodologies
employed in the analyses.
  Evidence from the USA suggests that outpatient
management of LVAD patients is both effective
and cost saving relative to inpatient
management. However, controlled studies
adequately powered to pick up differences in
outcome are needed.
  There is limited evidence suggesting that
outpatient management of LVAD patients 
is more cost-effective than management 
via optimal medical management. However, 
the cost of the LVAD device is not 
included in the derivation of these 
calculations. 
  Only three cost-effectiveness studies have been
published. These studies generally found that
use of LVAD devices falls within acceptable cost
boundaries, particularly when considered over
the long term.
  The only cost–utility evidence for the BTT
indication comes from the study by Christopher
and Clegg.121 The cost per QALY of £39,790 is
at the boundary of acceptability with regard to
National Institute for Health and Clinical
Excellence (NICE) evaluations. A reduction in
device cost would lower this value; however, the
analysis is also sensitive to the utility value 
used. There needs to be further research into
the generation of utilities in ESHF patients in
order to validate the utilities used in this
analysis.
Systematic review of the costs and cost-effectiveness of LVADs for people with ESHF
88  No studies have been conducted to date in the
BTR indication. Results from long-term studies
may show this to be an area where the use of
LVADs is particularly cost-effective.
  Studies conducted in the LTCS indication
(n = 4) are also of mixed quality.
  The limited evidence available suggests that
LVADs as destination therapy are more cost-
effective than when used in the BTT indication.
However, LTCS studies are necessarily based on
modelled data and hypothetically constructed
scenarios which may misrepresent actual
practice and experience. 
  The LTCS cost–utility analysis study calculated
a cost per QALY of between US$30,000 and
US$60,000, a value which if converted to
Sterling would fall well within acceptable
thresholds of cost-effectiveness. However,
comparisons between the two cost–utility studies
may well be misleading, as they are conducted
in different settings and employ different
methodologies.
  All the research to date focuses on first-
generation devices. Consideration of second-
generation devices is necessary in order to see if
this has a significant effect on outcomes.
  The generation of utilities is of paramount
importance as the only published large-scale
economic evaluation uses utilities derived from
a very small sample of patients. This limits the
robustness of such analyses. More research in
this area is essential.
  The publication of the REMATCH trial data will,
it is hoped, provide much greater insight into the
cost-effectiveness of LVAD devices. Data from this
trial will provide a benchmark for other studies.
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The systematic review of the costs and cost-
effectiveness of LVADs for people with ESHF
found 19 economic studies, with only one
economic evaluation directly relevant to the
UK.121 Although a reasonably well-conducted
evaluation, the study in the UK was shown to
suffer from several limitations and focused on the
use of LVADs as a BTT for patients with ESHF
(see Chapter 4). As a consequence, it was decided
to develop a separate economic evaluation to
assess the cost-effectiveness of LVADs for people
with ESHF within the UK, using evidence from
the systematic review of clinical effectiveness, data
from published studies identified in the review of
costs and cost-effectiveness and from specialist
NHS hospital trusts in the UK. Although the
original intention was to develop an economic
evaluation for the three different indications for
treatment of BTT, BTR and LTCS, insufficient
data on LVADs as a BTR for people with ESHF
precluded further analysis. Subsequent sections
will outline the components of the economic
evaluations, including the structure of the
economic model, the sources of information for
benefits and costs and the results of the analysis. 
Economic model structure
Model 1: LVADs as a BTT for people
with ESHF
The economic evaluation developed for this
assessment was based on a 5-year decision analytic
model examining the benefits and costs of LVADs
as a BTT compared with usual medical care for
ESHF at the patient level. A simple deterministic
approach was adopted as it involves fewer
assumptions than a probabilistic approach, which,
given the limited, poor-quality data available on
benefits and costs, may have led to greater
uncertainty. In effect, the model presents the
probabilities of an average patient experiencing
particular events (i.e. health states or treatment
options) during the period of the evaluation, the
consequences of which can be assessed in terms of
benefits to the patients (survival duration and
QoL) and the costs that are incurred. The model
was developed using evidence from the systematic
review of clinical effectiveness and cost-
effectiveness, and also from expert advice. It
represents the pre- and post-transplant survival,
QoL and costs which determine the cost-
effectiveness of the two alternative treatment
options for people with ESHF. 
The economic evaluation focused on estimating
the ICER, that is, the marginal cost per QALY
from using an LVAD compared with usual medical
care. The intention was to allow recommendations
as to the most appropriate intervention given
current capacity (i.e. facilities, equipment and staff)
within the NHS. As a consequence, the evaluation
does not consider capital costs, training costs or
other overhead costs associated with developing or
providing the service. Non-direct costs were
excluded from the analysis as the primary question
to be addressed was the most cost-effective
treatment, rather than assessing the costs of
developing a service within the UK. Uncertainty in
the model parameters would be investigated
through probabilistic sensitivity analysis, with
different values used for specific model variables
to test how assumptions influence the outcome
and the generalisability of the evaluation.
The model shows that patients suffering from ESHF
have two treatment options, either implantation of
an LVAD or the use of usual medical care. Treatment
with either of these interventions may result in the
person surviving to heart transplantation or, if the
treatment fails, the person may die. Owing to the
advanced nature of their condition, people with
ESHF appear to have no other alternative treatment
options. The clinical effectiveness of the different
treatment options is assessed in terms of the length
of patient survival gained and the QoL experienced
by the patient. Importantly, the health gain resulting
from either of the treatment options is determined,
in part, by the availability of donor organs for heart
transplantation. Although a treatment option may
provide improved survival and QoL, if the
availability of donor organs is limited the benefits of
the technology may be modest. With declining
organ donation, this scenario is an increasing
possibility.
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Chapter 5
An economic evaluation of LVADS for people 
with ESHF in the UKModel 2: LVADs as LTCS for people
with ESHF 
The economic evaluation for the LTCS model was
based on a simple Markov methodology, which
allows the modelling of uncertain processes over
differing intervals. The benefits of this approach
to the evaluation of health technology in cardiac
care were shown by Sharples and colleagues150,151
in a retrospective analysis of a cohort of 387 heart
transplant patients over a 7-year period at
Papworth Hospital NHS Trust. The modelling
approach has been termed a ‘pseudo-Markov’
approach, which, in the absence of patient-level
data, uses Kaplan–Meier survival analysis data
reported in a clinical trial to track patients
through periods of a defined duration. The data
from the survival analysis is used to populate a
matrix of the probabilities of survival during the
period of the evaluation. 
The pseudo-Markov model developed for the
assessment of LVADs as an LTCS is shown in
Figure 1. As with the decision analytic model for
LVADs as a BTT, the pseudo-Markov model shows
that people with ESHF have the option of
treatment with either usual medical care or an
LVAD and that the possible outcomes are survival
or death. Where the pseudo-Markov model differs
from the decision analytic model is that it assesses
patient survival at 3-monthly intervals over a 
5-year period reflective of the transparency of the
data reported. Patient QoL through utility gains
and the costs of treatment can be attached to the
patients at the different periods, allowing ICERs
to be calculated. Importantly, the model evaluates
the cost-effectiveness of the different interventions
within current capacity in the NHS, excluding
consideration of capital costs, training costs or
other overhead costs associated with developing or
providing the service. Also, the pseudo-Markov
model focuses on first-generation devices, a
consequence of the limited evidence available for
second-generation devices such as the Jarvik 2000
and MicroMed DeBakey LVADs. The model was
populated with a hypothetical cohort of 100
patients, the characteristics of which reflect
evidence from the systematic review of clinical
effectiveness. Sensitivity analysis was used to
examine any parameter uncertainty.
The following section describes the inputs to the
models, provides justification for their use, details
their respective sources and explains their role in
the model. As the analysis needs to reflect a NHS
perspective (UK), it has tended to use UK-specific
resource use and costing data where available. A
number of sources were used for data including
published sources, local costing data from the
main centres providing an LVAD service to the
NHS in the UK and expert opinion from surgeons
and cardiologists within the UK.
Sources of data used in the
models
Efficacy – survival
Efficacy data in terms of Kaplan–Meier survival
curves for the BTT and LTCS indications were
extracted from the results of the systematic review
An economic evaluation of LVADS for people with ESHF in the UK
92
Medical Management Medical Management Medical Management
LVAD LTCS LVAD LTCS LVAD LTCS
Dead Dead
Dead Dead
tt  + 1 t + 2
FIGURE 1 Pseudo-Markov model for LVAD LTCS versus medical management (t = time)of clinical effectiveness (see Chapter 3). It is
acknowledged that the analysis of these data may
contain minor inaccuracies since they are obtained
from interpreting the published survival curves,
and in the absence of the raw data underlying
these survival curves.
Model 1: LVADs as a BTT for people
with ESHF
Survival data with an indication of time to an
event were limited for the assessment of LVADs as
a BTT. Three studies were found that report
survival data through survival curves.81,82,86 Of
these, only the studies by Frazier and colleagues86
and Aaronson and colleagues82 report
Kaplan–Meier survival curves for the actual LVAD
versus medical therapy ‘BTT’ period.
Furthermore, the study by Frazier and colleagues86
consists of a small number of patients (n = 19)
with only two of 19 on LVAD support dying within
a 2-year extended period of support. This
‘extended bridge’ analysis portrays a less robust
survival analysis. Massad and colleagues81 report a
survival curve for the post-transplant period only
and failed to report the proportion of patients
reaching transplant. As such, our evaluation uses
the survival data from the study by Aaronson and
colleagues,82 which reports survival curves for the
survival to transplant, post-transplant and overall
survival periods. The data comprising the survival
curves was censored to reflect the number of
events (Dj) divided by the number at risk (Nj) (i.e.
after taking account of withdrawals) so that event
free survival = 1 – (Dj/Nj). It has been argued that
the use of survival analysis in economic evaluation
is appropriate where data have been censored.152
Hence the model has been built upon the survival
data and time until transplant reported in each of
these two studies with the more complete
reporting in the latter forming our baseline
analysis.81,82 The duration of the study by
Aaronson and colleagues82 was 60 months and as a
consequence no extrapolation of the results was
necessary. Based on the reporting of these data,
the period for the model was defined as 1 month.
The area under the curve (AUC) was calculated for
the overall survival period. As noted above, there
may be minor inaccuracies since the raw data were
not available to plot an exact curve. Aaronson and
colleagues reported that the mean time to
transplant was 4.6 months in the LVAD arm
compared with 7.2 months in the medical therapy
arm.82 The implication is that in this study the
LVAD recipients were prioritised to an earlier
transplant. Aaronson and colleagues highlighted
that the LVAD recipients were more severely ill
than their drug therapy counterparts. The AUC
was 46.26 for the LVAD arm and 29.56 months for
the medical arm, an increment of 16.7 months for
the LVAD arm. Post-transplant survival can be
calculated by subtracting pre-transplant survival
from overall survival, which equates to
41.66 months in the LVAD arm compared with
22.36 months in the medical therapy arm. The
proportion of patients reaching transplant was
also calculated from the study by Aaronson and
colleagues.82 In the LVAD arm, 73% survived to
transplant and a further 9% were still awaiting
transplant (73/91 = 80%); in the medical therapy
arm it was 74% (all the others died before
transplantation). The data do infer some survival
benefit, at least in the population studied by
Aaronson and colleagues.82 These outcomes are
further explored in the sensitivity analysis.
The data in the study by Massad and colleagues81
were more evenly balanced in the post-transplant
period. The UNOS I status patients had a small
post-transplant survival gain over the LVAD
patients, whereas the UNOS II patients had a
small survival decrement (Table 45). The survival
curve was only reported for the post-transplant
survival period with overall survival calculated by
summing pre- and post-transplant survival. This
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TABLE 45 Comparative survival by period for key BTT studies
Aaronson et al.82 Massad et al.81 Noon et al.91
LVAD Medical LVAD Medical Medical  LVAD
therapy therapy, therapy,
UNOS I UNOS II
Pre-transplant (mean, months) 4.6 7.2 3.35a 2.70a 2.19a
Overall survival (mean, months) 46.26 29.56 44.61 44.10 42.32 N/R
Post-transplant survival (mean, months) 41.66 22.36 41.26 41.40 39.62 N/R
% reaching transplant 80 74 N/R N/R N/R 52.38
Italics, calculated data; N/R = not reported.
a Means calculated from median.negates the survival gain for the UNOS I patients
and leads to a marginal survival benefit for the
LVAD patients. Post-transplant survival was very
similar to that reported by Aaronson and
colleagues for the LVAD patients. Also, the shorter
waiting time to transplantation for the medical
therapy patients is suggestive of a more balanced
prioritisation to transplantation or even some
favouring of the medical patients.82 Massad and
colleagues81 show less evidence of survival benefit
for LVAD patients in the BTT scenario.
Importantly, as noted above, the analyses were
restricted to a first-generation HeartMate LVAD,
there being insufficient data to populate a model
reliably for a second-generation LVAD. However,
some generalisations were made in the sensitivity
analysis to simulate the possible impact of using a
second-generation device. First, the cost of a
second-generation device (provided by the
manufacturers) was used in the analysis, while
holding all other variables constant, thereby inter
alia assuming efficacy equivalence. Second, the
costs were combined with the efficacy data
available. These consisted of data from an
uncontrolled cohort study by Noon and
colleagues.91 The study presented limited
information on patient characteristics with no
information on either mean age or UNOS/NYHA
status. It reported on 32 patients receiving a
MicroMed DeBakey LVAD; 81% survived to
30 days, including patients transplanted and
remaining on LVAD support. Median duration of
support was 47 days (mean 1.55 months, median
2.19 months). During the BTT period, 11 of the
32 patients were transplanted and 10 died, a
survival to transplant percentage of 52.4% (11/21).
Lacking any longer follow-up, it was assumed that
survival mortality in the BTT period was equal to
that of the first-generation LVADs. These data
reported by Noon and colleagues91 on the
MicroMed DeBakey LVAD were favoured
compared with data on the Jarvik 2000 LVAD,
which were based on a limited number of
patients.95
Model 2: LVADs as LTCS for people with ESHF
In the LTCS scenario, only the REMATCH
randomised trial assessing the HeartMate VE
LVAD111 presented a Kaplan–Meier survival curve
using censored data. To extend the data reported
in the REMATCH trial, survival analysis was used
to calculate the impact of the LVAD and medical
therapy arms over a longer duration. The
geometric mean of the survival percentage was
applied to give a constant risk of death in the
projected period. It is evident, however, in Figure 2
that the real data (recorded up to the 10th period,
30 months) captured the majority of the survival
gain.
During 20 quarterly periods, the survival gain of
the LVAD LTCS arm over medical therapy was
6.84 months per person, of which 6.18 months
(90%) was within the period of the actual data and
only 0.68 months captured within the projected
data. Periods are described in terms of quarters
reflective of the REMATCH data reporting. The
baseline scenario follows the model for a duration
of 20 such periods (quarters), that is, until the
majority of patients are deceased. Calculations for
both models were undertaken at the midpoint of
each period.
Comparisons between the two model populations
Whilst the comparator for the two evaluations is
medical therapy, the patient groups differ. For the
BTT scenario patients will be those who are on
the heart transplantation waiting list, whereas the
patients in the LTCS scenario are more likely to be
those whose characteristics (e.g. age) or severity of
condition prevent them from consideration for
heart transplantation. Although the distinction
between the patient groups may reflect the clinical
status of the patients, it may in part reflect the
declining availability of donor organs. The
REMATCH LTCS populations were exclusively
NYHA Class IV with a mean age of 66–68 years
(i.e. with many of the patients contraindicated for
heart transplantation because of their
age >65 years),153 whereas the BTT populations
were made up of markedly younger and/or
healthier patients. The mean age of patients in
the study by Aaronson and colleagues82 was 49
(±13) years for the LVAD group and 49
(±15) years for the inotrope group, with 26%
inotrope group classified as UNOS status 1A, 37%
status 1B and 37% status 1. Similarly, in the study
by Massad and colleagues,81 100% of the LVAD
patients were UNOS status 1, whereas in the no-
LVAD group 62% were UNOS status 1 and 38%
UNOS status 2. The mean age was 53 years in the
LVAD group (range 34–66) and 50 years in the no-
LVAD group (range 17–66). The BTT LVAD
population is therefore made up of heart
transplant candidates and is a younger, healthier
group of patients, far distinct from the patients
who have received an LTCS LVAD and who have
tended not to be candidates for heart transplant.
As stated in the research methods for the study,
the economic evaluation focuses on the LVADs
that were shown to be clinically effective for the
different indications and relevant to the UK
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Intervention period (quarters) Medical therapy LVAD
Alive Dead Alive Dead
0 1.00 0.00 1.00 0.00
1 0.60 0.40 0.75 0.25
2 0.44 0.56 0.60 0.40
3 0.34 0.66 0.58 0.42
4 0.25 0.75 0.56 0.44
5 0.15 0.85 0.47 0.53
6 0.10 0.90 0.38 0.62
7 0.08 0.93 0.38 0.62
8 0.04 0.96 0.22 0.78
9 0.03 0.97 0.08 0.92
10 0.02 0.98 0.08 0.92
11 0.01 0.99 0.06 0.94
12 0.01 0.99 0.05 0.95
13 0.01 0.99 0.04 0.96
14 0.00 1.00 0.03 0.97
15 0.00 1.00 0.02 0.98
16 0.00 1.00 0.02 0.98
17 0.00 1.00 0.01 0.99
18 0.00 1.00 0.01 0.99
19 0.00 1.00 0.01 0.99
20 0.00 1.00 0.01 0.99
21 0.00 1.00 0.00 1.00
Italics, projected data. 
FIGURE 2 LTCS vs medical therapy – survival curves/analysis111 (extrapolated)setting. As such, the evaluations of both BTT and
LTCS assess the cost-effectiveness of a first-
generation device, the HeartMate. Some tentative
analyses are included for second-generation
devices, the Jarvik 2000 and the MicroMed
DeBakey, based on very limited data.
Costs
Cost data were obtained from a number of
primary and secondary sources. These sources and
the approach to calculating costs are described
below for each model. Costs were divided into
three headings: those associated with heart
transplantation, those with medical management
of patients and those associated with LVADs. 
Model 1: LVADs as BTT for people with ESHF
Heart transplantation initial and ongoing costs
The mean cost of a heart transplant (£14,114) was
sourced from the NHS Reference Costs 2003.154
The reported upper and lower quartile limits
(£5875–24,807) were explored in the sensitivity
testing. Further, patients submitted to the heart
transplantation waiting list incur assessment costs,
including a period of inpatient stay, estimated at
~£3500, which may explain why the UK waiting
list is capped or ‘reflective of donor supply’ 
(Large S, Papworth Hospital NHS Trust: personal
communication, 2003). One US study estimated
the act of managing a patient awaiting heart
transplantation is substantial at up to US$5000
per day.155
Following a cardiac transplantation, the
management patterns in both LVAD and medical
therapy arms are assumed to be equivalent. A
systematic review of the management of such
patients was outside the remit of this research but
is well described in the study by Sharples and
colleagues.150 Their audit of management patterns
and associated costs at Papworth Hospital
(coincidentally one of the current LVAD centres),
reported management costs by period (at 1–3,
4–12, and 13–60 months) and frequency and
management costs of significant adverse events
(Table 46). These costs have been inflated to 2003
prices using the Hospital and Community Health
Services indices from Netten and Curtis.156
The costs of the heart transplant operation are
incurred for the proportions of patients in both
arms surviving to transplant; the ongoing
transplant management costs are incurred
thereafter for the duration of survival. All patients
in both arms incur the transplant assessment cost
at the beginning of the model. 
LVAD initial and ongoing costs
LVAD-related costs used in the baseline model
were obtained from the device manufacturers and
published sources. Device costs were provided by
MicroMed DeBakey, one of the second-generation
manufacturers. The MicroMed device was
reported to cost £35,000 whereas the HeartMate
and Novacor first-generation devices were £48,000
(MicroMed DeBakey submission). A submission by
Jarvik Heart (personal communication, 2004)
reported the price for a Jarvik 2000 heart was
US$75,000 (including US$15,000 for external
components). This was converted to UK£ prices
using an exchange rate of $1.8316 = £1.157
LVAD costs were from one of the UK centres
operating the National Specialist Commissioning
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TABLE 46 Management costs following cardiac transplantation,150 inflated using HCHS indices from Netten and Curtis156
Months
1–3 4–12 13–60
(period 1) (periods 2–4) (periods 5–20)
Base costs (1995), uninflated (£) 1,188 486 388
Probability of rejection 0.11222 0.00931 0.0003
Probability of CMV 0.02045 0.001 0.00001
Probability of infection 0.03335 0.0012 0.00003
Probability of malignancy 0 0.0003 0.00003
Probability of renal failure 0 0 0.0002
Cost of rejection (£) 262.26 11.00 0.35
Cost of CMV (£) 142.54 7.85 0.09
Cost of infection (£) 99.75 1.33 0.04
Cost of malignancy (£) 0 0.28 0.03
Cost of renal failure (£) 0 0 0.34
Total monthly cost (£) 1,692 506 389
Inflated to 2003 prices (£) 2,105 630 484Advisory Group (NSCAG) national service for
ventricular assist devices and their ongoing
research to evaluate the service [Evaluation of the
Ventricular Assist Device programme in the UK
(EVAD study), HTA reference number 01/19/01].
These costs are reproduced in full in Appendix 31
and summarised in Table 47.
Importantly, these are not actual costs incurred
but rather are estimates of projected costs or
charges or prices to NSCAG, the funder of the
EVAD study, under which the LVAD work will be
undertaken. Since actual costs incurred are being
recorded during the EVAD project it is likely that
these will provide a more accurate representation
of costs at the conclusion of the project (the UK
VAD programme has thus far used a variety of
devices with the most commonly used at Papworth
Hospital being Thoratec and HeartMate). The
implant operation and follow-up/readmission costs
are significantly higher than those provided by
Papworth Hospital for the study by Christopher
and Clegg121 and may have been influenced by
the clinical trial setting and protocols (for
example, the 65-day average LOS for the implant
procedure). Usefully both sets of cost data refer to
the same hospital (the costs presented by
Christopher and Clegg121 have been generated
bottom-up from Papworth Hospital in 1999). The
assessment cost is the equivalent of the pre-heart
transplant assessment cost and is very similar. The
implant procedure cost is significantly higher than
that presented by Christopher and Clegg.121 It is
possible the real cost has increased as newer
devices are more difficult to transplant or the
availability of specialists has fallen, leading to
higher staff costs. Interestingly, a closer
examination of the breakdown of the cost shows
that it is driven by ICU stay, which could again be
protocol driven. However, the costs used by
Christopher and Clegg121 have been criticised for
being based on hospital price banding predating
the NSCAG contract (Buxton M, Brunel
University: personal communication, 2004). As a
consequence, the baseline analysis in the economic
evaluation has favoured the EVAD programme
costs reported above. For upper and lower
estimates the baseline costs were multiplied by a
factor of ±20%.
All patients in the LVAD arm incur the LVAD
assessment, operation and device cost. The LVAD
ongoing management cost is incurred for the
duration of LVAD support. The medical therapy
arm does not incur any LVAD-related costs.
Ongoing medical management costs
Ongoing medical management costs for those
patients not able to receive a heart transplant or
LVAD were the most challenging to obtain.
Despite approaches to numerous UK bodies,
including NHS trusts caring for such patients, it
was not possible to obtain a reliable source. Given
this, the literature and published non-UK relative
resource usage have been used as a proxy vehicle
to calculate a cost for medical management. This
resource use data are summarised in Table 48.
The limitations of using US data in this way are
acknowledged, particularly in the light of the
different treatment protocols between the two
countries, but no viable alternative was available.
Stewart and colleagues158 estimated that in the UK
there were 988,000 individuals requiring treatment
for heart failure at a cost of £751 million in 1995.
Inflating this to current prices gives £876 million at
a cost per patient of £887, approximately that of
LVAD management. This assumes no increase in
the individuals requiring treatment, however, and
will not take account of recent novel drugs or
technological developments. 
In this model, the period of medical management
covers the cost of managing the patient through
the assessment period until heart transplantation
occurs. Therefore, for this model, it is the pre-
transplant period from Table 48 that is of most
relevance. The ratio of LVAD to non-LVAD days
was 5.57:1 (or 39 versus 7 days) from Aaronson
and colleagues.82 This figure was applied to the
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TABLE 47 EVAD programme costs from Papworth Hospital, 2002–03
Cost per event (£) Event rate per patient Cost per patient (£)
Assessments (n = 21) 2,202 1.3125 2,891
Implant operation (n = 16) 36,986 1 36,986
Follow-up outpatient visit (n = 96) 99 6 595
Readmissions (n = 48) 5,391 3 16,174
Total charge excluding device  56,645
Average device costs 42,300
Total charge including device 98,945baseline analysis. For the upper bound an
equivalence of cost with LVAD management was
assumed, whereas for the lower bound the baseline
was reduced by a factor of 20%. The nearly
threefold increase in ICU resource usage in the
medical therapy arm reported by Bank and
colleagues83 was used.
The medical management costs are incurred in
both patient groups for the duration of survival
following transplant. 
A summary of costs used in the BTT model is
provided in Table 49.
Model 2: LVADs as LTCS for people with ESHF
Heart transplantation initial and ongoing costs
Heart transplantation is not included in the LTCS
scenario, hence costs are not relevant. Therefore,
no patients in either arm of this model incur any
costs related to heart transplantation. 
LVAD initial and ongoing costs
The LTCS model has used the same LVAD-based
costs as detailed above for the BTT model. All
patients in the LVAD arm incur the LVAD
assessment, operation and device cost at the start
of the model. The LVAD ongoing management
cost is incurred every quarter for the duration of
survival in the LVAD arm. The medical therapy
arm does not incur any LVAD-related costs.
Ongoing medical management costs
For the LTCS model, the period of ongoing medical
management costs was likely to be longer owing to
the severity of the patients’ condition and nature of
the indication for treatment (i.e. managing patients
unsuitable for heart transplant). In Table 48, the
ratio of hospitalisation resource units (the
predominant cost component of managing heart
failure patients) reported in the USA by Rose and
colleagues111 for LTCS was 88 days for the LVAD
arm compared with 29 days for the non-LVAD arm
(ratio 3.03:1). In the baseline model, this ratio was
used relative to the LVAD management costs
(sourced from Papworth Hospital). For the lower
cost estimate the baseline was reduced by a factor of
20% whereas for upper estimate the same cost of
managing LVAD patients was used. 
The medical management costs are incurred every
quarter in the medical therapy arm for the
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TABLE 48 LVAD resource use data reported in clinical trials
BTT BTT BTT BTT LTCS 
Aaronson Massad  et al.81 El Banayosy  Bank et al.83 Rose et al.111
et al.82 et al.80a
Post-transplant LOS (days)
LVAD arm 20 18 N/R 23 N/R
No-LVAD 16 18 N/A 15 N/R
Ratio LVAD: non-LVAD 1.25 1.00 N/A 1.53 N/A
Total hospital LOS (days)
LVAD arm 59 N/R 55.6/58.6a 100 88
Non-LVAD 23 N/R N/A 57 29
Ratio: 1 2.57 N/A N/A 1.75 3.03
Total ICU stay (days)
LVAD-arm N/R N/R 16.7/12.2 22.8 N/R
Non-LVAD N/R N/R N/A 48.4 N/R
Ratio: 1 N/A N/A N/A 0.47 N/A
Pre-transplant ICU stay (days)
LVAD arm N/R N/R N/R 15 N/R
Non-LVAD N/R N/R N/R 42 N/R
Ratio: 1 N/A N/A N/A 0.36 N/A
Pre-transplant LOS (days)
LVAD arm 39 N/R N/R N/R N/R
Non-LVAD 7 N/R N/R N/R N/R
Ratio: 1 5.57 N/A N/A N/A N/A
N/A, not applicable; N/R, not reported.
a Study only reports Novacor/HeartMate comparison (i.e. no medical management arm).duration of survival. The LVAD arm does not incur
any medical management-related costs. 
A summary of costs used in the LTCS model is
provided in Table 49. 
Utilities
There are commonly three options available to
value benefits in terms of QALYs: to obtain
utilities through subjective judgment (usually done
by the researchers themselves, interviews with
clinical experts or panels), using published utilities
from the literature or adopting an approach of
directly eliciting values from patients. There is an
algorithm to derive utilities from the commonly
used SF-36 questionnaire, but this requires the raw
patient data, which investigators are often
reluctant to provide. Utilities can also be
generically derived (from a sample of the general
population) or condition specific (from a sample
of affected people). In the UK, NICE favours
generically derived QALYs, which are less likely to
be biased from personal interest. Utilities can also
be derived directly from ‘multi-attribute utility
scales’ (MAUS), of which the EQ-5D is one of the
best-known examples. The EQ-5D consists of five
multiple-choice questions covering mobility, self-
care, usual activities, pain/discomfort and
anxiety/depression using a VAS. It confers only a
very small burden on the patients, taking about
3 minutes to complete. Finally, there are some
direct measurement techniques such as the SG and
TTO methods. These require the patients to be
asked a series of questions such as how much of
their life they would be willing to give up in order
to improve their QoL. In the TTO, patients are
asked to trade off a number of years in full health
to be equivalent to the rest of their life in their
current (or retrospective) health state. This is
performed via face-to-face interviews and requires
a flipchart-type booklet for changing the values of
each option until the respondent is indifferent
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TABLE 49 Costs and sources used in the models (baseline, upper and lower estimates)
Baseline Lower  Upper  Source
(£) (£)a (£)a
LVAD assessment cost  2,891 2,313 3,469 EVAD Project, Papworth Hospital (assessment 
(both models) cost), ±20%
LVAD operation (both models) 36,986 29,589 44,383 EVAD Project, Papworth Hospital (implant
operation cost), ±20%
LVAD device costs (both models):
HeartMate 48,000 38,400 57,600 MicroMed DeBakey submission159
Novacor 48,000 38,400 57,600 MicroMed DeBakey submission159
MicroMed DeBakey 35,000 28,000 42,000 MicroMed DeBakey submission159
Jarvik 40,948b 32,758 49,137 Jarvik Heart submission; includes external
components160
Heart transplant preparatory  3,500 2,800 4,200 S Large, Papworth Hospital NHS 
assessment (BTT model only) Trust: personal communication, 2003
Heart transplant operation  14,114 6,511c 22,970c NHS Reference Costs 2003, mean154
(BTT model only)
Ongoing management costs 
per month (BTT model)
LVAD  1,397 1,118 1,677 EVAD Project, Papworth Hospital (cost of
outpatient visit and readmission), ±20%
Medical therapy 251 201 1,397 Calculated as a relative proportion of LVAD
resource usage (see text for details)
Cost per quarter (LTCS model)
LVAD  4,192 3,354 5,031 EVAD Project, Papworth Hospital (cost of
outpatient visit and readmission), ±20%
Medical therapy 1,382 1,105 4,192 Calculated as a relative proportion of LVAD
resource usage (see text for details)
a Where a range of estimates was unavailable, a value of ±20% of the baseline was used for upper and lower estimates,
unless stated otherwise.
b Converted from US$75,000 at $1.8316 = £1 (Wall Street Journal Europe, 9 January 2004).157
c Upper and lower quartile range of unit costs.between choices. More validity is generally
attached to soliciting values from those patients
living with the condition.
The availability of published evidence in this field
is limited to one study138 as reported in Chapter 4.
Model 1: LVADs as a BTT for people with ESHF
The model was populated using published data
reported in Moskowitz and colleagues138 despite
the limitations of the study identified in the
systematic review. It was not possible to solicit
primary patient-based utilities in the UK centres
for the patients on BTT owing to the limited
number of patients undergoing support and the
problems associated with using historic data. Two
published studies139,140 generated patient-based
utilities for ESHF patients of approximately the
same magnitude as the control group in the study
by Moskowitz and colleagues,138 which offer some
validation. In the baseline model, the strong
relative estimates of the pairwise responses were
used (see Table 40). The impact of other
observations and variation was explored in the
sensitivity analysis. 
Model 2: LVADs as LTCS for people with ESHF
There were no published utilities reported for
LVADs used as LTCS. Utilities have been solicited
in the REMATCH study (Moskowitz AJ, Columbia
University: personal communication, 2003) but
have not yet been reported and were unavailable.
In the baseline scenario, rather than use the
published BTT utilities, utilities were solicited
using a new panel-based approach developed by
Stein and colleagues at the Peninsular Medical
School at the Universities of Exeter and Plymouth.
A pilot exercise mapped the Minnesota Living
with Heart Failure Questionnaire (MLHFQ) to
utilities from the summarised data reported in the
pivotal REMATCH study. A brief explanation of
how this exercise was conducted follows. (All data
generated remain the intellectual property of
Stein and colleagues, comprising part of a grant
funded by the Directorate of Health and Social
Care South, Ref No. R/21/10.00/Ste.)
The MLHFQ is a 21-question QoL instrument
divided into five domains specifically designed to
measure the impact of heart failure on patients’
QoL. The instrument is scored out of 105 with the
lower score the better health. The REMATCH trial
reported mean scores for the MLHFQ at baseline
(score 75/105) and at 1 year for the LVAD (41/105)
and medical therapy (58/105) arms. Scores by
subscale and patient were unavailable, however.
The mapping exercise assumed scores were
achieved by a uniform set of responses across
subscales and for each item within each subscale.
This results in the imputed scores for each subscale
and item shown in Table 50. Variations to the
assumption are assessed in the sensitivity testing.
The item scores were then rounded to whole
numbers in order to construct the scenarios for the
utility panel. Therefore, the baseline was 4, medical
therapy 3 and the LVAD group 2. Again, variation
on the rounding exercise which could be argued to
overstate the ill health of the baseline/medical
groups has been examined in the sensitivity
analysis. The following scenarios were then
constructed using the following statements to depict
each possible level within items: 1 = very little or
rarely or very slightly; 2 = a little or occasionally or
slightly; 3 = moderately or often; 4 = quite a lot or
very often or severely; and 5 = very much or always
or extremely often or very severely. 
The scenarios used in generation of panel utilities
were specified as follows (Stein K, University of
Exeter: personal communication, 2003):
Scenario – baseline 
  You are restricted quite a lot in everyday things
you would normally do, such as walking or
climbing stairs, going places from home,
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TABLE 50 MLHFQ summary scores from REMATCH study and assumption underlying distribution for construction of scenarios
MLHFQ subscale Weight Max.  No. of  Baseline Av. score  LVAD Av. score  Medical Av. score 
points items per item per item therapy per item
Activities of daily living 0.19 20 4 14 3.6 8 2.0 11 2.8
Psychological 0.19 20 4 14 3.6 8 2.0 11 2.8
Symptoms 0.38 40 8 29 3.6 16 2.0 22 2.8
Socioeconomic 0.14 15 3 11 3.6 6 2.0 8 2.8
Physical 0.10 10 2 7 3.6 4 2.0 6 2.8
Total 1 105 75 42 58
Source: Stein K, University of Exeter: personal communication, 2003.working around the house or garden, taking
part in recreational activities. 
  Any physical activity brings on discomfort and
symptoms occur at rest.
  It is difficult or impossible for you to work
because of your condition.
  You have to take medication which gives you
quite a lot of side-effects and you are very often
in hospital.
  You are affected quite a lot by feelings of worry
or depression and a feeling that you have lost
control over your life. You feel you are a burden
to your family quite a lot.
  You very often find it difficult to concentrate or
remember things.
  You very often feel tired and short of breath
and need to sit or lie down during the day quite
a lot.
  Your appetite is quite a lot worse than usual.
  Your ankles and legs are very often swollen.
  Sleeping is often difficult and you are tired and
low on energy quite a lot of the time.
  It is very often difficult to have sexual activities.
LVAD
  You are restricted a little in the everyday things
you would normally do, such as walking or
climbing stairs, going places from home,
working around the house or garden, taking
part in recreational activities.
  You are comfortable at rest or with mild
exertion.
  It is possible for you to work because of your
condition but you have some limitations.
  You have to take medication which gives you
occasional side-effects and you are occasionally
in hospital.
  You are affected a little by feelings of worry or
depression and a feeling that you have lost
control over your life. You feel you are a burden
to your family but these feelings come only a
little, or occasionally.
  You find it a little difficult to concentrate or
remember things.
  You feel slightly tired and short of breath and
need to sit or lie down during the day
occasionally.
  Your appetite is slightly worse than usual.
  Your ankles and legs are swollen and this causes
slight problems.
  Sleeping is a little difficult and occasionally you
are tired and low on energy. 
  It is occasionally difficult to have sexual activities.
Medical therapy
  You are moderately restricted in the everyday
things you would normally do, such as walking
or climbing stairs, going places from home,
working around the house or garden, taking
part in recreational activities.
  Any physical activity brings on discomfort and
symptoms occur at rest.
  It is moderately difficult for you to work
because of your condition.
  You have to take medication which often gives
you side-effects and you are often in hospital.
  You are moderately affected by feelings of worry
or depression and a feeling that you have lost
control over your life. You often feel you are a
burden to your family.
  You often find it difficult to concentrate or
remember things.
  You feel tired and short of breath and need to
sit or lie down during the day extremely often.
  Your appetite is worse than usual.
  Your ankles and legs are often swollen.
  Sleeping is moderately difficult and you are
moderately tired and low on energy.
  It is often difficult to have sexual activities.
A panel of 12 members was asked to attach
utilities to these scenarios, which represented each
of the baseline, LVAD, and drug therapy
conditions. The results for each expert are
reported in Table 51.
Patient-based estimates would favour using the
mean values, but as these are estimates of a true
utility rather than a pool of patients, it was felt
that the median was more appropriate. The table
shows that one member gave very low scores,
giving an argument in favour of using the median
values. Furthermore, permitting negative utilities
has also recently been shown to affect QALY
estimates.161 As such, the median values from the
panel have been applied in the baseline analysis.
Generally, the responses were consistent, with the
exception of one of the members who responded
logically (i.e. rated the LVAD group > the control
group > baseline) to the MLHFQ-generated
scenarios. The effect of using the mean values is
explored in the sensitivity analysis. 
Importantly, the scores are similar to those
patient-generated scores in the BTT study
reported by Moskowitz and colleagues.138 The
before implantation utility reported by Moskowitz
and colleagues was 0.548 (mean of 14 patients)
compared with 0.55 (median) from the utility
panel, whereas the LVAD support yielded 0.809 in
the study by Moskowitz and colleagues (mean of
20 patients) compared with 0.925 from the utility
panel. However, it should be noted that the
MLHFQ scores are measured at 1 year and it
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overcome any difficulties in the period of early
adjustment. Furthermore, neither the utility panel
nor the facilitator were aware of the existence of
the study by Moskowitz and colleagues when
recording their utilities.
Although the approach used was a pilot study and
intended as a tentative attempt to measure utilities
from an LTCS LVAD group, the utilities appear to
be generally representative in terms of the other
evidence available to us of the relative QoL of
these patients. The patient-level utilities from the
REMATCH study are eagerly anticipated to
provide a comparison.
It is important to remember that the BTT utilities
from the study by Moskowitz and colleagues138
and the panel-based LTCS utilities extrapolated
from REMATCH data reflect the experience with
first-generation HeartMate devices. There have
been no attempts to generate utilities for second-
generation LVADs and there do not appear to be
any plans to do so at present. Limited QoL data
were available on second-generation devices to
extrapolate to the analysis. Siegenthaler and
colleagues99 in a three-patient study noted a mean
postoperative MLHFQ score of 30.0 at 2 months
compared with 75.2 pre-LVAD. Although the
baseline score was similar to the REMATCH study
population and the improvement greater, it should
be noted that the sample was small. In the study
by Westaby and colleagues95 of four patients
receiving Jarvik 2000 LVAD, patients were in a
worse state than the patients in the REMATCH
study (MLHFQ pre-LVAD scores 76–89) with post-
transplant scores of 24–38 for the three surviving
patients. These data may be suggestive of
improved QoL with second-generation devices,
but because of the small numbers involved they
should be treated as being highly speculative.
Discounting
Following accepted UK NHS practice, in the
baseline scenario of each model costs were
discounted at 6% and benefits at 1.5%. In the
sensitivity testing a variety of other rates were
employed. In the BTT model, an annual
discounting approach was taken. Costs and
benefits incurred in the first year were not
discounted; thereafter costs were discounted on an
annual basis by multiplying the undiscounted total
cost or total benefit by the respective discounting
multiplier for that year. In the Markov model
(LTCS), costs are discounted on a quarterly basis.
Once the cost and benefit per period (quarter)
have been calculated for the cohort, the
discounting multiplier is applied to each period.
In each case, a half-cycle adjustment is made to
ensure the costs are incurred at the midpoint of
each period.
Sensitivity analyses
A range of one-way scenarios were examined
considering variation in all the costs, utilities,
discounting and efficacy.
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TABLE 51 MLHFQ mapped utilities for LTCS and medical therapy patients
Patient group
Utility panel  Baseline,  LVAD treatment  Control group,  Baseline variant Baseline variant 
member MLHFQ = 75 group, MLHFQ = 41 MLHFQ = 58 1 2
A 0.2 0.875 0.775 0.4 0.825
B –0.8 0.05 –0.625 –0.675 0.55
C 0.6 0.925 0.725 0.55 0.65
D 0.45 0.975 0.7 0.8 0.925
E 0.775 0.925 0.825 0.775 0.775
F 0.425 0.925 0.625 0.475 0.8
G 0.625 0.875 0.725 0.375 0.75
H 0.725 0.95 0.975 0.575 0.625
I 0.725 0.925 0.775 0.725 0.825
J N/A 0.725 0.125 0.925 0.875
K 0.5 0.975 0.55 0.375 0.5
L 0.7 0.925 0.7 0.725 0.775
Mean 0.45 0.84 0.57 0.50 0.74
Median 0.55 0.925 0.7 0.55 0.775
Source: Stein K, University of Exeter: personal communication, 2003.Sensitivity tests applied to both models
The upper and lower estimates of costs described
in Table 49 were evaluated in the sensitivity testing.
As a general rule for costs, when high/low
estimates were unavailable the baseline estimates
were increased/reduced by a factor of ±20%; for
the device costs themselves this may, for example,
mimic the reuse of an LVAD. Discounting rates
were varied for both costs (3–9%) and benefits
(1.5–6%). Threshold analysis was undertaken on
the LVAD-related costs, which would yield
acceptable cost per QALY of around £40,000.
Further analyses in the form of spider graphs,
tornado plots, stochastic simulation, histograms,
cost-effectiveness acceptability curves and scatter
plots were produced where appropriate.
Model 1: LVADs as BTT for people with
ESHF
For the heart transplantation cost, the upper and
lower quartile costs were used. Heart transplant
preparatory cost were varied by ±20% from the
baseline, and ongoing heart transplant
management costs by ±20% from the estimates by
Sharples and colleagues.150 Data from the study by
Massad and colleagues81 were included, as were the
limited data on the MicroMed DeBakey VAD
reported by Noon and colleagues91 (Table 45). The
pairwise and three-way patient-based utilities from
Moskowitz and colleagues138 were evaluated, as
were the ESHF utilities from Havranek and
colleagues.139 The systematic review offers some
evidence of improved QoL with second-generation
devices,95–100 although no utilities are presented.
Thus pre-transplant utilities were varied between no
gain to perfect health in favour of the LVAD group. 
Model 2: LVADs as LTCS for people
with ESHF
In order to test the assumptions underlying the
generation of the panel-based utilities, the impact
of two different combinations of item and subscale
scores that lead to the same overall score were
examined. It is noteworthy that in the baseline
calculation an even distribution of item and
domain scores was assumed to achieve the overall
summary score reported in the REMATCH study.
Therefore, two alternative scenarios were
developed which attempted to represent the same
baseline score in different ways. One of these
scenarios, which over-represented the
psychological subscale of the MLHFQ, was given a
much higher preference value by the utility panel
than the baseline scenario. This shows how
assumptions about underlying item score
distributions can have a dramatic effect on the
preference value for the scenario. The second
variant which rated poorer on recreational
pastimes, burden on or relation to family, anorexia
and poor concentration or memory, was rated by
the panel members very similar to the original
baseline scores. Albeit in a small sample, and
therefore being highly speculative, it could be
postulated that the psychological domains of the
MLHFQ attract relatively less weight than the
other domains but that social and physical
domains are approximately equal in their
influence on the summary preference values. It
would be interesting to compare this effect in
patients experiencing the conditions. The variant
utilities reported in Table 51 were also examined.
Regrettably, there were no effectiveness data which
could suitably be extrapolated in a second-
generation LTCS model. To attempt to simulate
the cost-effectiveness in a younger population or,
perhaps, of increased efficacy from second-
generation devices, event-free survival was inflated
by a factor of 20–60% and a threshold analysis
conducted to evaluate what level of increase in
survival would lead to an acceptable cost-
effectiveness threshold.
Quality assurance
In addition, a health economist (Adam Lloyd) not
involved in the project subjected the models to
internal audit. This consisted of a series of ‘top
down’ tests conducted to confirm that the model’s
outputs respond predictably and consistently to
changes in the input assumptions; and a ‘bottom
up’ review of the contents of individual cells to
confirm that the model’s calculations were
coherent and cells were correctly referenced.
Results of economic analysis
Results for each of the models are described
separately below.
Model 1: LVADs as a BTT for ESHF
In the baseline analysis, the cost per QALY of a
HeartMate LVAD as a BTT was £65,242. Over the
5 years of the model there were 18.3 quality-
adjusted months gained in the LVAD arm at an
incremental cost of £99,636 per person (Table 52).
This cost per QALY figure is outwith current
thresholds applied to current treatment
programmes.
Sensitivity tests
The full range of one-way sensitivity tests conducted
for the BTT scenario are presented in Table 53. 
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two columns) determined the basis for the
following more sophisticated sensitivity analyses.
Results were not sensitive to changes in the cost of
a heart transplant, LVAD or post-transplant
management costs, discount rates or the
proportion of patients reaching transplant. 
These results can be visualised diagrammatically
with the aid of a spider graph (Figure 3). The
circles represent various cost-effectiveness
thresholds. The dark circle inside these represents
the baseline cost per QALY of £65,242. Finally, the
dashed line represents variation from baseline
resulting from changes in input parameters (the
discontinuity period is a result of the huge cost
per QALY when a no survival gain assumption is
introduced). 
The model is sensitive to the one-off costs
associated with the LVAD: assessment, operation
and device. In the baseline the total is £87,877 per
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TABLE 52 Baseline results from the BTT model
Annual calculations LVAD group Medical group Increment
Year 1
Pre-transplant survival (months) 4.6 7.2 –2.6
Post-transplant survival (months) 5.20 0.84 4.365
Transplant assessment cost £3,500 £3,500
LVAD cost £87,877 £0 £87,877
Heart transplant cost £11,322 £10,444 £878
Pre-transplant cost £6,428 £1,806 £4,622
Post-transplant cost £9,089 £7,451 £1,638
Total cost £118,216 £23,201 £95,015
Total QAL months 8.73  4.75  3.98
Year 2 – undiscounted
Post-transplant survival (months) 9.41 5.84 3.57
Post-transplant cost  £6,478 £6,858 –£380
Total QAL months 9.07  5.63  3.44
Discounted
Post-transplant cost £6,111 £6,470 –£359
Total QAL months 8.93  5.55  £3
Year 3 – undiscounted
Post-transplant survival (months) 9.24 5.28 3.96
Post-transplant cost £4,470 £2,554 £1,916
Total QAL months 8.91 5.09 3.82
Discounted
Post-transplant cost £3,978 £2,273 £1,705
Total QAL months 8.65 4.94 3.71
Year 4 – undiscounted
Post-transplant survival (months) 9.24 5.28 3.96
Post-transplant cost £4,470 £2,554 £1,916
Total QAL months 8.91 5.09 3.82
Discounted
Post-transplant cost £3,753 £2,144 £1,608
Total QAL months 8.52 4.87 3.65
Year 5 – undiscounted
Post-transplant survival (months) 9.21 5.28 3.93
Post-transplant cost £4,456 £2,554 £1,902
Total QAL months 8.88 5.09 3.79
Discounted
Post-transplant cost £3,529 £2,023 £1,506
Total QAL months 8.37 4.80 3.57
Total cost – discounted £135,587 £36,112 £99,475
Total QAL months – discounted 43.20  24.90  18.30 
£ per QALY gained –discounted £65,242Health Technology Assessment 2005; Vol. 9: No. 45
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TABLE 53 One-way sensitivity analyses for LVADs as a BTT for people with ESHF
Parameter varied Base  Range of values Cost per QALY (£)  Variation from 
case tested (range) baselinea
Baseline £65,242
LVAD operation cost £36,986 £29,589 £44,383 £60,391 £70,094 0.07 0.07
LVAD management cost/month £1,397 £1,118 £1,677 £64,399 £66,086 0.01 0.01
Heart transplant operation cost £14,114 £6,511 £22,970 £64,932 £65,603 0.01 0.00
Medical management cost/month £251 £201 £1,397 £59,828 £65,478 0.08 0.00
Post-transplant management costs See Table 46 £64,442 £66,042 0.03 0.03
HeartMate/Novacor device costb £48,000 £38,400 £57,600 £58,946 £71,539 0.10 0.10
MicroMed DeBakey deviceb £35,000 £28,000 £42,000 £52,125 £61,307 0.20 0.06
Jarvik device costb £40,984 £32,758 £49,137 £55,246 £65,988 0.15 0.01
Costs discount rate 6% 3% 9% £64,999 £65,517 0.00 0.00
Benefits discount rate 1.5% 0% 6% £63,343 £70,925 0.03 0.09
Assuming equal pre-transplant  £64,667 0.06
duration
Assuming no overall survival gain 29.72 46.90 £497,708 6.63
Assuming equal proportions reaching  £64,667 0.01
transplant
Assuming no utility benefit in  £72,710 0.11
pre-transplant period
Post-transplantation utility 0.964 0.75 1 £62,866 £84,152 0.04 0.29
a In the last two columns, cells in italics indicate a ≥ 5% variation from baseline; cells in bold indicate ≥ 20% variation from
baseline.
b Device costs represent base case costs for the separate devices; however, the baseline used in the original model was
£48,000 for the HeartMate LVAD.
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LVAD operation cost
LVAD management cost/month
Medical management cost/month
Post-transplant management costs
HeartMate/Novacor device cost
2G MicroMed DeBakey device
2G Jarvik device cost
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Equal pre-transplant duration
No overall survival gain
Equal proportions reaching transplant
No utility benefit in pre-transplant period
Post-transplantation utility
£40,000
£20,000
£60,000
£0
FIGURE 3 Spider graph of variation from baseline of changes in one-way parameters patient. This is driven by the LVAD device cost
(£48,000) and operation cost (£36,986). For the
following analysis it was thought best if LVAD costs
were bundled together, giving an overall package
cost for an LVAD. Figure 4 shows the impact of
variation in this per-person cost of the LVAD
package and gives manufacturers and providers an
indication of what will be the impact of the costs
of their device or at their centre if these are
significantly different from the estimates in our
model. Only when the total cost falls below
£50,000 does the intervention approach an
acceptable cost-effectiveness with an incremental
cost per QALY below £40,000.
Of course, these results are based on a particular
study by Aaronson and colleagues,82 which showed
a proven survival gain. If different inputs were
used from other studies, the outcome may differ
considerably. In the study by Massad and
colleagues,81 the survival gain from an LVAD is
eliminated and the cost per QALY unsurprisingly
soars to £404,289 for the UNOS II group and
£1,017,630 for the UNOS I group (Table 45). The
simulated second-generation analysis using pre-
transplant survival and survival to transplant from
Noon and colleagues,91 in conjunction with lower
device costs of £35,000, produced a cost per QALY
that ranged from £59,642 to £366,270. Given the
limited data of Noon and colleagues,91 this
analysis used the post-transplant survival reported
by Aaronson and colleagues.82
To examine variability further, a stochastic
simulation was conducted to determine a CI
around the baseline deterministic model. Table 54
shows the parameters which comprised inputs to
the stochastic modelling, together with the
assumed distributions and the range of possible
values. Whereas the cost and survival inputs
formed a normal distribution, the utility
parameters were assumed to have a beta
distribution using standard deviations reported in
the published studies (indicated in the column
P2). The stochastic analysis randomly selects a
value within each of these distributions as inputs
to the model and generates the cost-effectiveness.
A simulation was run 1000 times to obtain the
confidence limits.
The 95% CI of the 1000 iterations was a cost per
QALY of £34,194 to £364,564. A histogram
(Figure 5) shows the proportion of each of the
1000 iterations to fall into each cost-effectiveness
threshold. The £60,000 cost per QALY threshold
contains the highest number of iterations at
164/1000.
The cost and effectiveness pairs in the stochastic
analysis are used to generate a cost-effectiveness
acceptability curve (CEAC). The CEAC (Figure 6)
demonstrates the likelihood that the intervention
is cost-effective or not cost-effective across a range
of cost-effectiveness thresholds. CEACs are
particularly useful when the threshold for
acceptability is unknown or is likely to vary over
time.
Finally, a scatter plot (Figure 7) constructed from
the 1000 stochastic simulations of cost and
effectiveness pairs shows that the majority of the
variation in cost-effectiveness, of the variables
included in the analysis, are attributable to the
efficacy. Cost has relatively little impact. This
An economic evaluation of LVADS for people with ESHF in the UK
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FIGURE 4 Impact of varying the initial LVAD cost (assessment, operation, device) on cost-effectivenessanalysis reinforces the need for reliable, good-
quality BTT studies. 
Model 2: LVADs as an LTCS for ESHF
In the baseline analysis, the incremental cost per
QALY of a first-generation HeartMate LVAD as an
LTCS was £170,616. This is based on HeartMate-
specific data at a cost of £48,000 per device and
the EVAD costs. Sixty QALYs are gained in the
100 patient cohort (0.6 QALYs per person) at an
additional cost of £102,000 per patient over the
5 years, or £10.2 million for the 100 patient
cohort (Table 55).
Sensitivity tests
The results of the sensitivity analysis are
summarised in Table 56. The cost-effectiveness of
LVADs as LTCS was not sensitive to changes in the
discount rate, costs or changes in the utility
assumptions within the upper and lower bounds.
In all of these results the cost per QALY was well
above generally accepted norms. The most
uncertain variable (owing to a lack of reported
data) in the analysis was the ongoing cost of
medical management. In the event, even when the
medical management costs are assumed equal to
LVAD ongoing management costs, there is little
Health Technology Assessment 2005; Vol. 9: No. 45
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FIGURE 5 Stochastic estimate of ICER sampling distribution
TABLE 54 Parameters varied as inputs to the stochastic modelling
Distribution P1 P2 Base case Source
Cost of LVAD operation Normal £27,740 £46,233 £36,986 EVAD project
Cost of transplant operation Normal £5,875 £24,807 £14,114 NHS Reference Costs
2003154
Cost per month, LVAD Normal £1,118 £1,677 £1,397 EVAD project
Cost per month, medical care Linked £176 £326 £251 Aaronson et al.82
(proportionate of LVAD)
Cost per month, post-transplant Uniform 0.8 1.2 1.0 Sharples et al.150,151
(proportionate)
Pre-transplant medical survival (months) Normal 7.2 1.49 7.2 Aaronson et al.82
Pre-transplant LVAD survival (months) Normal 4.6 0.74 4.6 Aaronson et al.82
Overall survival gain (%) Normal 0.58 0.29 0.578 Aaronson et al.82
Utility pre-transplant, medical care Beta 0.548 0.074 0.55 Moskowitz et al.138
Utility pre-transplant, LVAD Beta 0.809 0.080 0.81 Moskowitz et al.138
Utility, post-transplant Beta 0.964 0.027 0.96 Moskowitz et al.138An economic evaluation of LVADS for people with ESHF in the UK
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FIGURE 7 Scatter plot of cost and effectiveness pairsimpact on cost-effectiveness. Similarly, even when
medical management costs were four times those
of LVAD management, there was little impact
made on cost-effectiveness of LVADs as an LTCS.
There were insufficient data to populate the
analysis of a second-generation device on any
parameter except cost. However, some threshold
analysis was attempted anchored to the first-
generation survival curves. If a second-generation
device was to show an improvement in survival
over and above the first-generation values of
40–60% (using the £35,000 MicroMed Debakey
VAD device cost), the cost per QALY ranges from
£44,339 (with a 60% improvement) to £54,692
(40% improvement). These figures approach
acceptable cost-effectiveness thresholds and give
an indication of the improvement which must be
shown in future second-generation studies for
their cost-effectiveness to be considered
favourably. 
For the LTCS model, only the most extreme
sensitivity analysis results in an ICER that might
generally be considered viable. These parameters
have been best dealt with as an input parameter to
the model (as has been addressed in this sensitivity
analysis) rather than assigning a distribution.
Therefore, for the LTCS model, the analysis has
focused on a deterministic analysis (Table 55)
rather than embarking on a stochastic analysis, as
undertaken in the BTT model. 
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TABLE 55 Summarised baseline results from the LTCS model
LVAD Medical therapy Increment
Costs per patient per period
Initial period £87,877 £1,382 £86,495
Each subsequent period (2–21) £4,192 £1,382 £2,811
Utility per patient 0.93 0.70 0.23
Cohort (100 patients)
Total cost – undiscounted £11,033,131 £562,991 £10,470,141
Total QALYs – undiscounted 114.60 50.07 64.53
Total cost – discounted £10,675,641 £475,807 £10,199,835
Total QALYs – discounted 104.19 44.41 59.78
ICER £170,616
TABLE 56 One- and multi-way sensitivity analyses for LVADs as an LTCS for people with ESHF
Parameter varied Base case Range of values tested Cost per QALY (£)
(range)
Baseline £170,616
Upper and lower estimates of costs See Table 49 £136,597 £190,283
LVAD operation cost £36,986 £29,589 £44,383 £158,242  £182,989
LVAD management cost £16,769 £13,415 £20,123 £164,300  £176,932
Medical management cost £5,526 £4,421 £16,769 £154,423 £172,207
HeartMate/Novacor device cost £48,000 £38,400 £57,600 £154,557 £186,674
MicroMed DeBakey device £48,000 £28,000 £42,000 £137,161 £160,579
Jarvik device cost £48,000 £32,758 £49,137 £145,120 £172,518
Improvement over REMATCH survival N/A 40% 60% £49,120 £61,154
Improvement over REMATCH survival,  N/A 40% 60% £44,339 £54,692
MicroMed DeBakey VAD device cost
Costs discount rate 6% 3% 9% £169,638 £171,656
Benefits discount rate 1.5% 0% 6% £167,059 £181,491
Mean expert-based utilities See Table 51 £172,731Budget impact/resource
management issues
The British Heart Foundation recently produced
an updated breakdown of the NHS costs
associated with heart failure based on 2000 data
(see Table 57).162
The predominant cost component is
hospitalisation, accounting for 60% of total costs.
Severity of heart failure is classified according to
the NYHA staging criteria. These rate patients as
Class I–IV, with Class IV representing the greatest
degree of debilitation, encompassing severe
difficulties in daily activities and problems in
breathing even at rest. Furthermore, the cost of
heart failure increases exponentially with an
increase in NYHA classification. In a study across
four European countries by Berry and
colleagues,163 costs of NYHA Class III patients
were 2–4 times those of Classes I and II. The
figures were even more marked for the costs of
NYHA Class IV, which varied from 8 to 33 times
those of Class I and II patients. Putting this in
context, Class IV patients account for between
61% and 92% of heart failure costs. Of the non-
medical expenditure on heart failure (including
productivity losses, carer support, welfare support
ambulance transport and nursing care), few
estimates have been reported.
The decision to place a patient on a waiting list
for transplant is a multidisciplinary one driven by
the age and underlying co-morbidity of the
patient. Patients >60 years old or suffering from
chronic current systemic infection are
contraindicated for transplant.164 There are
protocols in operation and a number of criteria
must be met before a patient is eligible for waiting
list status. The process generally works as follows:
“Patients waiting for a heart or liver who are
classified as urgent are given priority. This is
because their life expectancy without a transplant
can be measured in days or even hours. If there
are no urgent patients on the waiting list, the
organ is offered for patients on the non-urgent list
who are nearest in age and blood group to the
donor. The location of donor and recipient is also
considered to minimise the delay between
retrieving and transplanting organs” (UK
Transplant).
Although there appears to be no adequate way of
assessing unmet need (for the purposes of budget
impact analyses) in the UK (Large S, Papworth
Hospital NHS Trust: personal communication,
2003), using information from studies of incidence
and prevalence, mortality data and waiting list
data, the potential need and demand for LVADs
within England and Wales were estimated (see
Table 58 and the section ‘End-stage heart failure
and the needs and demands for healthcare’ (p. 10)
for a discussion of the methodology used for
estimating need, demand and supply).
Although this analysis estimates that between 3000
and 34,000 people annually could benefit from
treatment for ESHF, it is likely that actual need
will be between 6000 and 8000 people. Although
these figures are only an estimate, they give an
idea of the potential for heart transplants were the
availability of donor hearts unrestricted.
Furthermore, it is likely that the figures will
increase when the potential expansion of the
LVAD market is expanded to patients unsuitable
for heart transplant. As noted above, the UK
waiting list population is capped, as is likely the
case in the USA, at a lower level than our
projection and consequently reflective of supply as
opposed to need.
The baseline analysis in the cost-effectiveness
model put the annual increased burden on the
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TABLE 57 Costs of heart failure to the NHS in 2000162
£ million % of total
Primary care 103.8 17
Hospital inpatient care 378.6 60
Hospital day-case care 0.45 <1
Hospital outpatient care 51.25 8
Outpatient investigations 37.44 6
Drugs 54.08 9
Total 628.6 100
TABLE 58 UK projections (England and Wales) of need,
demand and supply
Year
1995 2003 2000
Total need 6,782 3,146 34,329
Total demand 893 414 402
Unmet demand 574 266 198
Transplants (met demand) 319 148 204
Actual donor supply 338 157 224
Potential donor supply 1,183 549 756
Unmet need 6,463 2,998 34,125
Waiting list 469 218 156
Unrecognised need 5,892 2,734 33,927
Figures in bold are from published sources and those in
italic were estimated.NHS at £99,636 per patient for the BTT model
and £101,998 per patient for the LTCS model.
This is an incremental cost to be incurred since
no LVADs are currently provided on the NHS. If
the use of the technology is expanded, first as a
BTT for everyone on the waiting list (n = 156),
the impact on the budget would increase to 
£15.5 million. Second, when the use of LVAD is
not confined to transplant candidates but
extended to wider definitions of ESHF, as in the
LTCS scenario, the cost to the NHS will be
significantly higher. It is estimated that the
discounted costs will range from £42.2 million
with a total demand of 414 people to £321 million
when encompassing a total need of 3146 people.
The costs of this technology will have to fall
considerably before it achieves such widespread
usage. Furthermore, any proposed expansion
needs to consider issues of capacity. There are few
experienced centres able to carry out LVAD
operations, currently limited to four main UK
specialist centres. The cost of training additional
clinicians and support staff and equipping 
centres would also have to be taken into
consideration and would require a considerable
step change in funding to provide such a service
within the NHS.
Conclusion
The economic evaluation has shown that LVADs
do not appear to be a cost-effective use of NHS
resources when used as either a BTT or an LTCS
for people with ESHF given current UK
thresholds of £30,000 per QALY. The baseline
analyses produced a cost per QALY of £65,242 for
BTT and £170,616 for LTCS, with substantial
decreases in the costs associated with the device
and its implantation and/or increased benefits to
patients in terms of survival and QoL necessary to
achieve acceptable ICERs and justify developing a
service. Concerns about the declining availability
of donor hearts for transplantation in the UK may
also affect the nature of the service, limiting the
possibilities for the use of LVADs as a BTT.
Importantly, the results of the analysis should be
viewed with caution owing to the uncertainties
associated with the information on clinical
effectiveness of the devices (particularly the
second-generation LVADs), the costs of
implantation and of the ongoing costs of medical
management and the QoL gained by people with
ESHF receiving the different treatment options.
Additional research is required to allow a more
accurate assessment of the costs and benefits of
developing a service for the NHS.
Discussion
In an environment of diminishing donor hearts,
“only a privileged minority receive transplants”165
and as a consequence the potential of this
technology is huge. The number of transplants
carried out in the UK has nearly halved in
10 years (from 302 in 1993 to 153 in 2002).164
The reasons for this decline are not clear and it
may be that further research may explore the
possibility of developing a strategy to increase
organ donation that may compare favourably with
the development of a service to provide LVADs to
people with ESHF. Alternatives, such as
xenotransplantation, are experimental166 and
innovative therapies such as growing new heart
tissue from cells167 are a long way off routine
usage. Improving outcomes in BTT patients
through the use of LVADs, although itself
rewarding, will have limited effect on the use of
LVADs as demand will be dependent on the
availability of donor hearts. With the declining
supply of organs for donation, it is unlikely that
the role of LVADS as a BTT will grow. It is more
likely that the future for these devices lies in their
use as an LTCS. However, the economic
evaluation undertaken for this report using the
data available has shown that LTCS is not cost-
effective, except under the most extreme scenario
(a 60% improvement in survival over current first-
generation devices). In effect, it appears that the
benefits of LVADs as an LTCS in terms of life-
years saved are arguably being outweighed by
their prohibitive cost. Although these findings
suggest a limited future for this technology, they
should be seen within the context of the
evaluation of this technology (i.e. patients with
ESHF have a high mortality rate168 and limited
treatment options), in addition to the key elements
that determine the outcome of the cost-
effectiveness analyses and the uncertainties that
remain within the models. This is particularly
important for the model assessing LVADS as an
LTCS for people with ESHF, where data on
benefits and costs are relatively limited.
The effectiveness of LVADs as a BTT and as an
LTCS for people with ESHF was assessed using
survival of patients through the different stages of
the clinical pathway used during their
management. Unfortunately, survival data were
limited. Only a small number of studies presented
survival data for the different stages involved in
managing ESHF. Studies often involved small
numbers of patients, limiting the reliability of
their findings. Also, as second-generation devices
are relatively new, only a limited number of studies
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evaluation of LVADs as a BTT for people with
ESHF, it was evident that the cost-effectiveness was
sensitive to the difference in the survival of
patients with LVADs compared with medical
management after transplant. It was evident from
the systematic review of clinical effectiveness that
patients receiving an LVAD appeared to have an
improved survival compared with those patients
receiving medical management. The extent of the
benefit was difficult to judge, given some variation
between studies and possible differences in
prioritisation of the different patient groups for
transplant (i.e. short waiting times for transplant
for LVAD patients). Additional good-quality,
longer term, controlled evaluations are required to
establish the relationship further. In the evaluation
of LVADs as an LTCS for patients with ESHF, the
sensitivity analysis showed that the cost-
effectiveness was not sensitive to survival. 
The availability of utilities for the comparator
interventions during the different stages of the
clinical pathway followed by the patients was a
particular concern for the evaluation. Originally, it
had been intended, with the collaboration of
senior clinicians at LVAD centres within the UK, to
solicit patient-based utilities from the LVAD
population for this study. It had been hoped that
it would be possible, through patients’ routine
appointments, to administer a simple
questionnaire via a research nurse. Unfortunately,
it became clear during the study that such an
exercise was not feasible and regrettably it was
abandoned and efforts were focused on other
approaches. [There were reported recruitment
problems to the EVAD study at Papworth and
Harefield hospitals for LVAD patients and heart
transplant comparison patients at Newcastle
General Hospital. The EVAD team could not
support our methodology, principally owing to
their perception of the doubtful scientific or policy
value of retrospective utility assessment in a small
sample of patients, the time and effort involved in
such an exercise and the degree to which it may
complicate the EVAD study itself. The EVAD
collaborators kindly offered access to their clinical
experts to construct treatment pathways and
utilities, and the NSCAG cost database in lieu
(Caine N, Papworth Hospital NHS Trust,
Cambridge: personal communication, 2003).] At
the time of planning the patient-based exercise
there were only around 19 surviving patients (60%
of 32 transplanted patients) at Papworth Hospital
who had previously been on LVAD support. It was
then planned to undertake a retrospective process
to solicit the patients’ QoL at three points: prior
to placement of the LVAD, during LVAD support
and their current status (giving us potentially 57
responses). [We had planned to administer both
the EQ-5D instrument and an SG exercise
following Moskowitz’s scenarios with minor
rewording with permission of the author
(Moskowitz AJ, Columbia University: personal
communication, 2003) facilitated by a booklet with
laminated cards.] This was to be augmented with
data from patients associated with the LVAD
programme at the John Radcliffe Hospital,
Oxford, but unfortunately it was not possible to
obtain these data either.
As a consequence, the evaluation focused on a
panel-based utility mapping exercise, which also
has potential limitations. Mapping exercises are
necessarily long drawn-out processes of validation
and testing, which were impossible within the time
horizon of this research. The final report on the
process undertaken by Stein and colleagues in
developing the utilities used is awaited with
interest, so judgements can be made about the
validity and the reliability of the process followed.
It will be important to compare the utilities from
the mapping exercise used within this evaluation
with those from other studies, particularly those
from the REMATCH study when published. It is
understood that the utilities collected in the
REMATCH trial used the EQ-5D instrument and
the authors may also wish to compare these with
utilities estimated via the algorithm developed by
Brazier and colleagues169 to calculate utilities from
the individual patient-level SF-36 scores, which are
summarised by Rose and colleagues.111
Comparison of another study that performed a
mapping exercise linking the NYHA classification
with the EQ-5D170 with the utilities presented in
the systematic review of cost-effectiveness shows
some variations. The utility scenarios examined by
Kirsch and McGuire170 resulted in markedly lower
values for ESHF (in their case NYHA Class IV
patients, median utilities 0.284 to 0.372) than
reported in other studies (see Chapter 4). Kirsch
and McGuire170 expressed concerns with respect to
decreasing proportionality over longer term
survival after a period of getting one’s “affairs in
order” (a view shared by Waugh and Scott171).
Other concerns with the utilities reported by
different studies is that they do not measure all
patients at each stage of the clinical pathway and
that the time period at which the utilities were
solicited do not cover the whole of the period for
which the utilities are assigned. Usually values are
mean (or median) utility estimates reflective of the
point of assessment only, implying they could be
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a waiting list could be expected to grow steadily
worse, the QoL profile or QoL over time for an
LVAD recipient may indicate a poorer state of
health while the patient adjusts to the device
before improving steadily or utility in ESHF may
be a function of time since diagnosis. This type of
analysis has been evaluated in oncology using the
Quality-adjusted Time Without Symptoms and
Toxicity (Q-TWiST) approach. Future LVAD
modelling research may wish to construct a similar
quality-adjusted survival analysis or partitioned
survival analysis models.172
Finally, there are concerns over the validity of
extrapolating reported utilities from first
generation devices to second-generation devices.
Owing to the increasing preference for calculating
cost per QALY by bodies such as NICE,
coordinators of trials including second-generation
devices are recommended to solicit patient-based
utilities through instruments such as the EQ-5D,
which confers only a very small additional burden
on the patients (it takes about 3 minutes to
complete). Strong representation has been made
to those in the UK involved in undertaking
research into the use of LVADs as an LTCS for
people with ESHF to use the EQ-5D instrument in
subsequent trials.
Despite these concerns about the utility data, the
estimates for ESHF patients across a variety of
definitions are generally consistent (~0.6), and
there is a positive increment between LVAD
support and ESHF in the available literature. Also,
the utilities from the expert panel, and their
similarity to the utilities for the patients receiving
an LVAD in the study by Moskowitz and
colleagues,138 provide a counter to the argument
that patient-based condition-specific values are
biased by a ‘heroic intervention’ effect (i.e. the
patient is so relieved to be still alive that s/he
uplifts the utility score accordingly). Future
researchers should also consider soliciting
generically derived QALYS (as favoured by groups
such as NICE) over condition-specific QALYS that
tend to be provided by most of the literature. 
As long-term follow-up data become available and
studies utilise second- (and future-) generation
devices, both the uptake and outcome of LTCS
could be expected to improve. Generation of data
will allow for robust comparisons between the cost-
effectiveness of the different indications. The
economic evaluation of the REMATCH trial,
where the HeartMate VE (first-generation) LVAD
was used as an LTCS, together with patient-based
utility estimates collected in that study 
(Moskowitz AJ, Columbia University: personal
communication, 2003) are eagerly anticipated.
Similarly, further data on second-generation
LVADs (such as the Jarvik 2000, MicroMed
DeBakey LVAD or HeartMateII LVAS) are awaited
to populate economic models. Further research
should also consider indirect or patient-borne
costs, particularly if outpatient or home care is to
be proposed.
As with other elements of the economic
evaluation, cost data for the different aspects of
treatment were difficult to obtain and comparisons
provided some concerns about their reliability.
Importantly, the sensitivity analyses undertaken
for the BTT indication revealed that the
combined cost of the procedures (LVAD device,
assessment and implantation) had a significant
influence on the overall cost-effectiveness. A
previous evaluation by Christopher and Clegg121
of the use of LVADS as a BTT for ESHF found a
cost per QALY of £39,790, markedly lower than
that found in the current evaluations of LVADs as
a BTT or an LTCS. The difference reflects the use
in this evaluation of up-to-date LVAD specific costs
which were far higher than those reported by
Christopher and Clegg.121 The LVAD operation
cost observed in the previous study was £10,812
(inflated) compared with £36,986 used in this
evaluation. Similarly, the ongoing LVAD
management costs were £844 (inflated) compared
with the value used in this evaluation of £16,769.
It is clear that these apparent differences in LVAD-
related costs have pushed the BTT scenario
beyond generally accepted cost-effectiveness
norms and such costs would need to be controlled
if the technology is to meet the current
benchmark for acceptable cost-effectiveness within
the UK. Also, there has been a marked fall in the
published cost for heart transplantation reported
in NHS Reference Costs. Christopher and
Clegg121 reported the cost of heart transplantation
at £23,000 in 1999; by 2003 it had fallen to
£14,114 (2002, £16,712), although variation in
this parameter has little impact on this scenario.
Uncertainties remain about the costs of the
comparator interventions assessed in the economic
evaluations. It proved impossible to obtain the
ongoing costs of medical management from the
UK and, as a consequence, US hospitalisation
resource use data were used as a proxy for the
relative cost of medical management compared
with management with an LVAD. Such estimates
are vulnerable to US hospital, health provider and
FDA protocols. Sensitivity analyses undertaken
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impact on the outcomes of the economic
evaluations. Further scenarios considered in the
sensitivity analyses showed that when medical
management of a waiting list or non-transplant
candidate are substantial then the favourability of
LVADs increases. The economic evaluations from
the REMATCH study of LTCS in the USA and
from the NSCAG EVAD study of BTT in the UK
are eagerly awaited as they will provide additional
information on benefits and costs. 
Other factors may affect the cost of the use of
LVADs in the UK in the future. The results in the
economic evaluation of BTT in this report are
within the inpatient setting. Several studies in the
USA have examined the use of LVADs in the
outpatient setting, where the costs of management
may be lower. At present no studies have
undertaken such an evaluation in the UK. Another
possibility for reducing the high cost of the LVAD
devices is the potential for their re-use after
transplantation or death. Naturally such a strategy
must overcome such issues as sterilisation, ethics,
legalities and consent.173 Pacemakers, in particular,
have a proven history of reuse.173 However, the
devices are not currently reused. First-generation
devices were designed with a lifespan of 1 year
whereas second-generation devices were designed
for up to 5 years (Banner N, Royal Brompton and
Harefield NHS Trust: personal communication,
2003). Replacement surgery, moreover, may be
more risky than the initial operation and is only
done in an emergency situation.
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The main findings of the systematic review of the
clinical effectiveness of LVADs as a BTT, BTR and
LTCS are summarised.
Clinical effectiveness of LVADs as a BTT
for people with ESHF
Despite the relatively poor quality of the evidence,
it was evident from the systematic review that
LVADs as a BTT, compared with inotropic agents,
optimum usual care or no care, appear to be
beneficial for patients with ESHF when assessed
using patient survival, functional status and QoL.
When compared with inotropic agents, LVADs
appeared to provide a benefit in patient survival
that increased with the length of support
(difference in actuarial survival: 1 month 3%,
3 months 17%) and extended beyond heart
transplantation (difference in actuarial survival:
1 year 24%, 4 years 30%). Comparisons of the use
of LVADs with usual care were less certain, with
outcomes varying from no difference in survival
to, or after, heart transplantation, to improved
survival for LVADs patients to heart
transplantation (survival difference: range
14–59%) and post-transplantation (difference in
actuarial survival: 1 and 2 years 100%). Studies of
LVADs which did not include a comparator were
often the only evidence available, particularly for
the new devices. In these studies, implantation of
an LVAD provided support for up to 390 days,
with as many as 70% of patients surviving to
transplantation. Comparisons of different LVADs
were limited. Only the HeartMate and Novacor
LVADs were compared, with little difference in
survival to transplantation. There was limited
evidence assessing the effects of LVADs on the
functional status and QoL of patients with ESHF
bridged to heart transplantation. Patients
supported by an LVAD appeared to have an
improved functional status compared with those
on usual care. Also, patients with an LVAD
experienced an improvement in their QoL from
before implantation of the device to the period
during support. The use of LVADs is associated
with risks of adverse events, with patients suffering
mechanical device failures, bleeding,
thromboembolic events, infections, reoperations
and psychiatric conditions. Adverse event rates
varied between different LVADs and studies and
some caution should be taken in interpreting these
results. With scarcity of evidence directly
comparing the different LVADs, it is difficult, and
perhaps inappropriate, to identify specific devices
as the most clinically effective. However, the
HeartMate LVAD is the only device that has
evidence comparing it with several different
alternatives, appearing to be more clinically
effective than inotropic agents and usual care and
as clinically effective as the Novacor device. Of the
second-generation devices, the evidence suggests
limited difference in the clinical effectiveness of
the Jarvik 2000 and the MicroMed DeBakey
LVADs. Although early in their development,
studies of second-generation devices appear to
show lower rates of adverse events, such as
infection, bleeding and thromboembolism, that
have affected the development and use of the
first-generation devices. Some clinicians have
questioned this finding, reporting difficulties with
second-generation devices and thromboembolism
compared with first-generation devices. Longer
term outcomes are needed to ensure that these
adverse events and other consequences associated
with the non-pulsatile nature of the devices are
accurately identified.
Clinical effectiveness of LVADs as a BTR
for people with ESHF
Evidence of the clinical effectiveness of LVADs as a
BTR for people with ESHF was limited to non-
comparative observational studies, which were
judged to be of poor methodological quality. The
studies appeared to show that LVADs provided
benefit in providing support for the patients until
myocardial recovery. As there were no direct
comparisons of different interventions, it is not
possible to assess whether the LVADs are more
effective than other alternatives or specific devices.
No evidence was found to judge the effects of the
devices on the QoL or functional status of
patients. Limited information on adverse events
was reported, although infections and bleeding
were the main concerns.
Clinical effectiveness of LVADs as 
an LTCS for people with ESHF
Although the nature and methodological quality
of the evidence to assess the clinical effectiveness
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between the different devices, it was evident that
LVADs provided benefits for patients in terms of
improved survival, functional status and QoL. The
REMATCH trial provided good-quality evidence
that the HeartMate LVAD provided a statistically
significant 48% reduction in the risk of death from
any cause when compared with optimal medical
management. Actuarial survival was significantly
higher for patients with the HeartMate LVAD
compared with optimal medical management at
1 year (52% versus 25%) and 2 years (23% versus
8%) of follow-up. Importantly, improvements in 
1-year survival were evident for patients aged
<60 years and those aged 60–69 years. Less
rigorous evidence for the Novacor, Toyobo and
Jarvik 2000 devices showed relatively high survival
(90%), with patients supported for up to 4 years.
Limited information of changes in patients’ QoL
and functional status suggested that patients
experienced improvements on specific scales
following implantation of the HeartMate and
Jarvik LVADs. Inevitably there are adverse events
associated with the use of LVADs, with device
malfunctions, infection and bleeding associated
with their use. The HeartMate LVAD was
associated with twice as many serious adverse
events than optimal medical management, with
significantly higher rates of non-neurological
bleeding and neurological dysfunction. Other
adverse events affected the different treatment
options, whether devices or drug treatment.
Despite these adverse events, the benefits of these
LVADs appear to outweigh limitations. Evidence of
the clinical effectiveness of the different devices
indicates that the HeartMate LVAD appears to be
effective when compared with optimal medical
management. For the second-generation devices,
the early evidence suggests that the Jarvik 2000
shows promise; however, further research is
needed to assess whether there will be any long-
term consequences associated with the change in
the nature of the circulatory support.
Systematic review of the 
cost-effectiveness of LVADs for people
with ESHF
Although there are a number of simple costing
studies, this review has shown there is relatively
little published literature on the cost-effectiveness
of LVADs. A number of the costing studies
reported in this review had serious methodological
flaws. Even those judged of ‘higher quality’ had
caveats limiting applicability and generalisability
to a UK population. Significant limitations of the
studies in this review were their limited sample
size and the lack of comparators against which to
judge the significance of the reported costs. There
was only one UK-based cost–utility analysis,
conducted by Christopher and Clegg121 in 1999.
The authors populated their model with costs
based on treatment protocols, data from individual
Trust finance departments and utilities derived in
the study by Moskowitz. Their analysis reports cost
per QALY values at the boundary of acceptability
given recent decision-making. Based on total
treatment costs of both LVAD BTT support and
heart transplantation, the discounted cost per
QALY was ~£39,790 (range from £28,510 to
£74,000). Christopher and Clegg121 used
threshold analysis to calculate that an LVAD device
and procedure cost of £19,300 would equate to a
cost per QALY of £20,000 or less.
Economic evaluation to assess the 
cost-effectiveness of LVADs for people
with ESHF within the UK
The economic evaluation has shown that neither
LVAD indication considered, that is, BTT or
LTCS, is a cost-effective use, by generally accepted
thresholds in the UK, of scarce NHS resources.
The baseline analysis for the use of LVADs as a
BTT for ESHF shows that the cost per QALY for
the HeartMate LVAD was £65,242, whereas the
cost per QALY for LVADs as an LTCS for ESHF
was £170,616. The BTT indication approaches
cost-effectiveness only if the one-off costs
associated with an LVAD were to fall considerably
(by >40%). Unfortunately, even assuming this
eventuality, the BTT indication use parallels an
ever-decreasing supply of donor hearts, capping
the ability of this innovative technology to yield
widespread benefit. In the less restrictive
indication, LTCS, where LVADs are not just given
to patients awaiting transplantation, the analysis
undertaken using the available data has shown
that LTCS is not cost-effective. Although our
analyses recognise the benefits in terms of survival
and QoL, these are outweighed by associated
increases in cost. Sensitivity analysis suggested that
significant changes would be needed in costs or
improvements in benefits for the device to near
suggested cost-effectiveness thresholds.
Uncertainties remain particularly with the lack of
trial data on LTCS, research on second-generation
devices and ongoing costs of medical
management. The REMATCH population was
older and in NYHA Class IV, whereas the BTT
studies comprised younger, healthier patients.
Trial data establishing LVADs as LTCS in a
younger, healthier population may lead to a more
favourable economic argument. The use of expert-
based utilities in the LTCS data is also
controversial but our sensitivity testing has shown
Discussion
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effectiveness at the margin. Further research is
needed if LVADs are to achieve their potential to
benefit to a substantial ESHF population. 
Strengths and limitations of the
systematic review and economic
evaluation
This review has certain strengths, including the
following:
  It is independent of vested interest.
  The systematic review brings together the
evidence on the effectiveness of LVADs as a
BTT, BTR and LTCS for people with ESHF,
applying consistent methods of critical appraisal
and presentation.
  The systematic review was guided by the
principles for undertaking a systematic review.75
Prior to undertaking the systematic review and
economic evaluation, the research methods were
set out in a research protocol (Appendix 2),
which was commented on by an advisory group.
The protocol defined the research question,
inclusion criteria, quality criteria, data
extraction process and methods employed to
undertake the different stages of the systematic
review and economic evaluation.
  An advisory group has informed the systematic
review and economic evaluation from its
inception, through the development of the
research protocol and completion of the report.
The advisory group included a broad range of
people associated with the technology within
the UK and world-wide, such as clinicians,
commissioners, public health professionals and
academics. A list of the members of the advisory
group, their conflicts of interest declared and
the input provided at the different stages of the
study are outlined in Appendix 32.
  Contact was made with the manufacturers of the
different LVADs to inform them of the study, its
aims and research methods, and to invite them
to submit any additional information that may
inform the systematic review and the economic
evaluation. Unfortunately, only a limited
number of these manufacturers responded,
despite reminders being sent. All submissions
are outlined in Appendix 4 and
acknowledgement is made to those who took
the time to provide the information.
Information was considered for inclusion within
the systematic review and economic evaluation
using the research methods outlined and
applied to all such information.
  Initially contact was made with a sample of
authors of studies included within the
systematic review where clarification of
information was required. The response from
these authors was very poor, with very few
replying to these requests. As a consequence, 
it was decided not to continue with this 
process and to assume that any information
about the methods of the study or results 
not reported were not undertaken in the
study.174
  The key providers within England and Wales
who currently implant LVADs and/or provide
care for patients with ESHF, specifically
Papworth Hospital in Cambridge, Harefield and
Brompton Hospitals and John Radcliffe
Hospital in Oxford, were contacted to try to
obtain relevant information for the systematic
review and economic evaluation. Obtaining
relevant information was difficult. The fast
changing nature of the technology, the limited
number of patients undergoing such treatment
annually and the importance of patient
confidentiality have limited the availability 
of information on patients’ outcomes of
survival, QoL and costs. Despite these
limitations, some information was provided 
on the costs and professional opinions of
patient QoL.
  The quality assessment of studies included in
the systematic review of the clinical effectiveness
of LVADs for ESHF used a recognised tool that
was thought to allow comparison across
different study designs, essential for decision-
makers when comparing alternative
treatments.78 The tool provided the opportunity
to assess possible biases, whether inherent in
the study design used or through deficiencies in
the application and reporting of methods and
other information. Only the components of the
tool were judged and discussed, and no overall
score was calculated as it may be misleading.174
The approach may be criticised as the standard
criteria used may include components that
could not be met when assessing this technology
(e.g. blinding of patients and surgeons) and for
not using separate lists of criteria specific to the
different study designs, so that potentially good-
quality observational studies are judged to be of
poor quality compared with an unachievable
‘gold standard’. However, comparison across the
range of evidence on the different devices was
important to this health technology assessment
and an appreciation of the potential biases was
key. As a consequence, it was felt that the
advantages of the approach outweighed any
disadvantages.
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up-to-date modelling of data on benefits of
treatment and the costs within the UK, using
data from relevant primary research to populate
aspects of the clinical effectiveness of the
technology, utilities from an independent
expert panel and cost data from current service
providers in the UK.
In contrast, there were certain limitations:
  Owing to differences in the design, duration,
outcome measures and reporting of studies,
synthesis of the included studies was through
narrative review with no formal meta-
analysis.
  Despite efforts, there was limited information
provided by study authors, manufacturers and
service providers that may have benefited the
clarity of the information considered and the
extent of the analyses undertaken.
  Different methods were used for the systematic
review of clinical effectiveness and that of the
cost-effectiveness of LVADs. Whereas the
systematic review of clinical effectiveness
undertook inclusion and exclusion decisions,
extracted data and assessed quality using two
independent reviewers, the systematic review of
cost-effectiveness used one reviewer with
decisions checked by a second reviewer. This 
may have reduced the robustness of the
approach.
  The economic evaluation suffered from the
inadequacies of the data available. Clinical
effectiveness data varied in nature and
methodological quality, making direct
comparison difficult. Data on patient utilities
were very limited and as a consequence experts
from an independent panel used scenarios to
provide estimates of patient utility. Costs were
from one of the UK centres operating the
NSCAG national service for ventricular assist
devices and their ongoing research to evaluate
the service, the EVAD study. As a consequence,
the costs may be unrepresentative of the
average within England and Wales. It was
disappointing not to be able to obtain more
information on clinical protocols, costs and 
QoL from the main clinical and research 
groups within the NHS in the UK. Concerns
over historical data and academic
confidentiality of current research data
precluded access to such information. In
addition, the limited information on the
incidence and prevalence of ESHF renders
estimates of the effect of developing a service
for the NHS difficult.
Other issues
Several other issues should be taken into
consideration in appraising the clinical and cost-
effectiveness of LVADs for ESHF:
  LVADs are a relatively new and fast changing
technology, with limited diffusion within the UK
and worldwide. As a consequence, the evidence
base for the technology is relatively limited in
scope and methodological quality, whether
considering first- or second-generation devices.
Studies are often retrospective, observational
and non-comparative, focusing on specific
conditions and narrowly defined patient groups.
The pace of development looks set to persist,
with new devices and guidance for their use and
management continuing to emerge. Also,
research has suggested new strategies for
managing heart failure by combining LVADs
with other technologies (e.g. drugs),175 and also
possible limitations of combining with other
technologies (e.g. pacemakers). With such
change, it will be important to monitor and
update this assessment regularly.
  Currently LVADs have tended to be limited to
use within people suffering from ESHF and are
often seen as treatment of last resort whether as
a BTT, BTR or LTCS. However, it has been
proposed that these devices might offer greater
benefit to people if they were implanted before
they progress to the severe state of ESHF,
allowing people to survive for longer durations
and to benefit from a better QoL. If so, it would
suggest that these devices could be more cost-
effective, although much would depend upon
the marginal benefits and costs offered over a
different group of competing technologies. At
present it is too early to make any judgement as
to their future cost-effectiveness for these
differing indications, as changes in their use
would inevitably result in changes in the cost of
competing alternatives. It would be
inappropriate to compare these technologies
through cost-effectiveness league tables. 
  As technologies diffuse and competing
alternatives emerge, so their cost usually
decreases. It is likely that the cost of LVADs,
whether first- or second-generation devices, will
continue to fall. In addition, with few long-term
studies, the benefits of using these devices may be
undervalued. As research into their use continues,
the clinical and cost-effectiveness may change.
  Often the limited nature of the research into
such technologies is a consequence of their
focus on meeting regulatory requirements.
However, it may reflect the lack of research
Discussion
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constraints of using specific devices within
particular patient groups limiting the scope of
their research.
  It is a common concern in health technology
assessment that conditions for research, such as
patients, their condition and the setting, rarely
reflect reality. It has been suggested that this is
a concern for the assessment of LVADS for
ESHF. Limitations in the evidence base limit
the extent to which the findings of this research
can be generalised.
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An important factor in planning NHS services for
people with ESHF is whether the benefits of
particular treatment options are sufficient to
justify the costs of developing, and operating, the
service. Current treatment options provide
differing benefits to people with ESHF. Current
medical management helps to provide some relief
to patients but can only provide limited long-term
benefit, with patients’ condition declining with
time. Heart transplantation has become an
accepted form of treatment for patients at risk of
dying from, or incapacitated by, severe or end-
stage heart failure. Unfortunately, the availability
of heart donors continues to decline, severely
limiting the use of this option to all but a very
small proportion of people. The use of mechanical
devices, such as LVADs, provides a treatment
option with considerable promise. Currently,
LVADs appear to be a clinically effective but not
cost-effective treatment for bridging people with
ESHF to heart transplantation. The availability of
heart transplants renders this option of limited
long-term benefit to patients and the NHS. The
future of LVADs lies in their use as an LTCS for
people with ESHF. At present the evidence for
their clinical and cost-effectiveness is relatively
limited, but more continues to emerge. The
REMATCH trial has shown that the first-
generation HeartMate device provides
considerable survival benefit to people with ESHF.
Case series and case studies in the UK, Germany
and USA have shown that second-generation
devices, such as the Jarvik 2000 and MicroMed
DeBakey, appear to be clinically effective although
the cost incurred limits their cost-effectiveness.
Judging the acceptability of LVADs as an
alternative to current treatment options will
necessitate careful consideration of the costs of
developing and operating the service against the
consequences of other options. Limited numbers
of LVADs are implanted in people with ESHF in
England and Wales currently. Uncertainty remains
about the extent of the need and demand for
these devices within England and Wales, although
there may be as many as 8000 people with the
costs of providing such a service equating to as
much as £800 million annually. Costs of setting up
and developing the service would be in addition to
this amount. Inevitably there may be some impact
on other parties both within and outside the NHS,
unless additional funding is available to fund any
service developed. From a patient’s perspective,
LVADs, whether as a BTT, BTR or LTCS, provide
benefit in terms of survival compared with the
alternatives of medical management in a condition
with a predictable and poor prognosis. Although
the effect on QoL is less clear, the limitations of
the early devices are progressively being addressed
with people able to lead active and productive
lives within the community. Given their condition
and prognosis, people with ESHF are likely to
demand LVADs as their only option, especially
with the decreasing availability of donor organs for
heart transplantation.
To meet any increased need for LVADS for ESHF,
the NHS would need to ensure that there are
adequate multidisciplinary teams available to
undertake the procedures and support the patient
through the long-term phase of managing life on
the device. The availability of the different health
professionals with appropriate training and
experience in implanting and managing patients
with LVADs for ESHF may be a limiting factor in
developing the service. Inevitably there may be a
considerable lead time to ensure that an
adequately trained and funded service is put in
place. Services would need to be located in
specialist regional facilities to allow experienced
teams to develop with the appropriate facilities.
Recommendations for future
research
In undertaking the systematic review and
economic evaluation, certain implications for
research have become evident. These include the
following:
  Despite studies on the epidemiology of heart
failure, there appears to be little good-quality
evidence on the epidemiology of ESHF. As a
consequence, it is difficult to establish clearly
the characteristics of the different patients who
may require treatment and the possible need
and demand for any health service. A systematic
review of the epidemiology of ESHF should be
Health Technology Assessment 2005; Vol. 9: No. 45
121
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
Chapter 7
Conclusionsundertaken to assess incidence and prevalence
of ESHF and characteristics of the sufferers.
  The systematic review of the clinical and cost-
effectiveness of LVADs for ESHF revealed the
limited nature and the poor quality of the
evidence. Further research is needed to
examine the clinical effectiveness of LVADs for
people with ESHF, assessing patient survival,
functional ability, QoL and adverse events.
Although difficult to undertake with such fast
changing technologies and with the different
nature of the comparators, evaluations should
be RCTs. These should focus on head to head
comparisons of different technologies, whether
different devices or usual medical care.
Importantly, these studies should encompass
the breadth of patient groups that may benefit
from these devices for the different indications.
Importantly, studies should focus on the use of
LVADS as a treatment for LTCS. 
  Studies of the effectiveness of LVADs should
include economic evaluations. It has become
evident from this study that data for
undertaking such studies are very limited. Data
on QoL, utilities, resources and costs are not
readily available. Changes in the technology,
the clinical management of the condition and
the patient groups benefiting have rendered the
use of historical data problematic. As a
consequence, studies should try to include
appropriate data collection for assessment of
clinical and cost-effectiveness. 
  Studies should look at long-term outcomes
beyond 2 years of follow-up. This will be
particularly important with second-generation
devices, where concerns have been raised about
the effects of non-pulsatile devices.
Research in the UK is ongoing and will provide an
important insight into the clinical and cost-
effectiveness of LVADs for ESHF, including:
  The NSCAG evaluation of the ventricular assist
device programme in the UK (EVAD).
  Clinical evaluation of the Thoratec implantable
ventricular assist device (IVAD) at Papworth
Hospital NHS Trust.
  Jarvik 2000 Clinical Evaluation (evaluation of
ventricular assist device – bridging to cardiac
transplantation in the United Kingdom) at
Newcastle upon Tyne Hospitals NHS Trust.
  A prospective longitudinal study comparing
QoL and psychosocial adjustment for heart
failure patients managed by medical therapy, an
LVAD or by transplantation, led by Dr Claire
Hallas at Royal Brompton and Harefield NHS
Trust.
  Potential recovery of heart function in patients
with advanced heart failure by treatment with a
combination of LVAD, novel drug therapy and
exercise training, led by Mr Asghar Khaghani at
Royal Brompton and Harefield NHS Trust.
  A multicentre prospective trial of the HeartMate
II LVAS for patients at risk of imminent death,
by Mr Asghar Khaghani at Royal Brompton and
Harefield NHS Trust.
  A multicentre trial of the VantraAssist device,
led by Dr Steven Tsui at Papworth Hospital
NHS Trust.
It will be important to monitor these and other
studies not identified in study registers in the UK
and worldwide, to include their results in revisions
of this evaluation and to make further
recommendations.
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